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Abstract 
A key step in the cancer metastatic process is the ability of the cancer cells to 
survive in foreign tissue microenvironments. Two factors thought to be pivotal in 
cancer metastasis are altered cellular interactions with extracellular matrix (ECM) 
proteins within the tumour microenvironment and exposure to elevated levels of 
mitogenic hormones and growth factors. A compelling body of evidence suggests 
that the ECM protein, vitronectin (VN), can modulate tumour metastasis by 
providing traction and directionality to migratory cancer cells in addition to its effect 
on promoting cancer cell survival. While an increased deposition of VN has been 
reported at the leading edge of breast tumours, few studies have investigated the 
downstream VN-induced transcriptional changes responsible for its effect on cell 
survival and metastasis. In order to fill this knowledge gap, this project aimed to 
identify specific downstream mediators of VN induced in breast cancer cells with 
functional roles in cell survival and metastasis.  
In addition to VN, insulin-like growth factors (IGFs) are known to play a 
critical role in the growth and development of the non-malignant cells as well as 
malignant cell types. The IGF system is complex and the biological effects of the 
IGFs are determined by their diverse interactions between many molecules, including 
their interactions with ECM proteins. Studies over the past decade have 
demonstrated that IGF ligands associate with VN, forming IGF:VN complexes that 
are capable of stimulating biological functions, namely survival and migration in 
both normal and malignant cell types. Considering the important role of IGF-I in the 
progression of breast cancer and its association with VN, this project also aimed to 
identify specific molecular mediators that are important in IGF-I:VN-mediated 
survival. 
In order to identify the molecular mediators underpinning VN- and the IGF-
I:VN complex-stimulated breast cancer cell survival, transcriptional profiling was 
performed using DNA microarrays to identify the transcriptional responses of MCF-
7 breast cancer cells stimulated with VN and the IGF-I:VN complex. Bioinformatics 
analysis identified a substantial number of differentially expressed transcripts in 
response to each treatment, whereby there was a considerable overlap observed 
between the transcripts differentially regulated by VN and the IGF:VN complexes. 
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To select transcripts for functional validation studies, we employed a strategy 
focused on selecting candidates to target not only VN, but potentially IGF-I:VN 
complex-mediated biological actions. Gene ontology and functional pathway 
enrichment were used to identify candidates that were regulated by both VN and the 
IGF-I:VN complex with a bias toward biological functions relevant to breast cancer 
cell survival. Based on published literatures, we identified a number of genes 
differentially expressed in common by VN and the IGF-I:VN complex with 
important roles in cell survival, such as TGFβ2, Smad6, S100A4, S100P, ANXA2, 
CCN1/Cyr61, CCN2/CTGF, RASGRP1, c-FOS, c-JUN, CAV1, snail 2 (slug), mir21 
and LAMB1. Among the candidates identified, CCN family members, Cysteine-rich 
angiogenic inducer 61 (CCN1/Cyr61) and Connective Tissue Growth Factor 
(CCN2/CTGF), were selected to investigate their role in VN- and IGF-I:VN-induced 
breast cancer cell survival. It was demonstrated that VN and the IGF-I:VN complex 
increase Cyr61 and CTGF expression in a number of breast cancer cell types ranging 
from the weakly metastatic luminal-like to the highly metastatic basal-like breast 
cancer subtypes. Studies using functional blocking antibodies and chemical 
inhibitors confirmed the critical involvement of VN-binding αv-subunit containing 
integrins and the activation of the intracellular Src complex, PI3-K/AKT and 
ERK/MAPK signal transduction pathways. Furthermore, the functional role of Cyr61 
and CTGF was assessed using shRNA-mediated gene suppression, which reduced 
VN- and IGF-I:VN-stimulated MCF-7 cell viability in both 2-dimentional and 3-
dimentional cultures. Moreover, Cyr61 was observed to be important for the 
increased viability induced by VN and the IGF-I:VN complex in the highly 
metastatic MDA-MB-231 cell line, whereas CTGF had a more prominent role in the 
invasive and migratory phenotype.  
In summary, this PhD project has identified for the first time the changes in 
global gene expression profiles underpinning VN- and the IGF:VN complex-
mediated cancer cell survival. In addition, the outcomes of this study provide 
valuable new information on the mechanistic events underpinning VN- and IGF-
I:VN-mediated effects on breast cell functions. Importantly, the up-regulation of 
Cyr61 and CTGF mediated by VN and the IGF:VN complex was determined to have 
an important functional role in breast cancer cell growth, survival and migration. 
Targeting Cyr61 and CTGF proteins or associated signalling pathways may disrupt 
  vii 
IGF- and VN-mediated cancer progression, and with further development have the 
potential to be prognostic indicators and therapeutics for cancer patients.  
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1.1 INTRODUCTION  
The metastatic spread of cancer cells to distant sites and their subsequent 
establishment in critical organs of the body is the major cause of death among 
patients with epithelial cancers (termed carcinomas), including breast cancer. The 
ability of cancer cells to invade and migrate away from the primary tumour site and 
survive within foreign tissue microenvironments is one of the key factors underlying 
cancer metastasis. Altered interactions between the malignant cells and the 
extracellular matrix (ECM) proteins within the tumour microenvironment are 
considered to be one of the most important factors contributing to cancer progression 
(Lochter & Bissell, 1995). It is well established that the interactions between cells 
and surrounding ECM proteins influences cell behaviour and function through 
adhesion receptors (Hynes, 1992, 2009). Less well established is the extent to which 
these ECM components directly mediate cancer progression. It is also unclear as to 
the identity and involvement of downstream molecular mediators in cell-ECM-
mediated tumour progression.  
One such ECM protein is the multifunctional adhesive glycoprotein vitronectin 
(VN), which has well documented roles in normal tissue development and 
progression of numerous malignancies, including breast cancer (Aaboe et al., 2003; 
Hurt et al., 2010; Leavesley et al., 2013). The biological effects of ECM proteins are 
known to be influenced by their diverse interactions with various growth factors 
(GFs), including the insulin-like growth factor (IGF) system (Beattie et al., 2010). 
The IGF system also has well documented roles in the development and progression 
of numerous malignancies, including breast cancer (Annunziata et al., 2011; Hartog 
et al., 2013). A comprehensive set of studies from the Tissue Repair and 
Regeneration (TRR) program have demonstrated that VN binds to the components of 
the IGF system to form IGF:VN complexes that are capable of stimulating breast 
cancer cell functions, namely cell attachment, migration and survival (Noble et al., 
2003; Hollier et al., 2008; Kricker et al., 2010; Kashyap et al., 2011). Given that VN 
and IGFs are both implicated in breast cancer progression and the lack of information 
regarding the downstream molecular mediators of their biological functions in 
tumour cells, studies described herein aimed to address this void in our 
understanding. In view of this, the following review focuses on VN and its binding 
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receptors, in particular integrins and their downstream signalling pathways with a 
focus on their implications in breast cancer. This review will also focus on 
interactions of the IGF system with VN and their implications in breast cancer and 
will further highlight the current knowledge gaps.  
1.2 BREAST CANCER 
Breast cancer is one of the most commonly diagnosed form of cancer and the 
leading cause of cancer related deaths in women worldwide (Globocan, WHO 2012). 
Breast cancer accounts for more than 25% (1.67 million) of newly diagnosed cases 
and 14% (522,000) of total cancer associated deaths annually (WHO, 2012). In 
Australia, it accounts for 28% of all diagnosed cancers with 14,181 newly diagnosed 
cases per annum and 16% of cancer-associated deaths among women (AIHW, 2010). 
Despite significant advances in diagnosing and treating breast cancer, several major 
unresolved clinical and scientific problems remain. These are related to: (1) 
prevention; (2) specific and sensitive methods for diagnosis; (3) tumour progression 
and recurrence (understanding the mechanism of recurrence and predicting its rate); 
(4) treatment (various molecular subtypes of breast cancer require different 
therapies); and (5) therapeutic resistance (developing reliable biomarkers predicting 
response to targeting agents to prevent, and overcome resistance). However, these 
problems are further exemplified as breast cancer is not a single disease but is highly 
heterogeneous at both the molecular and clinical levels (Perou et al., 2000; Sorlie et 
al., 2001). 
Gene expression profiling studies from multiple independent groups have 
defined six major molecular subtypes of breast tumours: luminal A, luminal B, basal 
A, basal B, human epidermal growth factor 2 (HER2) positive and claudin-low 
subtypes (Perou et al., 2000; Sotiriou et al., 2003; Neve et al., 2006; Sorlie et al., 
2006; Prat et al., 2010). Among these subtypes, the basal-like and claudin-low 
subtypes are found to be associated with higher risk of development of distant 
metastasis; poorer clinical outcomes and higher rate of mortality (Banerjee et al., 
2006; Fulford et al., 2007). These six subtypes can also be distinguished by 
immunohistochemical analysis of estrogen receptor (ER), progesterone receptor 
(PR), and HER2 to yield three broad groups: (1) ER-positive tumours (when ER is 
positive and HER2 is not amplified), (2) HER2-possitive tumours (which may be ER 
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positive or negative), and triple-negative breast cancer (TNBC) (when ER, PR and 
HER2 are all negative) (Nielsen et al., 2004; Hu et al., 2006; Foulkes et al., 2010).  
Luminal tumours are estrogen and progesterone receptor positive (ER+ and 
PR+, respectively), with luminal A being low grade and luminal B being in general a 
higher grade (Voduc et al., 2010). ER+ tumours make up about 60% of breast 
cancers diagnosed in pre-menopausal woman and offer the best prognostic outcome 
(Jonat et al., 2006; Kulendran et al., 2009), with the majority responding to hormonal 
interventions, including Tamoxifen, Toremifene and Fulvestrant. HER2+ tumours 
have amplification and overexpression of HER2 oncogene (Ross et al., 2003) and 
can be controlled with a diverse array of anti-HER2 therapies available in the current 
market, such as Herceptin and Perjeta (Arteaga et al., 2012). Basal-like tumours lack 
hormone receptors and HER2; thus, the majority of these tumours are also called TN 
breast cancer. TNBC is linked to aggressive tumour development and has the worst 
prognosis among all forms of breast cancer, and cannot be treated with endocrine 
therapy or therapies targeted at HER2 (Dent et al., 2007; Foulkes et al., 2010). The 
claudin-low subtype is contained within the broader TNBC subtype and has 
characteristic enrichment for epithelial-to mesenchymal transition (EMT) and cancer 
stem cell-like features that most closely resemble the mammary epithelial stem cell 
showing the biologic heterogeneity of breast cancer (Prat et al., 2010).  
Histologically, the breast tissue is composed of mammary glands, basement 
membrane and stroma. Mammary glands have milk-producing lobules linked by 
numerous ducts which are populated with luminal epithelial cells and transversely 
oriented myoepithelial cells (Figure 1.1 A). The surrounding stroma comprises ECM 
(composed of proteins such as laminin, collagen and VN), various cell types (for 
example, fibroblasts, immune cells, and adipocytes), and organised structures 
(namely, blood vessels, lymph vessels and lymph nodes) (Place et al., 2011). The 
architecture of the normal breast is maintained by the cross-talk between the stromal, 
epithelial and myoepithelial cells (Barsky & Karlin, 2006). As such interactions 
between the ECM proteins, growth factors, hormones, and the corresponding 
receptors present on the breast epithelial cells are crucial for the maintenance of the 
mammary gland architecture, and any perturbations in their interaction may lead to 
cancer development and progression (Howlett & Bissell, 1993).  
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Breast cancer progression is characterised by multiple well-defined stages 
which initiates as flat epithelial atypia, progresses to ductal or lobular 
hyperproliferation (atypical ductal/lobular hyperplasia; ADH/ALH), evolves to in 
situ (ductal/lobular carcinoma in situ; DCIS/LCIS), invasive carcinomas, and 
eventually metastatic disease (Burstein et al., 2004; Bombonati & Sgroi, 2011). 
Factors involved in tumour progression and methods to selectively interfere in 
specific stages of progression, while not clear, are under intense investigation 
worldwide. Primary in situ carcinomas (DCIS and LCIS) are rarely the cause of high 
mortality associated with breast cancer (Barnes et al., 2012). Rather, the high 
mortality is caused by the metastatic dissemination of breast cancer cells to distant 
organs of the body (Weigelt et al., 2005). Genetic mutations influenced by the 
stromal and ECM interactions with primary tumour cells, can lead to changes in cell 
function that can facilitate these tumour cells to acquire proliferative, migratory and 
invasive capabilities. This in turn leads to the conversion of basement membrane-
bound in situ lesions to escape from tissue boundaries (metastasise), survive and 
establish secondary tumours within alternate tissue sites (Kim et al., 2005; Bissell & 
Hines, 2011; Place et al., 2011) (Figure 1.1 B). 
 
Figure 1. Schematic depiction of normal and cancerous breast architecture. 
The architecture of the normal breast (A) is made up of networks of alveoli containing the milk-
producing lobules linked by numerous ducts, surrounded by intact basement membrane and 
extracellular matrix (ECM). This architecture is disrupted on the acquisition of tumorigenic properties 
by cells within the mammary tissue. A heterogeneous mass of primary tumour is depicted (B) along 
with the processes key to metastasis; ECM remodelling, acquisition of proliferative, migratory and 
invasive characteristics by the transformed cells, disorganisation of the basement membrane, 
infiltration of fibroblasts into to the tumour mass and intravasation of cancerous cells into adjacent 
blood and lymphatic vessels. Three dimensional illustration of the breast (left panel) is adapted from 
Patrick J. Lynch, medical illustrator. 
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Multiple factors can influence the ability of cancer cells to metastasise. 
Microenvironmental factors have been reported to play a key role in the metastatic 
progression of breast cancer (Lochter & Bissell, 1995; Ronnov-Jessen & Bissell, 
2009; Quail & Joyce, 2013). It is very well established that the interactions between 
breast cancer cells and the constituents of ECM within the tumour microenvironment 
play a central role in controlling the tumorigenic process (Lochter & Bissell, 1995; 
Bergamaschi et al., 2008; Muschler & Streuli, 2010). The ECM is a complex mixture 
of proteins, adhesive glycoproteins and proteoglycans. The interactions between the 
ECM components and cells through their cognate cell surface receptors coordinate 
downstream signals and subsequently gene expression that directly control cell 
behaviour and functions (Hynes, 2009). Besides the roles of the ECM proteins, 
growth factors (GFs), chemokines and cytokines present within the ECM have also 
been involved in breast cancer progression (Lin & Karin, 2007; Mantovani et al., 
2010; Witsch et al., 2010). 
For example, in xenograft models of breast cancer, co-injection of various 
fibroblasts or mesenchymal stem cells within the tumour stroma promotes breast 
tumour growth (Zhu et al., 2006) and metastasis (Karnoub et al., 2007). This may be 
attributed to paracrine factors such as chemokines (CXC ligand-12), cytokines 
(interleukin-11) and GFs (IGF, epidermal growth factor [EGF], transforming growth 
factor β [TGFβ]) released from these stromal cells (Kang et al., 2003; Orimo et al., 
2005). This can in turn up-regulate cognate receptors present on the cancer cells 
(normally overexpressed), thereby favouring an invasive and proliferative phenotype. 
Since most tumour cells remain responsive to the extracellular signals mediated by 
these GFs (Hankinson et al., 1998), several studies have been directed at developing 
inhibitors to specific growth factor receptors (Eke & Cordes, 2011; Tognon & 
Sorensen, 2012; Marlow et al., 2013; Wolff et al., 2014). The IGF system is one such 
GF system that has been extensively studied in breast cancer due to its frequent role 
in mediating processes central to breast cancer progression, with several therapeutic 
strategies being designed to combat its downstream effects (Gao et al., 2012; Tognon 
& Sorensen, 2012; Ma et al., 2013). Together with cytokines, GFs and cell-cell 
interactions, the ECM determines whether cells survive, differentiae, proliferate or 
migrate (Streuli, 2009).  
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1.3 THE EXTRECELLULAR MATRIX (ECM) AND BREAST CANCER 
PROGRESSION 
The ECM helps to maintain normal tissue structure and functions and regulates 
cell behaviour by providing contextual information to the cells. During tissue 
development, remodelling, and maintenance, ECM components are synthesised and 
degraded in a tightly regulated manner to conserve its delicate balance (Page-McCaw 
et al., 2007). The ECM has significant effects on cell function through cell-ECM 
interactions that depend on specific ECM composition and organisation (Cox & 
Erler, 2011). Altered ECM dynamics and disruption of regulatory mechanisms over 
ECM maintenance can cause abnormal behaviour in surrounding cells, and are 
known hallmarks of cancer (Hanahan & Weinberg, 2011). For example, 
overexpression of laminin, one of the key components of the ECM, in certain 
contexts can be a poor diagnostic factor and has been related to tumour invasiveness 
in a number of cancers, including malignant glioma (Fukushima et al., 1998), lung 
(Moriya et al., 2001) and breast (Fujita et al., 2005) carcinomas. Correspondingly, 
increased deposition of collagen type I, III, IV and V is reported during tumour 
formation and cell invasion in breast and glioma cancers (Kauppila et al., 1998; 
Sangaletti et al., 2003; Huijbers et al., 2010). Similarly, in breast and glioma cancer 
cells, increased levels of VN can induce cell differentiation and tumour formation 
(Hurt et al., 2010), survival (Uhm et al., 1999), and invasion (Pola et al., 2013). 
Tenascin-C (TN-C) and FN were also found to be highly distributed during vascular 
organisation in several different carcinomas (Berndt et al., 2010). This leads to 
enhanced cell proliferation, vascular morphogenesis, tumour angiogenesis and 
growth, while promoting invasion and metastasis (Van Obberghen-Schilling et al., 
2011).  
In normal mammary tissue, epithelial, endothelial, and stromal cells produce 
and maintain the basement membrane ECM while stromal cells alone contribute to 
the interstitial matrix. These ECM layers in turn provide structural and mechanical 
support to the cells and tissues while also providing physical interactions between the 
ECM and the cells (Lu et al., 2012). The interactions between the ECM components 
and epithelial cells provide information that is necessary for almost all aspects of 
mammary development and function such as ductal formation, branching of ducts 
and alveoli as well as production of the milk-producing luminal epithelial cell layer 
 Chapter 1: Literature Review 8 
during lactation (Muschler & Streuli, 2010; Polyak & Kalluri, 2010). The 
composition of the ECM and subsequently its mechanical properties are known to be 
among the most important factors contributing to the development and progression of 
breast cancer at every stage from pre-malignancy to metastasis (Bissell & Radisky, 
2001). As outlined above, strong deposition of a number of integrin-binding matrix 
proteins, including laminin, collagens (types I, III, IV and V), FN, VN and TN-C 
have been found in the extracellular space around breast tumours (Kauppila et al., 
1998; Ioachim et al., 2002; Kadar et al., 2002; Aaboe et al., 2003). Abnormal ECM 
composition can increase tissue stiffness to the levels that are detrimental to the 
mammary epithelial cells, altering their morphology and cell-specific characteristics 
(Paszek & Weaver, 2004). Indeed, differential expression of the ECM components 
delineates the breast cancer subtype likely to progress (Bergamaschi et al., 2008; 
Triulzi et al., 2013). In addition, during breast cancer development and progression, 
the abnormal composition of the ECM surrounding the breast tumour cells has a 
major impact in modulating a number of biological processes namely, cell survival, 
inhibition of apoptosis, migration and invasion that control the disease progression 
(Lu et al., 2012).  
During tumorigenesis in the breast, primary tumors are characterised by 
increased deposition of FN (Christensen, 1992; Vasaturo et al., 2005). FN is known 
to stimulate breast cancer cell survival through activation and phosphorylation of 
Phosphoinositide 3-kinase (PI3-K)/protein kinase B (AKT) pathway (Xing et al., 
2008). FN is also shown to increase expression of MMP-9 (Maity, Choudhury, et al., 
2011) which is found to be associated with lymph node metastasis and higher tumour 
grades in breast cancer (Wu et al., 2008). Similarly, TN-C induces a number of 
MMPs, especially MMP-9 in breast cancer cells indicating the involvement of TN-C 
in breast cancer progression (Kalembeyi et al., 2003). Moreover, an increase in 
collagen deposition promotes cell survival and proliferation of breast cancer cells 
through up-regulation of integrin-mediated FAK signalling (Wozniak et al., 2003). 
Additionally, a growing body of experimental evidence has shown that 
multifunctional glycoprotein VN can also be involved in breast cancer progression 
and metastasis by promoting cell survival, migration and invasion (Carriero et al., 
1999; Aaboe et al., 2003; Hurt et al., 2010; Pola et al., 2013). Indeed, 
immunohistochemical evidence indicated increased deposition of VN protein at the 
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peritumoral stroma, blood vessel walls (Carriero et al., 1997) and in ECM 
surrounding breast cancer cells (Aaboe et al., 2003), with the VN-binding integrins 
and urokinase also being up-regulated in breast cancer cells (Andreasen et al., 1997; 
Meyer et al., 1998; Wong et al., 1998; Rezaeipoor et al., 2009).  
1.4 VITRONECTIN 
VN is a multifunctional adhesive glycoprotein and was first discovered as a 
protein that induced the immediate growth of unadapted cells in culture in vitro 
(Holmes, 1967). Initially, due to its cell attachment promoting activities, VN was 
described as ‘serum spreading factor’ (Hayman et al., 1983), but has also been 
named ‘S protein’ (Jenne & Stanley, 1985); and ‘heparopexin’ (Stanley, 1986). VN, 
with its high degree of conformational flexibility and multimerisation, can exist in 
both monomeric (native) and multimeric (denatured) forms, which along with its 
numerous binding domains can confer unique multivalent properties, especially 
within ECM sites (Stockmann et al., 1993; Seiffert & Loskutoff, 1996). In contrast to 
classical ECM proteins such as FN, collagen or laminin, VN acts as a matricellular 
protein and thereby does not contribute structurally to the ECM, but rather acts to 
coordinate cell-ECM interactions (Preissner & Reuning, 2011). Multimeric VN is a 
constituent of the ECM and platelet cells, while monomeric VN is found in the 
circulation. VN is synthesised predominantly by the liver and is present at high 
concentrations in the circulation (300 to 400 μg/mL) (Izumi et al., 1989; Boyd et al., 
1993). Normal tissues generally lack VN immunoreactivity, however, VN deposition 
is enriched in areas of tissue injury, including membranous nephropathy, 
arteriosclerosis, degenerative central nervous system disorders and cancers (Reilly & 
Nash, 1988; Seiffert, 1997). Immobilised VN with high molecular weight and altered 
configuration is associated with abnormal ECM composition, and it is normally 
found in areas of sclerosis or fibrosis predominantly in the multimeric form of its 
structure (Preissner & Reuning, 2011).  
1.4.1 Structure of VN  
VN is a 75 kDa protein containing 459 amino acids and is secreted from its site 
of production, hepatic cells, through a cleaved leader peptide of 19 residues upon 
processing (Jenne & Stanley, 1985). VN as a glycoprotein with adhesive properties 
contains three glycosylation sites, with its carbohydrate moiety accounting for 
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approximately one-third of its molecular mass. While its three dimensional structure 
remains unknown, VN contains six domains and multiple binding sites for cells and 
other components of the ECM (Schvartz et al., 1999). These include, starting from 
the N-terminus, somatomedin-B domain (SMB), Arginine-Glycine-Aspartate (RGD) 
motif, a connecting region and two hemopexin-like (HX) domains, the second one of 
which contains the heparin binding domain (HBD) (Figure 1.2). 
The SMB domain (residues 1 – 44) contains amino acid residues involved in 
binding plasminogen activator inhibitor-1 (PAI-1) and urokinase-type plasminogen 
activator receptor (uPAR) (Seiffert & Loskutoff, 1991), via which VN can regulate 
cell adhesion and migration (Wei et al., 1994). Located next to the SMB domain, VN 
contains an Arginine-Glycine-Aspartate (RGD) recognition sequence (residues 45 – 
47) through which it binds a variety of integrin receptors, including αvβ1, αvβ3, αvβ5, 
αvβ6, αvβ8 and αIIbβ3 (Felding-Habermann & Cheresh, 1993). Downstream of the 
RGD sequence there is a stretch of acidic amino acids (residues 53 – 64) sitting 
within the connecting linker domain (residues 48 – 130) which are involved in 
binding thrombin-antithrombin (TAT) complexes (Gechtman et al., 1997), and 
collagen (Izumi et al., 1988). Through an ionic interaction this acidic segment is also 
known to help neutralise the basic region presented at the carboxyterminal end 
(residues 348 – 379) (Stockmann et al., 1993).  This may help stabilise VN’s three 
dimensional structure (Schvartz et al., 1999) and is also thought to be involved in its 
ability to form multimeric forms (Tomasini & Mosher, 1991). Located within the 
HX-2 at the carboxy-terminus edge (residues 332 – 348) is the binding site for 
plasminogen (Kost et al., 1992). Downstream of this domain also accommodates a 
cluster of basic amino acids (residues 348 – 376), containing binding sites for 
heparin, glycosaminoglycans (Liang et al., 1997) and plasminogen activator inhibitor 
1 (PAI-1) (Gechtman et al., 1997). The relative binding positions of proteins 
interacting with VN are outlined in Figure 1.2.  
VN also contains consensus sequences for phosphorylation by various protein 
kinases, including cAMP-dependent protein kinase, protein kinase C and casein 
kinase II (CK2), which modulate its conformation as well as function (Shaltiel et al., 
1993; Seger et al., 1998). For example, phosphorylation of VN at its Thr
50
 and Thr
57 
by CK2 is shown to promote VN-induced cell adhesion and migration (Seger et al., 
1998). Additionally, a number of matrix associated proteins are also found to bind to 
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VN, however the precise effect of these interactions has not yet been identified. For 
instance, matrix Gla protein (MGP) is found to bind VN which is thought to be 
important for regulation of growth factors and morphogens, such as TGFβ and 
human bone morphogenetic protein 2 (BMP-2) to regulate cellular development 
through migration and differentiation (Nishimoto & Nishimoto, 2005). More 
recently, matricellular cysteine-rich angiogenic inducer 61 (Cyr61) was found to bind 
to the SMB domain of both monomeric or multimeric forms of VN with high affinity 
(Francischetti et al., 2010). Upon association with the ECM, VN from its original 
closed state becomes “denatured”, or unfolded, and exposes previously cryptic 
binding domains to form VN multimers, in turn facilitating the binding of VN to 
other ligands (Morris et al., 1994). Indeed, VN exists within the ECM in the 
multimeric form which can exert preferential binding to several ligands including 
integrins, collagen, PAI-1 and uPAR mediating its multifunctional effects (Seiffert, 
1997; Felding-Habermann et al., 2001).  
 
Figure 1.1. Schematic representation of the domain structure and key binding regions within VN. 
VN includes the somatomedin-B domain (SMB), the integrin-binding RGD domain (RGD), the 
connecting region (CON) and two hemopexin-like domains (HX-1 and HX-2). The N-terminus (N-) 
binding sites within VN include those for PAI-I/uPAR (residues 1-44), integrins (45-47), TAT 
complex and collagen (48-64). Binding sites within the C-terminus (-C) include those for Plasminogen 
(332-342) and PAI-I/Heparin (343-376). A 19 amino acid signal peptide is cleaved to form the mature 
459-amino acid protein (reviewed in Schvartz et al., 1999). 
1.4.2 Function of VN 
VN is capable of modulating numerous biological functions. These include 
vascular remodelling, thrombosis, hemostasis, fibrinolysis and immune defense 
through coordination of cell adhesion, survival, and migration primarily by specific 
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binding interactions with cell surface urokinase and integrin receptors, in particular 
αv-subunit containing integrins (Preissner & Seiffert, 1998; Schvartz et al., 1999). 
Through interactions with uPAR, VN can mediate cell attachment (Wei et al., 1994) 
while also promoting cell migration through PAI-1 regulation of interactions 
between uPAR and VN (Waltz et al., 1997). It is also believed that the direct 
engagement of uPAR by VN can influence the activation state of integrins as well as 
integrin-mediated adhesion to VN (Madsen & Sidenius, 2008). This is supported by 
various studies showing that uPAR interacts with different integrins to promote  VN 
signalling, leading to enhanced cell adhesion or migration in a variety of cell types 
(Degryse et al., 2001; Wei et al., 2001; Wei et al., 2007). Increased cellular migration 
and invasion is thought to be mediated by the co-localisation of VN-binding uPAR 
and the αvβ5 integrin within focal contacts of human keratinocytes (Reinartz et al., 
1995) and breast cancer cells (Carriero et al., 1999).  
VN can also mediates attachment and migration of cells within the ECM via 
ligation of VN-binding integrins, including αvβ1, αvβ3, αvβ5 and αvβ6, (Felding-
Habermann & Cheresh, 1993). VN ligation of integrins causes integrins to become 
clustered in the plane of the cell membrane, which leads to the formation of focal 
adhesion contacts linking the cells to the ECM (Giancotti & Ruoslahti, 1999). These 
focal adhesions are essentially large clusters of integrins, cytoskeletal proteins, 
growth factors and signalling molecules that facilitate integrin signalling and are 
critical for cell survival and proliferation. In endothelial cells, VN/αvβ3 ligation is 
shown to induce survival via Nuclear Factor- kappa B (NF-қB) pathway activation 
(Scatena et al., 1998). Likewise, VN engagement with β1, β3 and β5 integrin subunits 
has been observed to modulate neutrophil survival through integrin activated 
signalling pathways (Bae et al., 2012). Furthermore, treatment of human umbilical 
vein endothelial cell (HUVEC) cells with VN also induced their migration through a 
αvβ3-dependent pathway (Naik & Naik, 2006). Taken together, it is no surprise that 
VN interactions with integrins, which are frequently overexpressed in a variety of 
cancers (Mizejewski, 1999), including breast cancer (Meyer et al., 1998) can 
modulate cellular processes important in cancer progression.. Indeed, in cancer 
biology, ECM-integrin engagement is known to not only be critical for coordinating 
key biological functions, such as adhesion, migration, survival or death responses 
(Stupack & Cheresh, 2002; Mitra & Schlaepfer, 2006), but can also directly 
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influence the tumour growth as well as its microenvironment (Desgrosellier & 
Cheresh, 2010). 
1.5 INTEGRIN SIGNALLING  
Integrin signalling is complex as the cytoplasmic domains of these receptors 
are extremely short and lack kinase activity. However, ligation of integrins causes 
the phosphorylation of a number of cytoplasmic proteins via the association of 
adapter proteins. A majority of the signalling molecules implicated in ECM-integrin 
interactions appear to be rather ubiquitous mediators of signal transduction. For 
example, protein kinases including, focal adhesion kinase (FAK), Src family kinases, 
Rho family of GTPases, Raf kinases, PI3-K, and Mitogen-activated protein kinases 
(MAPKs) such as Extracellular signal-regulated kinase (ERK), can be recruited to 
the ECM-integrin binding site (Giancotti & Ruoslahti, 1999; Stupack & Cheresh, 
2002) (Figure 1.3). However, a major hub of integrin signalling is the recruitment 
and activation of FAK, a cytoplasmic protein kinase that co-localises within focal 
adhesion sites (Mitra & Schlaepfer, 2006).  
Upon ligation of integrins, FAK is auto-phosphorylated on Tyr
397
 causing a high-
affinity binding site for the SH2 domain of Src-family kinases which subsequently 
lead to the recruitment and activation of Src through the formation of a dual kinase 
complex (Giancotti & Ruoslahti, 1999). Formation of the FAK-Src complex can 
phosphorylate various adaptor proteins such as paxillin (Bellis et al., 1995) and 
p130Cas (Cary et al., 1998) as well as a number of kinases, such as PI3-K, ERK and 
myosin light chain kinase (MLCK) (Schlaepfer et al., 2004; Webb et al., 2004). 
Phosphorylation of paxillin and p130Cas recruit the Crk-DOCK180 complex which 
subsequently activates Rac, a prototypical member of the Rho family, leading to 
activation of p21-activated kinase (PAK), Jun amino-terminal kinase (JNK), and NF-
κB (Parsons & Parsons, 1997; Schlaepfer & Hunter, 1998; Cary et al., 1999). 
Additionally, FAK phosphorylation recruits the SH domain of PI3-K, allowing 
translocation of PI3-K-p110 complex (Fruman et al., 1998), leading to 
phosphorylation of lipid second messengers such as phosphatidylinositol-3,4,5-
trisphosphate (PIP3) to bind and recruit AKT (Persad et al., 2001). Morever, FAK 
phosphorylation activates ERK/MAPK by recruiting the RAP1 guanine nucleotide-
exchange factor (GEF) and subsequent activation of proto-oncogene B-Raf (Guo & 
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Giancotti, 2004). Alternatively, FAK-Src complex can activate ERK/MAPK by 
requirement and phosphorylation of the growth factor receptor bound-2 (Grb2) and 
son-of-sevenless (SOS) complex (Wary et al., 1998) (Figure 1.3). These physical 
cues mediated by constituents of the ECM such as adhesive proteins can control cell 
behaviour and functions directly through regulation of gene expression programs 
(Kim et al., 2011). 
 
Figure 1.2. Schematic representations of major signalling pathways stimulated upon ligand-binding to 
integrin receptors. 
 Binding of VN, present within the ECM, to its corresponding integrin receptors leads to the formation 
of FAK-Src complexes which activate downstream signalling pathways, including PI3-K/AKT, JNK, 
NF-ҚB and ERK/MAPK pathways. Activation and recruitment of these pathways regulates changes in 
the gene expression, promoting key cellular functions (reviewed in Guo and Giancotti 2004).  
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1.6 ECM-INDUCED CHANGES IN GENE EXPRESSION  
Recruitment and activation of many aforementioned signalling pathways can 
influence cellular behaviour and function by mediating changes in downstream gene 
expression programs. For instance, collagen type I-induced β1 integrin clustering 
increases expression of the membrane type-1 MMP (MT1-MMP), a major 
transmembrane collagenase expressed by ovarian tumours as well as early growth 
response protein 1 (EGR1) through a Src kinase dependent pathway to regulate 
ovarian cancer cell invasion and metastasis (Barbolina et al., 2007). Collagen type 
I/αvβ3 integrin engagement has also been shown to initiate EMT in lung cancer cells 
by up-regulation of transforming growth factor β (TGFβ)-1 and -3 via activation and 
involvement of PI3-K and ERK cascades (Shintani et al., 2008). VN ligation to 
integrin αvβ3 is reported to enhance ovarian cancer cell adhesion, proliferation and 
invasion by differential expression of a number of genes, including EGF receptor, 
integrin-linked kinase (ILK), c-myc, prothymosin-α (PTMA), the transcription factor 
fos-related antigen (Fra-1), and the cell adhesion molecule SQM-1 with key roles in 
these cellular processes (Hapke et al., 2003). Moreover, FN-binding integrin α5β1 
induced down-regulation of the tumour suppressor genes LKB1 and EIF4EBP1 
through activation of the Akt/mammalian target of rapamycin (mTOR)/p70S6K 
pathway can stimulate non-small cell lung carcinoma cell (NSCLC) cell 
proliferation, invasion and metastasis (Han et al., 2006). In breast cancer cells, 
FN/α5β1 engagement induced MMP-9 expression and activity by recruiting ILK, 
FAK, PI3-K and NF-κB cascades (Maity, Choudhury, et al., 2011). Likewise, 
laminin, via binding to α2β1 integrin up-regulated MMP-9 mRNA expression in 
human cervical cancer cell via recruitment of similar pathways (Maity, Sen, et al., 
2011). MMPs are proteolytic enzymes that are necessary for tissue remodelling and 
growth. The overall levels and the activation of the MMPs are known to be higher in 
tumours compared to their corresponding normal tissues (Egeblad & Werb, 2002). It 
is likely that altered ECM composition found in tumour tissues are contributing 
either directly or indirectly to the changes in MMP levels as well as its growth and 
development. 
1.7 VN IN CANCER PROGRESSION 
Immunohistochemical studies have reported increased accumulation of VN in a 
number of human tumours (Gladson & Cheresh, 1991; Tomasini-Johansson et al., 
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1994; Aaboe et al., 2003; Edwards et al., 2006). VN has been identified in breast 
carcinomas where it has been found in the peritumoral stroma, blood vessel walls 
(Carriero et al., 1997) and in the ECM surrounding cancer cells (Aaboe et al., 2003). 
VN can modulate cancer metastasis, by providing traction and direction to migrating 
tumour cells during invasion, and/or migrating endothelial cells during angiogenesis 
(Bello et al., 2001; Aaboe et al., 2003; Pola et al., 2013), while also conferring a 
survival advantage to advancing tumour cells (Uhm et al., 1999; Leavesley et al., 
2013). The overexpression of the VN receptor αvβ3 integrin is linked to increased 
lymphatic dissemination and metastasis in melanoma cells through enhanced binding 
ability to VN in the lymph node (Nip et al., 1992). Likewise, in ovarian cancer, 
VN/αvβ3 complex is reported to result in the activation of FAK/pFAK pathway to 
ultimately promote MAPK-induced cell adhesion, proliferation and motility (Hapke 
et al., 2003). Moreover, VN is demonstrated to stimulate prostate cancer cell 
differentiation, tumour formation, invasion and metastasis through the αvβ3/FAK/Src 
pathway (Hurt et al., 2010; Franzen et al., 2012). 
In breast carcinomas, VN through interactions with αv integrins has been 
shown to induce migration in a number of breast cancer cell lines (Wong et al., 
1998). Indeed, migration of the highly metastatic MDA-MB-231 and MDA-MB-435 
breast cancer cell lines is inhibited when αvβ3 and αvβ5 VN-receptors are blocked 
with antagonists (Bartsch et al., 2003). More recently, interaction of VN and αvβ3 is 
found to mediate breast cancer cell invasion through a mechanism that involves ILK 
pathway, and mTOR activation of eukaryotic translation initiation factor 4E (EIF4E)-
dependent mRNA (Pola et al., 2013). In addition, interactions between uPAR and the 
αvβ5 VN receptor enhance breast cancer cell migration and invasion (Carriero et al., 
1999). Similarly, a strong correlation has been observed between expression of both 
PAI-1and uPAR with the invasiveness of cells derived from normal and malignant 
mammary tissue (Tong et al., 1999; Zannetti et al., 2000). Recently, small molecules 
targeting the VN-binding site of uPAR are reported to block migration in response to 
VN in a number of cancer cell types, including breast cancer (Rea et al., 2013). VN 
is also shown to drive breast cancer stem cell differentiation and ultimately initiate 
tumour formation through an αvβ3/FAK/Src-dependent pathway by altering mRNA 
expression of a number of stem cell genes, including the basal cell maker cytokeratin 
14 (K14), luminal marker cytokeratin 8 (K8), Nanog, SMO, Oct3/4 and BMI-1 (Hurt 
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et al., 2010). Additionally, Ablation of VN or disruption of its uPA and integrin 
binding sites strongly impaired tumour formation by MDA-MB-231 mammary 
carcinoma cells xenografted into mice (Pirazzoli et al., 2013).  
It is well established that stimulation of integrins and subsequent 
phosphorylation and activation of intracellular pathways by ECM components, such 
as VN, causes integrins to become clustered in the plane of the cell membrane. This 
in turn facilitates the formation of focal adhesion contacts that link the cells to the 
ECM (Giancotti & Ruoslahti, 1999). Interestingly, present within these focal 
adhesion contacts are growth factors (GFs). Indeed, integrin clustering and its 
association within focal adhesions in turn facilitate the formation of integrin-GF 
complexes that regulate cell behaviour. This in turn provides a mechanism for bi-
directional communication or “crosstalk” between receptors and regulation of  
intersecting signalling pathways that control specific cellular responses to stimuli 
originating in the extracellular microenvironment (Eliceiri, 2001; Schwartz & 
Ginsberg, 2002; Beattie et al., 2010).  
1.8 INTERACTIONS BETWEEN THE ECM, INTEGRINS, GROWTH 
FACTORS AND THEIR RECEPTORS  
Integrins are reported to facilitate crosstalk with numerous GF receptors and to 
modulate various cellular functions and behaviours, suggesting a potentially 
important role for these interactions in cancer biology. For example, FN regulates 
migration of mesenchymal stem cells (MSCs) during vascular remodelling via αvβ5 
integrin-mediated activation of platelet-derived growth factor receptor (PDGFR) and 
phosphorylation of FAK which subsequently mediates PDGFR-induced PI3-K 
activity (Veevers-Lowe et al., 2011). Interestingly, FAK is known to act as a 
receptor-proximal bridging protein that links integrin and GF receptor signalling 
pathways that activate the GF receptors through its N-terminal domain important for 
both integrin and GF stimulated effects (Sieg et al., 2000). Indeed, inhibition of both 
FAK and epidermal growth factor receptor (EGFR) pathways induces apoptosis in 
human breast cancer cells (Golubovskaya et al., 2002). Similarly, FAK and IGF-IR 
pathway association has been shown to be critical for human pancreatic 
adenocarcinoma cell survival (Liu et al., 2008). The αvβ5 integrin and EGFR 
crosstalk has been reported to promote pancreatic carcinoma cell invasion and 
metastasis through EGF-mediated recruitment of Src kinase and αvβ5 activation 
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(Ricono et al., 2009). In addition to EGF, IGF-I is also known to interact with 
integrin system whereby the IGF-I-mediated adhesion and migration of human 
melanoma cells was observed to be dependent on β1 integrin activation and PI3-K 
phosphorylation (Tai et al., 2003). On the other hand, regulation of EGFR signalling 
by β1 integrins has roles in the maintenance of tumorigenic properties of lung cancer 
cells (Morello et al., 2011). Interactions between β3 integrin and the TGFβ type II 
receptor lead to enhanced TGFβ-stimulated MAPK activation, Smad-2/-3/-4-
mediated gene transcription and subsequently induction of EMT in mammary 
epithelial cells (Galliher & Schiemann, 2006). Additionally, it has been suggested 
that a number of integrins such as αvβ3, αvβ6 and α6β4 cooperate with receptor 
tyrosine kinases (RTKs) to promote cancer cell invasion and metastasis (Guo & 
Giancotti, 2004). Indeed the association between integrins and growth factor 
receptors can lead to partial activation of the growth factor receptor, thereby bringing 
growth factor signalling closer to a threshold point of initiating activity (Moro et al., 
1998).  
In addition to the GF receptor-integrin crosstalk, several growth factors 
modulate their activity by directly binding to the integrins (Eliceiri 2001). For 
example, direct binding of αvβ3 integrin and TGFβ1 mediates EMT in mammary 
epithelial cells (Galliher & Schiemann, 2006). Likewise, it was found that 
αvβ3/VEGF axis plays an important role in pathological angiogenesis via direct 
involvement of Src family kinases (Mahabeleshwar et al., 2006; Mahabeleshwar et 
al., 2007). In addition, the α9β1 integrin dependent binding of nerve growth factor 
(NGF) is also found to have pro-angiogenic activities in glial tumours (Walsh et al., 
2012). The VEGF ligation to α9β1 induced migration and invasion of primary 
HUVECs and human dermal microvascular endothelial cells (HMVECs) through the 
direct activation of the integrin signalling intermediates Src and FAK (Oommen et 
al., 2011). Interestingly, in recent studies fasciclin 1 (FAS1) domain-containing 
protein, a soluble αvβ3 integrin-binding molecule, was shown to effectively inhibit 
tumour angiogenesis by blocking not only αvβ3 integrin-, but also VEGF-mediated 
angiogenic pathways (Nam et al., 2012).  
There have been increasing reports describing the specific and direct binding of 
GFs to ECM proteins (Hynes, 2009). These ECM:GF complexes are known to 
interact through direct binding and to activate synergistic or enhance signals 
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mediating biological functions in normal and pathological conditions (Clark, 2008) 
such as wound repair (Schultz & Wysocki, 2009) and cancer development (Brizzi et 
al., 2012). Lin et al demonstrated the direct binding of FN to PDGF through its 
growth factor-binding domains (FN-GFBDs) and found this interaction to be 
required for fibroblast survival (Lin et al., 2011). Likewise, VEGF physically links to 
FN via the heparin-II domain of FN, forming FN:VEGF complex, capable of 
promoting VEGF-induced biological activities in endothelial cells such as 
proliferation and migration through strong phosphorylation of VEGF receptor and its 
downstream signalling ERK/MAPK that may be important for angiogenesis and 
tumour growth (Wijelath et al., 2006). Indeed, FN can bind to various GFs via 
multiple binding domains to synergistically enhance the biological activities of both 
integrin and GF receptors (Zhu & Clark, 2014). In addition, VN is found to bind 
IGF-I and IGF-II, forming IGF-I:VN and IGF-II:VN complexes (Kricker et al., 
2003) that are capable of stimulating breast cancer cell migration and survival via 
activation of IGF-IR, PI3-K/AKT and ERK/MAPK (Hollier et al., 2008; Kashyap et 
al., 2011). Furthermore, antagonists to integrin signalling have also been shown to 
abrogate growth factor receptor-mediated signalling (Beattie et al., 2010), including 
the IGF-IR (Hollier et al., 2008). Altogether, this indicates an important role for the 
interaction between VN and its many binding partners, including integrin receptors, 
and their cross-talk with various signalling systems in processes essential to tissue 
remodelling and cancer progression. 
1.8.1 Interactions between VN, VN-binding integrins and IGF system  
There is strong evidence for crosstalk being frequently observed between the 
different receptor-mediated signalling systems even when they are not known to be 
directly linked to each other. This is also the case for members of the IGF system, 
where the interplay between IGF signalling and integrin-mediated signalling can 
modulate IGF biology in normal health and disease states (Beattie et al., 2010). IGF-
I-dependent co-precipitation of IGF-IR clearly demonstrates the presence of αvβ3 
integrin (Siwanowicz et al., 2005; Saegusa et al., 2009) and β1 integrin interaction 
with the IGF-IR (Kiely et al., 2006). The β3 integrin binding site on IGFBP-4 is also 
distinct from the IGF-I binding site (Siwanowicz et al., 2005). It is known that the 
ligand occupancy of the VN-binding αvβ3 integrin promotes phosphorylation and 
activity of the IGF-IR (Maile & Clemmons, 2002) and affects IGF and integrin 
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signalling mediated by insulin receptor substrate 1 (IRS-1), SHC Src homology 2 
domain containing (Shc), PI3K and MAPK (Clemmons & Maile, 2003, 2005). 
Studies have shown that αvβ3-integrin occupancy by VN was required for IGF-I 
stimulated migration of smooth muscle cells (SMC) (Jones et al., 1996; Zheng & 
Clemmons, 1998). Transfection of a mutant β3-integrin subunit into Chinese hamster 
ovarian (CHO) and SMC cells indicated that full length β3-integrin was required for 
subsequent IGF-I-induced cell migration in a wound assay model (Maile et al., 
2001). Specifically, the VN-binding domain (177CYDMKTTC184) in the β3-integrin is 
directly involved in the IGF-signalling cascade (Maile et al., 2006), whereas the C-
loop region of β3-integrin is critical for VN-induced enhancement of IGF-I signalling 
and IGF-I-stimulated cell proliferation (Xi et al., 2008).  
While the mechanisms outlined regarding SMCs may be specific for αvβ3 in 
modulating IGF-I responses, there is also evidence that other VN-binding integrins 
regulate cellular responses to IGFs. It has been reported that VN binding to αvβ5 
integrin is required for IGF-I-stimulated cell migration of the MCF-7 breast 
carcinoma cell line (Doerr & Jones, 1996). Similarly, melanoma cells expressing 
αvβ5 required insulin or IGF-I stimulation for migration on VN, whereas cells 
expressing αvβ3 supported IGF-independent migration (Brooks et al., 1997). 
Furthermore, Syndecan-1 (Sdc1), a matrix receptor, is shown to modulate αvβ3 and 
αvβ5 integrins activity by physically coupling them with the IGF-IR in human 
mammary carcinoma and endothelial cells (Beauvais et al., 2009). Furthermore, IGF-
IR docking and activation of the associated integrin is blocked by synstatin (SSTN92–
119), a peptide derived from the integrin engagement site in Sdc1 resulting in the 
inhibition of angiogenesis and impaired tumour growth in mice (Beauvais & 
Rapraeger, 2010; Rapraeger et al., 2013).  
1.9 THE IGF SYSTEM 
The IGF system can have prominent roles in a number of human malignancies 
and has prompted researchers to unravel its mechanism of action in several 
carcinomas, including breast cancer (Burroughs et al., 1999; Sachdev & Yee, 2007; 
Pola et al., 2013). The IGF system involves highly complex regulatory networks that 
operate at the whole organism level, including cellular and sub-cellular levels that act 
through endocrine, paracrine and autocrine mechanisms (Jones & Clemmons, 1995). 
 Chapter 1: Literature Review 21 
It comprises a phylogenetically ancient family of peptides involved in mammalian 
growth and development, as well as a range of cellular processes such as cell 
proliferation, survival, migration and differentiation in normal as well as neoplastic 
conditions (De Meyts & Whittaker, 2002). The IGF family comprises the ligands 
IGF-I, IGF-II and insulin, six high affinity binding proteins (IGFBP-1 to 6) and their 
proteases, and the ligand binding cell surface receptors, namely the type-I IGF 
receptor (IGF-IR), cation independent mannose 6-phosphate/type-2 IGF receptor 
(CIMPR/IGF-IIR), the insulin receptor isoforms A and B (IR-A and IR-B) and the 
hybrid IR/IGF-IR receptors (HyRs) (reviewed in Annunziata et al., 2011; Martin & 
Baxter, 2011). Moreover, it includes proteins involved in intracellular signalling 
distal to IGF-IR, such as members of the IRS family, mTOR and AKT.  
1.9.1 IGF system ligands: IGF-I and IGF-II 
IGF-I and IGF-II are single chain polypeptide growth factors (Wood, 1995). 
The majority of IGF-I and IGF-II peptides found in the circulation are produced by 
the liver, although extra-hepatic tissues also possess the ability to synthesize IGFs 
locally where they can exert autocrine or paracrine effects. The human IGF-I and 
IGF-II genes are located on the long arm of chromosome 12 (at position 12q22-23) 
and the short arm of chromosome 11 (at position 11p15.5), respectively (Brissenden 
et al., 1984; Tricoli et al., 1984). The IGF-I has a complex structure with multiple 
promoters and contains six exons, four of which are subjected to alternative splicing 
that generates different precursors without altering the structure of the mature peptide 
(Rotwein et al., 1986; Smith et al., 2002). On the other hand, IGF-II consists of only 
three promoters, five non-coding exons and three protein coding exons (Daughaday 
& Rotwein, 1989). The mature IGF-I is a single chain basic peptide with 70 amino 
acids and a molecular weight of 7.5 kDa, while IGF-II is a single chain neutral 
peptide with 67 amino acids and a molecular weight of 7.4 kDa (Daughaday & 
Rotwein, 1989).  
IGF-I and IGF-II resemble insulin in both primary and tertiary structure. 
However, unlike insulin, IGFs retain the C-peptide of the pro-insulin, in addition to a 
small D-chain extension to the A-chain of the IGF molecule (Blundell et al., 1978; 
Rinderknecht & Humbel, 1978). Also, amino acid positions 3, 4, 15, and 16 within 
the IGF-I molecule facilitate selective binding of IGF-I to a family of six high 
affinity binding proteins (IGFBP-1 to -6) (Annunziata et al., 2011), further 
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differentiating them from insulin, which does not bind to the IGFBPs. This allows 
the majority of the IGFs (~75%) to circulate as a 150 kDa complex with the acid 
labile subunit (ALS) and IGFBPs (Baxter et al., 1989; Leong et al., 1992), while 
insulin circulates unbound. IGFs are commonly found complexed with IGFBP-3 or 
IGFBP-5 (Clemmons, 1998; Martin & Baxter, 2011). Functionally, both IGF-I and 
IGF-II play central roles in stimulating tissue growth and maintenance especially 
during fetal development (Streck et al., 1992), normal postnatal growth (Yakar et al., 
1999), tissue repair after injury (Jennische et al., 1987) and during tumorigenesis 
(Pollak, 2012). The stimulatory effect of the IGFs, in normal tissue growth and in 
disease progression, is related to their ability to induce angiogenesis, and their 
influence on cellular mechanisms that govern proliferation, differentiation, apoptosis 
and migration (Samani et al., 2007).  
1.9.2 IGF binding proteins (IGFBPs)  
The IGFs in circulation are bound to a family of six high affinity binding 
proteins called the IGFBPs. The precursor forms of all IGFBPs contain a secretory 
signal peptide which is cleaved upon secretion into their mature forms (216-289 
amino acids), with molecular masses ranging from ∼24 to 50 kDa (Firth & Baxter, 
2002; Forbes et al., 2012). There are numerous reports indicating that IGFBPs 
prolong the half-life of bound IGFs to slow the clearance of IGFs and to maintain a 
large reservoir of IGF-I and IGF-II in the circulation (approximately 100 nM). 
Importantly, many IGFBPs, specifically IGFBP-2, -3 and -5, have defined heparin-
binding domains that are known to associate with several matrix proteins (Russo et 
al., 2005; Beattie et al., 2009; Sureshbabu et al., 2009). These extracellular matrix-
bound IGFBPs might serve as reservoirs of IGFs within tissues, concentrating IGFs 
in close proximity to the IGF-IR to mediate receptor activation (Jones et al., 1993; 
Beattie et al., 2010; Martin & Baxter, 2011). In addition, via its interaction with 
matrix proteins such as VN and FN, IGFBP-bound IGFs may enhance signalling by 
activating integrin and IGF-IR−integrin system cross-talk (Hollier et al., 2008). The 
increased proteolytic activities observed in the ECM of neoplastic tissues or tissues 
undergoing active remodelling, may lower the affinity of matrix-bound IGFBPs to 
IGFs, allowing for increased receptor activation (Yan et al., 2004). 
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1.9.3 Type-I IGF receptor (IGF-IR)  
The IGF-IR is a transmembrane tyrosine kinase receptor that mediates the 
effects of IGF-I and IGF-II. IGF-IR is a heterotetrameric protein, consisting of two 
di-sulphide bond-linked α- and β-subunits (Ulrich et al., 1986). The cysteine-rich α-
subunits are extracellular and form the ligand-binding domain, while the β-subunits, 
which contain short extracellular and transmembrane segments and a larger 
intracellular segment, transmit the ligand-induced signal (LeRoith et al., 1995). The 
IGF ligands bind to IGF-IR at the α-subunit, with a 4-fold higher affinity for IGF-I 
compared to IGF-II (Forbes et al., 2002). 
1.9.4 IGF-IR: Signalling 
Ligand binding to IGF-IR triggers the activation of several receptor substrates, 
including the IRS and Shc (Butler et al., 1998; Samani & Brodt, 2001). 
Phosphorylated IRS-1 activates the p85 subunit of PI3-K, which in turn activating 
AKT cascade (Giorgetti et al., 1993) to stimulate protein synthesis and to prevent 
apoptosis (Gilmore et al., 2002). IRS-1 is also involved in signalling events mediated 
by other growth factors (Siddle, 2012) and integrins, such as αvβ3 (Maile & 
Clemmons, 2002) and β1 (Wang et al., 2007), and may be an important part of the 
crosstalk between the different signalling systems. Phosphorylated IRS-1 can also 
recruit Grb2/SOS to activate the Raf-1/MEK/ERK pathway and other nuclear factors, 
resulting in cell proliferation (Hermanto et al., 2000; Grey et al., 2003). The 
dysregulation or hyperactivation of these pathways can have significant effects on 
the development of malignant tumours (Santarpia et al., 2012; Sheppard et al., 2012), 
including breast cancer (Samani et al., 2007).  
1.9.5 Type-2 IGF receptor (IGF-IIR)  
The typeII-IGF receptor (IGF-IIR) is a monomeric receptor that binds with 
high affinity to IGF-II (Morgan et al., 1987). The IGF-IIR is not a tyrosine kinase 
receptor (El-Shewy et al., 2007), but it is involved in the lysosomal degradation of 
various proteins including IGF-II and mannose-6-phosphate containing proteins to 
control their extracellular availability (Pollak et al., 2004; Brown et al., 2009) 
Although IGF-IIR is not directly involved in tyrosine kinase dependent signalling 
pathways, evidence suggests that IGF-IIR can modulate the activities of G-proteins 
to influence downstream signal transduction. Supporting this view, IGF-II/IGF-IIR 
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binding has been shown to activate ERK1/2 signalling to promote cell survival (El-
Shewy et al., 2007). 
1.10 THE IGF SYSTEM AND BREAST CANCER  
The IGF system plays a key role in the biological functions of various tissues, 
with a highly controlled regulatory network to reflect its importance in maintaining 
the normal tissue phenotype. Likewise, the IGF system is also heavily involved in 
tumour development, especially that of breast cancer (Maki, 2010; Becker et al., 
2011; Gallagher & LeRoith, 2011; Franks et al., 2012; Baxter, 2014). 
Epidemiological studies have suggested that elevated circulating levels of IGF-I can 
be associated with an increased risk of breast cancer among premenopausal women 
(Hankinson et al., 1998; Toniolo et al., 2000). IGF-I can rescue breast cancer cells 
from chemotherapy-induced cell death by induction of proliferation and inhibition of 
apoptosis (Gooch et al., 1999). Stimulation of breast cancer cells by IGF-I has been 
shown to stimulate a gene expression signature that most closely resembles basal-like 
(ER and HER2 negative) and the majority of luminal-B subtype tumours (ER 
positive but highly proliferative disease) which are highly correlated with poor 
clinical outcomes (Creighton et al., 2008).  
In vitro and in vivo studies suggested that IGF-II plays an important role in 
promoting angiogenesis (Kim et al., 1998; Bid et al., 2012), a process critical to the 
growth of cancer cell. This is evidenced by highly vascularised tumours displaying 
increased IGF-II expression in the stroma during the transition of normal epithelium 
to dysplastic and neoplastic breast disease (Heffelfinger et al., 1999). This stromal-
epithelial interaction is also thought to be critical for IGF action on breast cancer 
cells, as IGF-I and IGF-II are predominantly of stromal origin (Giani et al., 2002), 
with IGF-II also expressed by some breast epithelial cells (Yee et al., 1988).  
In vitro and in vivo evidence strongly suggests that IGF-IR, the predominant 
receptor for the IGF system, plays a key role in breast cancer progression. IGF-IR is 
reported to be 14-fold higher in malignant breast cancer tissue compared to normal 
breast tissue (Resnik et al., 1998). Overexpression of IGF-IR in breast epithelial cells 
disrupts mammary ductal morphogenesis (Yanochko & Eckhart, 2006) and 
predominantly induces the formation of basal-like breast tumours (Franks et al., 
2012). There is also evidence linking IGF-IR hyperphosphorylation with the early 
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stages of breast cancer, and primary breast tumours, with high IGF-IR levels being 
associated with shorter disease-free survival (Surmacz, 2000; Samani et al., 2007; 
Yerushalmi et al., 2012). Indeed the direct targeting of IGF-IR mRNA using 
antisense oligonuclietides by either direct intra-tumour or systemic administration of 
phosphorothioate antisense oligonucleotide (AS[S]ODNs) reduced mammary tumour 
growth in mouse models (Salatino et al., 2004).  
As noted earlier, the biological effects of IGF ligands and their signalling can 
be modulated by various ECM components and their binding receptors, including 
VN and VN-binding integrin receptors. Furthermore, integrin antagonists have also 
been shown to block IGF-IR-mediated signalling, suggesting the existence of 
crosstalk between growth factor and the integrin-mediated signalling pathways 
(Beattie et al., 2010). In addition, IGF-I co-precipitation of IGF-IR occurs in the 
presence of αvβ3 integrin (Siwanowicz et al., 2005; Saegusa et al., 2009) and β1 
integrin interaction with the IGF-IR (Kiely et al., 2006). Moreover, the β3 integrin 
binding site on IGFBP-4 is reported to be distanced from the IGF-I binding site 
(Siwanowicz et al., 2005), suggesting that IGF-IGFBP complexes may also interact 
with β3-integrin subunits. Furthermore, intracellular signalling mediated by the IGF-
I:IGFBP association with VN required the activation of both the IGF-IR and VN-
binding integrins (Hollier et al., 2008). As the members of the IGF system and the 
VN/integrin axis lie in close proximity to each other on the cell surface the adhesion 
to VN and/or VN-containing IGF:VN complexe promote receptor cross-activation to 
synergistically enhance cell survival and migration. Indeed, the dual nature of 
activation of IGF-I and the integrin axes has recently been exploited to produce 
chimeric IGF-VN ligands (Van Lonkhuyzen et al., 2007; Upton et al., 2008). These 
chimeric molecules can simultaneously engage the IGF-IR and integrins to stimulate 
migration of MCF-7 breast cancer cells (Van Lonkhuyzen et al., 2007; Kricker et al., 
2010). 
1.11 EVIDENCE FROM THE TRR LABORATORY SUPPORTING THE 
ROLE OF VN AND IGF INTERACTIONS IN BREAST CANCER 
PROGRESSION 
Research undertaken in the Tissue Repair and Regeneration (TRR) laboratory 
at QUT has led to the discovery that IGF-II binds directly to VN to form a dimeric 
IGF-II:VN complex (Upton et al., 1999). Furthemore, it was also found that IGF-I 
 Chapter 1: Literature Review 26 
can form trimeric IGF-I:IGFBP:VN complexes through the association of IGF-I with 
VN via IGFBP-2, -3, -4 and -5 (Kricker et al., 2003). Moreover, functional studies 
revealed that the proliferation and migration of several epithelial cells, including 
HaCaT keratinocytes and corneal epithelial cells are enhanced in the presence of the 
dimeric IGF-II:VN (Upton and Kricker, 2002; Hyde et al., 2004) and trimeric IGF-
I:IGFBP:VN complex (Hollier et al., 2005; Ainscough et al., 2006; Kricker et al., 
2010).  
As outlined in the previous section, given that there is a crosstalk between the 
IGF system and VN/VN-binding integrins, and that members of both these protein 
families have been shown to be overexpressed in breast cancer, the effects of these 
complexes on breast cell function is an important area of research in breast cancer 
biology. Indeed studies have shown that the IGF-II:VN complex (Noble et al., 2003) 
and the IGF-I:IGFBP-5:VN complex can stimulate the migration of MCF-7 cells in 
vitro, and that it is mediated through the IGF-IR only in the presence of the 
multimeric complexes (Hollier et al., 2008). Furthermore, results from previous 
studies indicated that both MCF-7 breast cancer cells and the non-tumorigenic 
MCF10A breast epithelial cell line show increased migration in response to the IGF-
I:IGFBP:VN complex (Hollier et al., 2008). These effects were shown to be 
mediated through the sustained activation of the PI3-K/AKT pathway and the 
transient activation of the ERK/MAPK pathway (Hollier et al., 2008; Kashyap et al., 
2011). Furthermore, function blocking antibodies against the IGF-IR and αv integrins 
demonstrated the activation of both these receptors, in essence IGF-IR/integrin cross-
talk, was critical for the IGF-I:IGFBP:VN-stimulated migratory effects (Hollier et 
al., 2008). 
Global gene expression analysis of MCF-7 breast cancer cells stimulated to 
migrate through Transwells
™
 in response to IGF-I:IGFBP:VN complex has identified 
a number of genes, such as stratifin (SFN), tissue factor (TF), ephrin-B2 (EFNB2) 
and sharp-2, to be uniquely dysregulated in these migrated cells (Kashyap et al., 
2011). These genes are known components of the IGF:VN/integrins axis and have 
well documented roles in cell migration and/or survival. Further functional studies 
revealed that TF and SFN play important roles in the IGF-I:IGFBP:VN complex-
stimulated breast cancer cell migration (Dr Abhishek Kashyap, PhD thesis). 
Additionally, cell survival was also investigated wherein the trimeric IGF-
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I:IGFBP:VN complex stimulated growth and viability of breast cancer cells in 2D 
and 3D cultures (Dr Abhishek Kashyap, PhD thesis) and protected these cells from 
drug-induced apoptosis (Kashyap et al., 2011). However, further studies need to be 
undertaken to identify the downstream molecular mediators of IGF-I:IGFBP:VN-
stimulated breast cancer cell survival and functionally validate the involvement of 
candidate target genes in this biological response. 
1.12 CONCLUSION AND KNOWLEDGE GAPS 
This literature review summarised the current knowledge supporting the 
critical role of ECM proteins and their integrin binding receptors in cell behaviour 
and function, and how its dysregulation is associated with cancer development and 
progression. VN is one such ECM protein which has been shown to play an 
important role in regulating a number of key biological functions, in particular, cell 
survival and migration during cancer progression. However, there remains a large 
gap in our understanding of specific mediators of VN-induced biological functions. 
Furthermore, this review highlighted the key and often overlooked influence of the 
ECM on the way cells respond to growth factors, specifically during breast cancer 
progression. Indeed, it was shown that VN, its αv integrin receptors and the IGF 
system were all frequently overexpressed in several types of breast cancer. It i also 
reported that interactions between these proteins could lead to increased breast 
cancer cell migration via dysregulation of a number of important downstream 
molecular mediators. These IGF:VN interactions were also found to be potent 
stimulators of cell viability and drug-induced apoptosis in breast cancer cells. 
Currently, no study has investigated the gene expression programs altered by VN 
and/or the IGF:VN complexes in the context of breast cancer cell survival. Indeed, 
identification of such changes in gene expression will not only increase our 
understanding of the mechanisms responsible for VN- and the IGF:VN complex-
stimulated survival, but may also provide insights into the early molecular events 
promoting breast cancer metastasis.  
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1.13  PROJECT OUTLINE  
1.13.1 Hypotheses 
The underlying hypotheses explored in my PhD studies were: 
1) Breast cancer cells that have survived in response to VN and the 
IGF:VN complexes differentially express genes with roles in cell 
survival; 
2) Differential expression of the candidate genes cysteine rich angiogenic 
inducer 61 (Cyr61) and connective tissue growth factor (CTGF) by VN 
and the IGF:VN complexes are mediated via the αv integrin and 
activation of downstream Src, MAPK/ERK and PI3-K/AKT signalling 
pathways; and 
3) VN- and the IGF-I:VN complex-induced breast cancer cell survival will 
be inhibited upon the downregulation of either Cyr61 and/or CTGF 
genes.  
1.13.2 Aims 
In order to address the aforementioned hypotheses, the aims of my PhD studies 
were to: 
1) Use microarray expression profiling to screen for candidate genes 
involved in VN- and IGF:VN complex-induced breast cancer cell 
survival; 
2) Identify differentially expressed candidate genes with important roles in 
breast cancer cell survival utilizing ingenuity pathway knowledge base 
and gene ontology analyses; 
3) Investigate the possible mechanisms underlying regulation of candidate 
genes by VN and the IGF:VN complexes; and 
4) Functionally validate the role of the candidate genes in VN- and 
IGF:VN-induced breast cancer cell survival and migration.  
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2.1 INTRODUCTION  
All materials and methods referred to in the following results chapters are 
outlined in this chapter. Any deviations from the standard protocols are described in 
the individual results chapters where they appear.  
2.2 PROTEINS AND REAGENTS  
Human VN was purchased from Promega (NSW, Australia). Human IGF-I, 
[L24][A31]-IGF-I and IGFBP-5 were obtained from GroPep (SA, Australia). 
Fraction V Bovine Serum Albumin (BSA) was purchased from HyClone (VIC, 
Australia). Recombinant human Fibronectin (FN), polyclonal sheep anti-human 
Cyr61/CCN1 and goat anti-human CTGF/CCN2 antibodies for immunoblot analyses 
were purchased from R&D Systems (MN, USA). Recombinant human collagen type 
I was obtained from FibroGen (CA, USA). Mouse monoclonal anti-human Cyr61 
and CTGF antibodies for immunofluorescence staining were from Santa Cruz 
Biotechnology (CA, USA). Mouse monoclonal antibodies against αv-integrin subunit 
(AV1), αvβ3 (LM609), αvβ5 (P1F6), β1-subunit (P4G11) and the IgG matched control 
antibody were obtained from Chemicon (CA, USA). The pharmacological inhibitors 
LY294002, U0126 and PP2 were purchased from Merck Biosciences (Darmstadt, 
Germany). Alexa Fluor
®
-conjugated secondary antibodies, Fluorescein Diacetate 
(FDA) for staining viable cells, as well as phalloidin and DAPI (4',6-diamidino-2-
phenylindole) fluorescent stains for immunofluorescence were purchased from Life 
Technologies (VIC, Australia). AlamarBlue and Trypan blue reagents for cell 
viability measurement and TRIzol
®
 reagent for RNA extraction, SuperScript
®
 III 
first-strand cDNA synthesis kit, SYBR green qPCR master mix and 96-well plates 
for RT-PCR analysis were also purchased from Life Technologies. Direct-Zol™ 
miniprep kit for RNA purification was obtained from Zymo Research (CA, USA). 
Gene specific short hairpin RNA (shRNA) against Cyr61 and CTGF target genes 
cloned into pLKO.1 lentiviral vectors were obtained from Open Biosystems (Thermo 
Fisher Scientific; VIC, Australia). Lentiviral packaging vectors pCMV-VSV-G and 
pCMV-delta-R8.2 were purchased from Addgene (MA, USA) and the FuGENE-6 
transfection reagent was from Promega. Stbl3 E.coli competent cells were obtained 
from Life Technologies. Growth factor-reduced (GFR)-Matrigel™ and glass 
chamber slides were obtained from BD Biosciences (CA, USA). Nunclon™∆ surface 
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multi-well cell culture plates were obtained from Nalge Nunc International 
(Roskilde, Denmark) and 8-μm pore 24-well Transwells® plates were purchased from 
Corning Inc. (NY, USA). All other reagents were purchased from Sigma-Aldrich 
(NSW, Australia) unless otherwise stated.  
2.3 CELL CULTURE 
The human breast adenocarcinoma MCF-7 (Cat no. HTB-22), T47D (Cat no. 
HTB-133), MDA-MB-231 (Cat no. HTB-26) and MDA-MB-468 (Cat no. HTB-133) 
cell lines were obtained from the American Type Culture Collection (ATCC; 
Manassas, VA). HEK293T human embryonic kidney cell lines were a gift from Dr 
Brett Hollier (Institute of Health Biomedical Innovation). Fetal Bovine Serum (FBS) 
growth supplement for cell culturing was purchased from HyClone (VIC, Australia). 
All other reagents used for cell culturing, including cell culture medium and 
penicillin + streptomycin mixture were purchased from Life Technologies. MCF-7 
and T47D cell lines were maintained in Dulbecco's Modified Eagle’s 
Medium/Nutrient Mixture F-12 (DMEM/F12) medium (1:1) supplemented with 10% 
FBS whereas highly metastatic MDA-MB-231 and MDA-MB-468 cells were 
maintained in Roswell Park Memorial Institute 1640 (RPMI 1640) medium 
containing 5% FBS. HEK293T cells were maintained in DMEM high glucose 
medium (Life Technologies) containing 10% heat inactivated FBS (iFBS). All media 
were also supplemented with penicillin + streptomycin (100 µg/ml) and gentamicin 
(10 mg/mL). All cultures were passaged regularly every 2-3 days using trypsin-
EDTA detachment and stocks of cells were maintained by freezing 2 x 10
6
 cells 
suspended in liquid nitrogen cyropreservation medium, which was growth medium 
containing 40% FBS and 10% DMSO (Dimethyl sulfoxide). 
2.4 TREATMENT APPROACH FOR IN VITRO INVESTIGATIONS OF VN 
AND IGF:VN COMPLEX-INDUCED CELL FUNCTIONS  
A standard methodology employed in vitro to study the effects of growth 
factors on cells is to add the growth factors to the culture medium. This results in the 
growth factors being in a solution-phase, whereby they are constantly exposed to the 
cells. This is despite the fact that in vivo it is thought that cells within organised 
tissues respond to growth factors bound within the ECM. Therefore, in an effort to 
more accurately mimic the in vivo cellular environment this study adopted the 
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“substrate-bound” strategy of pre-binding VN with or without growth factors to 
polystyrene multi-well cell culture plates prior to cell seeding. Growth factors and 
VN suspended in serum-free medium (SFM) were pre-bound to the tissue culture 
plastic for all viability assays as well as the lower chamber/under-side of the porous 
membrane of Transwells
® 
in migration assays prior to seeding cells according to 
procedures previously described in our laboratory (Kricker et al., 2003; Noble et al., 
2003; Hyde et al., 2004; Van Lonkhuyzen et al., 2007; Hollier et al., 2008; Kashyap 
et al., 2011).  
2.4.1 Pre-binding of VN, IGF-I, IGF-II and IGFBP-5 to 6- and 96-well plates 
Previous studies within our laboratory (Hollier et al., 2008; Kashyap et al., 
2011) have shown that optimal IGF-I:IGFBP-5:VN-mediated attachment, survival 
and migration of MCF-7 cells in multi-well plates is obtained by pre-binding human 
native-IGF-I, IGFBP-5 and VN at concentrations of 30 ng/mL, 90 ng/mL and 1 
μg/mL, respectively. The optimal IGF-II:VN concentrations have also been pre-
optimised to be 100 ng/mL of human native IGF-II and 1 μg/mL of VN (Noble et al., 
2003; Hyde et al., 2004). Hence, similar concentrations of these proteins were used 
for the experiments reported throughout this study. Nunclon™ 6- or 96-well plates 
were prepared by pre-binding VN either alone or in combination with IGF-II or IGF-
I+IGFBP-5 following procedures previously described (Kricker et al., 2003; Noble et 
al., 2003; Hyde et al., 2004; Hollier et al., 2008; Kashyap et al., 2011). Briefly, 
DMEM/F12 serum-free phenol-red free medium (SFM) containing 1 μg/mL VN was 
added to culture plates and incubated for 3 hours at 37 °C. Unbound VN was 
removed and the wells were washed twice with 1 mL SFM + 0.5% BSA. 
Subsequently, growth factors suspended in 0.5 mL SFM + 0.05% BSA containing 
native IGF-I (30 ng/mL), IGFBP-5 (90 ng/mL) or IGF-II (100 ng/mL), either alone 
or in combinations, were added to the culture plates and incubated overnight at 4 °C. 
Following day the solution containing unbound growth factors was removed and the 
wells were washed twice with SFM + 0.05% BSA and replaced with SFM + 0.05% 
BSA prior to cell seeding. All volumes added were adjusted to compensate for the 
relative differences in the culture surface areas, with volumes being 2 mL for 6-well 
plates and 100 μL for 96-well plates. 
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2.4.2 Pre-binding of VN, IGF-I and IGFBP-5 to Transwells® 
Cell migration in response to VN and IGF-I:IGFBP:VN complexes was 
assessed using the 8-μm pore 24-well Transwell® plates (Corning Inc.). Pre-binding 
of VN, either alone or in combination with IGF-I and IGFBP-5 to the lower chamber 
and under-side of the Transwell
® 
membrane was carried out according to the 
procedures used to pre-bind 6-well and 96-well plates (outlined in section 2.4.1). The 
volume added was adjusted to compensate for the relative differences in the culture 
surface areas, with volumes being 0.5 mL for Transwell
®
. 
2.5 MTS VIABILITY ASSAY 
The cells were split 1:1 24 hours prior to performing the viability assay to 
assist in synchronising the cells. The cells were serum-starved for 4 hours before 
seeding 5 x 10
3
 cells suspended in 100 μL SFM + 0.05% BSA into 96-well plates 
pre-coated with VN, either alone or in combination with IGF-II or IGF-I+IGFBP-5. 
The cells were incubated for 72 hours at 37 °C, 5% CO2 and cellular viability was 
assessed using the CellTitre 96
® 
AQueous One Solution Cell Proliferation Assay 
(MTS) (Promega). The MTS Assay is a colorimetric method for determining the 
number of viable cells in proliferation, cytotoxicity or chemosensitivity assays. The 
CellTiter 96
®
 AQueous One Solution Reagent contains a tetrazolium compound [3-
(4,5-imethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine 
ethosulfate; PES). After 72 hours, 20 μL of the MTS reagent was added into the 
spent medium in each well, incubated for 3 hours at 37 °C, 5% CO2 to allow for 
colour development and the absorbance was then recorded at 490 nm using a 96-well 
plate reader (Benchmark Plus, Bio-Rad). The quantity of formazan product as 
measured by the amount of 490 nm absorbance is directly proportional to the number 
of viable cells in culture (Cory et al., 1991). Wells containing SFM + 0.05% BSA 
medium without the cells were used as blanks. 
2.6 TRANSWELLS® MIGRATION ASSAY 
Migration assays were performed following protocols described previously by 
our laboratory (Kricker et al., 2003; Hollier et al., 2008). The cells in culture flasks 
were split 1:1 24 hours prior to performing the migration assay. The cells were 
serum-starved for 4 hours and a cell suspension containing 6 x 10
4
 cells in 200 μL 
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SFM + 0.05% BSA was seeded onto the upper-surface of the Transwell
® 
inserts pre-
coated on the underside with VN either alone or in combination with IGF-I+IGFBP-
5 and incubated for 15 hours at 37 °C, 5% CO2. Non-migrated cells from the upper-
surface were removed using cotton-swabs. The cells that had migrated to the lower-
surface of the Transwell
®
 membranes were fixed in 3.7% para-formaldehyde (20 
minutes) and stained with 0.01% Crystal Violet/PBS solution (20 minutes). The 
Transwell
®
 inserts were washed to remove excess stain and the number of cells that 
migrated to the lower-surface of the membranes was quantified by extracting the 
crystal violet stain in 10% acetic acid (10 minutes) and determining the optical 
density of the extracted stain at 595 nm using a 96-well plate reader (Benchmark 
Plus, BioRad). Transwells
®
 suspended without cells in SFM + 0.05% BSA were used 
as blanks. 
2.7 THREE-DIMENSIONAL (3D) MATRIGEL™ CULTURES 
A growing body of evidence suggests that the use of three-dimensional (3D) 
cell culture models, in contrast to the two-dimensional (2D) monolayer culture 
models, replicates more accurately depicts the microenvironment cells encounter 
within tissues; therefore the behaviour of cells cultured in 3D is more likely to 
exhibit responses observed in vivo (Abbott, 2003; Schmeichel & Bissell, 2003; 
Debnath & Brugge, 2005; Weigelt & Bissell, 2008). Hence, to confirm the findings 
from our 2D studies in a more relevant culture system, cells were grown in 3D using 
Matrigel™ as the scaffold. Matrigel™ basement membrane matrix (BD Biosciences; 
NSW, Australia) is a solubilised basement membrane preparation extracted from the 
Engelbroth-Holm-Swarm (EHS) mouse sarcoma, a tumour rich in extracellular 
matrix proteins including laminin (the major component of Matrigel™), collagen IV, 
heparan sulphate proteoglycans, and entactin/nidogen (Kleinman et al., 1986). 
Epithelial cells cultured in 3D Matrigel™ tend to grow in cell colonies resembling 
spheroids, whereas mesenchymal cells or highly invasive cancer cells tend to invade 
into the Matrigel™ and form spindle-like connections.  
The approach chosen for these assays was “3D on top” wherein the cells, 
suspended in growth medium containing 2.5% Matrigel™, were gently layered onto 
a layer of 100% Matrigel™ and allowed to form spheroids on the Matrigel™ layer. 
In the studies reported in this thesis such 3D cultures were set up to assess cell 
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proliferation, survival, invasive capabilities and the size and shape of the spheroids 
formed by the weakly metastatic MCF-7 and highly metastatic MDA-MB-231 breast 
cancer cells. Assays were performed in Nunc™ 96-well optical-bottom plates 
(Thermo Fisher Scientific; VIC, Australia) so that they were suitable for downstream 
image analyses using fluorescence or confocal microscopy. The bottom of each well 
was first layered with 30 μL of 100% Matrigel™ and 1,000 cells suspended in 100 
μL of 3D growth medium (3D-GM; DMEM/F12; 2.5% Matrigel™ + 1% FBS) were 
then seeded onto the 100% Matrigel™ layer. As these studies were performed to 
investigate the effects of the VN and IGF-I on cell behaviour, the growth factor-
reduced version of the Matrigel™ was used. The cells were then incubated at 37 °C, 
5% CO2 for three days without medium change. Care was taken to avoid dislodging 
the cells layered onto the 100% Matrigel™. Once visible spheroids of cells were 
formed (Day 3) the spent medium from the treatment-wells was removed and 
replaced with 100 μL solutions of 3D growth medium (DMEM/F12; 2.5% 
Matrigel™ + 1%FBS) containing VN (1 μg/mL) either alone or in combination with 
IGF-I (100 ng/mL) and IGFBP-5 (300 ng/mL). Solutions containing 3D growth 
medium with 1% and 5% serum served as negative and positive controls, 
respectively. To facilitate the formation of the protein complexes, the protein + 3D 
growth medium solutions were incubated at 2 hours at 37 °C, 5% CO2 prior to 
transferring into their respective wells. Duplicate wells were used for each treatment. 
The cells were then incubated at 37 °C, 5% CO2 for a further 6 days (for MDA-MB-
231 cells) or 9 days (for MCF-7 cells), with spent medium replaced every three days 
with fresh 3D growth medium containing the respective proteins. Cell morphology 
was observed every day with images recorded every three days using a phase 
contrast microscope (Nikon Eclipse TS100, Nikon; Libcombe, NSW, Australia). 
After Day 9 or 12, the cells were either subjected to AlamarBlue assay to assess cell 
survival/viability, or were processed for fluorescein diacetate (FDA) staining to be 
analysed using ImageJ software.  
2.7.1 AlamarBlue viability assay on cells grown in 3D Matrigel™ cell culture 
AlamarBlue assay was used to assess the survival/viability of cells grown in 
3D Matrigel™ cultures. AlamarBlue, also known as resazurin, is a water soluble and 
non-toxic dye that is transformed from blue colour to the highly fluorescent resorufin 
(pink) within a redox reaction process. Since the AlamarBlue assay is based on 
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fluorescence, little or no interference is recorded by the 3D Matrigel™ mesh. The 
fluorescence intensity is directly proportional to the percentage of viable cells within 
the culture.  
The AlamarBlue assay was performed following protocols reported by 
Loessner et al. (2010), with minor modifications. Briefly, spent medium was 
removed from cells grown in 3D and replaced with 100 μL of fresh 3D growth 
medium containing 5% (v/v) AlamarBlue solution (Life Technologies). AlamarBlue 
added to wells with 3D growth medium without cells served as blanks. The plates 
were incubated for 4 hours at 37 °C, 5% CO2 prior to being assayed. Fluorescence 
signals (excitation 544 nm, emission 590 nm) were detected using fluorescence plate 
reader (BMG PolarStar; BMG Labtech, Offenburg, Germany). Cell survival was 
calculated as a percentage of the fluorescence detected in untreated cells. 
2.7.2 FDA staining of cells grown in 3D Matrigel™ cell culture 
To visualise live cells and to reduce the signal to noise ratio for analyses using 
the ImageJ quantification software, 3D Matrigel™ cell cultures growing in 96-well 
plates were stained using the fluorescein diacetate (FDA) (Life Technologies). FDA 
is metabolised to fluorescein using acetyl esterase within the living cells. This polar 
fluorescent compound is retained within the live cells (Calich et al., 1979).  
Prior to staining, the AlamarBlue reagent that was added into the wells to 
measure cell viability was removed and cells were gently washed twice with 200 μL 
PBS. Cells were then stained with 100 μL FDA (20 µg/Ml) (1:500 in PBS) followed 
by 10 minutes incubation before imaging by fluorescence microscopy (Nikon Eclipse 
TS100, Nikon).  
2.7.3 ImageJ analysis of FDA-stained cells 
ImageJ, a publically available Java-based image processing software developed 
by the National Institutes of Health (NIH), was used to quantify the size and the 
shape of breast cancer cells grown in 3D Matrigel™ cultures. In order for ImageJ 
analyses to be performed on 3D cultured cells phase-contrast images were deemed 
sub-optimal due to the high signal to noise ratio. In order to remove the background 
the cells within the Matrigel™ cultures were fluorescently stained (using FDA), 
resulting in a dark background with only the live cells emitting fluorescence. Images 
were then recorded and were subjected to analyses via ImageJ. ImageJ calculates 
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area and pixel value statistics of user-defined selections with which the relative size 
or circularity of the cell colonies can be calculated. Once opened in ImageJ the image 
was converted to mono-chrome black and white image with the background being 
white and the spheroids being detected as dark opaque circles. The threshold value 
above/below which the spheroids are considered for further calculations can be set. 
The scale can be set in units of length (here in μm) which then converts pixels into 
length (here μm). Once these values were set the images were processed, with the 
software reporting the number of spheroids/colonies, the size of each spheroid (in 
μm2) and also its circularity score (ranging from 0 to 1; 0 being least circular) for 
each image. Once the spheroids identified by the software were manually checked, 
the results were exported to an Excel spreadsheet (.xls file) for data analysis. Three 
such images from 3 different quadrants within each well were recorded for each 
treatment, with treatments tested in duplicate in each experiment. The values for all 
such treatments from duplicate experiments were averaged, the standard error 
calculated and data plotted. 
2.8 RNA EXTRACTION FROM MONOLAYER CELL CULTURES 
2.8.1 Cell Lysis  
To identify the specific induced gene expression responses in cells treated with 
VN alone or in combination with IGF-I+IGFBP or IGF-II, all experiments were 
prformed in serume-free medium (SFM) to minimise binding of any inducer 
compound to albumins contained in serum. Due to the potential complications in 
affecting downstren gene expression and subsequently the data interpretation when 
serum-containig medium is used, cell grown in untreated control cell (SFM only) 
were used for comparative puposes. Since, MCF-7 cells attach weakly to the tissue 
culture plate in the absence of any adhesive ECM proteins, in all experiments 
reported throughout this study both attached and floating cells were collected for 
RNA and protein extraction to have more fair comparison between treated and 
untreated cells. For RNA extraction floating cells were first collected and the 
attached cells were harvested by adding 250 µL cell dissociation buffer (TrypLE™) 
to each well. For each treatment attached and floating cells were combined and 
collected as a cell pellet prior to lysis. The supernatant was carefully removed and 
the cell pellet was lysed by adding 1 mL TRIzol
®
 reagent (Life Technologies) to 
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isolate total RNA from cells lysates were homogenised carefully by pipetting and 
stored at -80 °C until further use.  
 
2.8.2 RNA isolation from cell lysate 
RNA was extracted from cell lysates using the Direct-zol™ RNA miniprep Kit 
(Zymo Research) following the manufacturer’s protocol. Briefly, one volume ethanol 
(95-100%) was added directly to the samples homogenised in TRIzol
®
 reagent and 
mixed well by vortexing. Mixtures were then loaded into Zymo-Spin™ IIC column 
in a collection tube and centrifuged at ~12,000g for one minute. Spin columns were 
then transferred into a new collection tube and treated with DNase cocktail for 15 
minutes at room temperature. The columns were washed with RNA pre-wash and 
RNA wash buffers to remove any cell debris and other solvents. Finally, RNA was 
eluted using 30-50 μL RNase-free MilliQ water and stored at -80 °C until further use.  
2.8.3 RNA concentration, purity and integrity check 
RNA concentration was measured using the Nanodrop
®
 ND-1000 
Spectrophotometer. The RNA suspension (2 μL) was loaded onto the Nanodrop® and 
RNA concentrations were measured using A260. The purity of samples indicated 
using A260/A280 ratios identified by Nanodrop
®
. Only RNA samples with A260/A280 
ratios of 2.05-2.15 were considered as having valid purity (ideal A260/A280 ratio for 
RNA is 2). To assess the integrity as well as the purity of the extracted RNA, 1 μL of 
each sample was separated on 2% agarose/tris-borate-EDTA gel electrophoresis for 
30 minutes at 110 volts. Quality of the RNA within the sample was assessed by the 
presence of two distinct 28S rRNA and 18S rRNA bands with an intensity ratio of 
2:1, respectively. RNA integrity was assessed by the absence of smearing or 
laddering in the 2% agarose gel sample wells, which usually indicates presence of 
degraded RNA or RNA with genomic DNA contamination.  
2.9 MICROARRAY ANALYSIS OF DIFFERENTIAL GENE EXPRESSION  
The HumanHT-12 v4 BeadChip
®
 array (Illumina
®
; VIC, AU) was used to 
identify changes in gene expression patterns induced by VN alone, dimeric IGF-
II:VN and trimeric IGF-I:IGFBP:VN complexes in MCF-7 breast cancer cells. The 
Illumina
®
 HumanHT-12 v4 expression BeadChip
®
 array technology provides 
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genome-wide transcriptional coverage of well-characterised genes, including both 
coding and non-coding genes. Each array on the HumanHT-12 v4 Expression 
BeadChip contains more than 47,000 probes derived from the National Centre for 
Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 
(November 7, 2009). Sequence clusters are created from UniGene and are refined by 
analyses and compared with a number of publicly available human genome 
databases.  
Each Illumina
®
 BeadChip array holds tens of thousands of different 
oligonucleotide probes synthesised in situ onto microscopic beads held (covalently 
attached) in microwells on the surface of an array substrate improving robustness and 
measurement precision. The Illumina
®
 BeadChip array-based expression profiling 
uses biotin-labeled aRNA (also called complementary RNA, or cRNA) as the target 
that has been optimised for high signal intensity on BeadChip arrays, enabling 
sensitive gene detection and reproducible differential expression results. The 
labelling of aRNA was produced using TargetAmp™-Nano Labeling Kit (Epicentre 
Biotechnologies; WI, USA). Labelled probe-targets presented on each bead are 
further used for a hybridisation-based procedure to map the array, identifying the 
location of each bead. In addition, probe-target hybridisation is quantified by 
detection of fluorophore-labelled target signals to determine the relative abundance 
of nucleic acid sequences in the target bead. Total strength of the signal, from a bead, 
depends upon the amount of target sample binding to the probes present on that bead. 
The intensity of a gene probe-target is compared to the intensity of the same gene 
probe-target under a different condition (control), and the identity of the feature is 
known by its position. Additional feature of the Illumina
®
 HumanHT-12 v4.0 array 
includes hybridisation-based quality control of each array feature, allowing 
consistent production of high-quality, reproducible arrays. For full details see 
www.illumina.com. 
2.9.1 The TargetAmp™-Nano single round Biotin-aRNAbiotin amplification kit 
– overview 
The in vitro transcription reaction produces biotin-labelled anti-sense (aRNA) 
by incorporating biotin-UTP into the RNA transcripts to map the array using a 
hybridisation-based procedure. All steps from cDNA synthesis through to the 
fragmentation of the biotin-labelled aRNA were performed by Australian Genome 
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Research Facility (AGRF) (Melbourne, VIC, Australia) using the TargetAmp™-
Nano Labeling kit for Illumina
®
 Expression BeadChip (Epicentre Biotechnologies). 
This method is based on the RNA amplification protocol developed by James 
Eberwine (Van Gelder et al., 1990). The procedure consists of reverse transcription 
(RT) with an oligo(dT) primer bearing a T7 promoter using a SuperScript
®
 III 
reverse transcriptase (Life Technologies). The cDNA then undergoes 2
nd
 strand 
synthesis and clean-up to become a template for in vitro transcription in a reaction 
containing biotin-modified UTP and T7 RNA polymerase. To maximise the yields of 
biotin-labelled aRNA, this kit uses an optimised mixture of biotin-labelled and 
unlabelled nucleotide tri-phosphates (NTPs) and the T7 transcription buffers to 
generate hundreds to thousands of aRNA copies from each existing copy of mRNA 
in a sample. The biotin-labelled aRNA is then purified for hybridisation to Illumina
®
 
BeadChip
®
 arrays (VIC, Australia) (Figure 2.1).  
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Figure 2.1. TargetAmp™-Nano single round Biotin-aRNA Amplification kit overview for the 
Illumina® System Procedure. Adopted from epibio.com. 
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2.9.2 In vitro transcription to synthesise biotin-labelled aRNA 
To prepare single stranded cDNA, one microliter of oligo(dT) primer 
containing a phage T7 RNA polymerase promoter sequence at its 5′ end was added 
to each tube containing 1 µg of total RNA sample diluted in a maximum volume of 9 
μL and incubated at 65 °C for 5 minutes. The reaction was cooled on ice for one 
minute and reverse transcription was performed by incubation at 50 °C for 30 
minutes with each reaction containing 0.25 μL of SuperScript® in a final volume of 2 
μL of the reverse transcription master mix (1.5 μL 1st strand cDNA PreMix + 0.25 
μL DTT). Single stranded RNA was then converted to double-stranded cDNA 
containing a T7 transcription promoter in an orientation that will generate aRNA 
during the subsequent in vitro transcription reaction without the need for purification. 
Double-stranded DNA was synthesised by adding 5 μl of the 2nd strand cDNA master 
mix, containing 2
nd
 strand cDNA PreMix (4.5 μl) and 2nd strand cDNA polymerase 
(0.5 μl) to each reaction. Reactions were gently mixed and incubated at 65 °C for 10 
minutes followed by incubation at 80 °C for 3 minutes. Reactions were performed at 
elevated temperatures (50-80 °C) to reduce the formation of RNA secondary 
structure. The samples were placed on ice before proceeding to in vitro transcription 
procedure. The in vitro transcription reaction was performed using in vitro 
transcription master mix to produce biotin-aRNA by incorporating biotin-UTP into 
the newly synthesised aRNA. The master mix was prepared in a final volume of 20 
μl containing biotin-UTP (3 µl), NTP (10 µl), T7 transcription buffer (2 µl), T7 RNA 
polymerase (2 µl) and DTT (3 µl) and added to each cDNA sample. The tubes were 
mixed gently by pipetting, spun down briefly and then incubated at 42 °C for 4 hours 
to achieve the optimal yield and quality (length) of biotin-labelled aRNA. 
2.9.3 Biotin-labelled aRNA purification and quantification 
Biotin-labelled aRNA was purified using the RNeasy
®
 miniprep Kit (Qiagen; 
Doncaster, VIC, Australia) following the manufacturer’s protocol. To purify aRNA, 
350 μL of RNA binding buffer was added to each sample and mixed briefly before 
adding 250 μL of 100% ethanol and pipette mixing. Each sample was then added to 
the purification columns and centrifuged at 10,000g for 15 seconds. The flow-
through was discarded and the columns were then washed with 650 μL of wash 
buffer, centrifuged again and the flow-through discarded. An additional 
centrifugation at full speed for 5 minutes was performed to remove any residual wash 
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buffer or solvents and the filters were transferred to clean elution tubes. Finally, 
RNA was eluted using 50 μL RNase-free MilliQ water and stored at -80 °C until 
further use. The concentrations of the biotin-aRNA samples were determined using a 
NanoDrop
®
 ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies). The 
quality of the samples was further assessed by running 2 μL of purified aRNA on a 
2% agarose/tris-EDTA gel and electrophoresed for 30 minutes at 110 volts. The 
samples were then separated into the smaller aliquots to avoid freeze thawing of 
aRNA and stored at -80 °C.  
2.9.4 BeadChip® Direct Hybridisation assay 
Tubes containing aRNA samples were incubated at 65 °C for 5 minutes, 
vortexed and allowed to cool at room temperature. For each sample 750 ng of aRNA 
was suspended in a total of volume of 15 µL of Gene Expression Hybridisation 
Buffer (GEX-HYB) (100 mM MES, 1 M NaCl, 20 mM EDTA and 0.01% Tween-
20) and loaded into a single array on the Illumina
®
 HumanHT-12.v4.0 BeadChip
®
. 
The BeadChips
® 
were
 
then sealed in the hybridisation chamber, placed on the 
rocking platform and incubated at 58 °C for 16 hours in the Illumina
® 
hybridization 
oven. Following hybridisation, the BeadChips
®
 were removed from the chambers 
and placed into the staining dish containing 250 mL of the wash E1BC solution. The 
chips were then placed into the Hybex
®
 water bath insert containing Illumina
®
 high-
temperature wash buffer and incubated at 55 °C for 10 minutes. Chips were 
immediately washed at room temperature with fresh wash E1BC buffer for 10 
minutes and 100% ethanol for 2 minutes prior to scanning.  
2.9.5 BeadChip® array scanning 
The hybridised arrays were treated with fluorescently labelled Streptavidin, a 
tetrameric protein with high binding affinity to biotin and the differential detection of 
florescence signals was performed using the Illumina
®
 iScan reader. Briefly, 
Streptavidin was purified from the bacterium Streptomyces avidinii using Affinity 
chromatography and then conjugated with Cy3 fluorescent dye (Streptavidin-Cy3). 
Following washing steps, BeadChips
®
 were transferred into Cy3-Streptavidin 
solution, incubated at room temperature for 10 minutes, and dried prior to scanning. 
The iScan reader uses a laser to excite the fluor of the hybridised single-stranded 
product on the beads of the BeadChip
®
 sections. The scanner operating software, 
GenomeStudio
®, then converts the signal on the array into a ‘txt’ file for analysis.  
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2.9.6 Samples and system Quality Control (QC)  
The quality and quantity of total RNA samples was ascertained prior to 
microarray analysis on the Agilent Bioanalyser 2100 using the NanoChip protocol. 
The Illumina
®
 Whole-Genome Gene Expression Direct Hybridisation assay control 
system covers every aspect of the array experiment, from the biological specimen, 
sample integrity to sample labelling, hybridisation, and signal generation. The 
intactness of the biological specimen was monitored by expression of housekeeping 
gene controls. These controls consist of two probes per housekeeping gene that 
should be expressed in each sample. Sample labelling was also controlled using the 
Ambion
®
 External RNA Controls Consortium (ERCC) RNA Spike-In Control Mixes 
(Life Technologies) pre-formulated with sets of 92 polyadenylated transcripts form 
ERCC plasmid reference library (for details, please see Ambion’s ERCC RNA 
Spike-In Control Mixes protocol). This kit uses control biotin-tagged 
oligonucleotides to assess the success of the labelling process. Secondary staining of 
these control biotin-tagged oligonucleotides with a detected signal was considered as 
the positive labelling for target probes. Negative control probes with no 
corresponding targets in the genomes were also used to detect any signal from non-
specific binding of dye or cross-hybridisation. To monitor the quality of the 
hybridisation assays, three oligonucleotides at low, medium, and high concentrations 
of Cy3 labelling with matches to the control oligonucleotides were also hybridised in 
each BeadChip array. An array with signal intensities from these concentrations of 
Cy3-labelling matching the control oligonucleotide signals were passed the 
hybridisation assay quality control (for details, please see Whole-Genome Gene 
Expression Direct Hybridisation assay manual). GenomeStudio
®
 application 
automatically tracks the performance of these controls and generates a report for 
each array in a cell summary probe control profile report. The integrity of total RNA 
was checked before the processing and is summarised in Appendix 1. All RNA 
samples passed the performance parameters and were used in subsequent processes.  
2.10 MICROARRAY DATA ANALYSIS  
2.10.1 Data analysis and presentation using GeneSpring GX11 
The data files containing individual raw array data (probe intensities) were 
imported to the GeneSpring GX 11 software and pre-processed using Robust Multi-
array Average with GC-content background correction (GC-RMA). Data which has 
 Chapter 2: Materials and Methods 45 
been normalised with GC-RMA was then further normalised using the ‘per gene 
normalisation’ step in which all the samples were normalised against the median of 
the control samples (serum-free medium; SFM). Therefore, the expression value for 
one gene across the different condition was centred on one, by dividing the 
expression value by the median expression value for that gene across the condition 
(treatments). This ensured that genes which did not change across conditions 
received a normalised expression value of one, allowing for easier visual detection of 
differentially expressed genes. Statistically significant differentially expressed gene 
probe setswere then identified from pair-wise comparisons using two-way ANOVA 
(parametric test, assuming unequal variances) with ‘Benjamini and Hochberg false 
discovery rate’ (BHFDR) as the multiple testing correction (p = 0.05). Additionally, 
a fold change threshold of 1.5 was applied to these statistically significant gene probe 
sets. Together, this generated a list of gene probe sets with expression either 
significantly increased or decreased by at least 1.5-fold. The selection criteria of 
±1.5-fold was used to ensure critical genes which may not have a large magnitude of 
change were identified, while also keeping data sets to a manageable size. 
2.10.2 R program to generate Heatmap of gene expression data 
The data containing normalised gene values were imported into R 3.0.2 
language to generate and plot the heatmaps using the “gplots” version 2.12.1 
package. The expression of each individual gene presented in the heatmap was 
compared across all the conditions and indicated using different colour keys. The 
genes and treatments were clustered using an algorithm based on similarity in 
expression using algorithms applying Ward's minimum variance method within the R 
package “gplots” and results were added to the heatmap as dendrograms (hierarchical 
tree). The Euclidean distance map demonstrating Euclidean distance between 
treatments was also generated using the Ward's method within the “gplots” package. 
2.10.3 Gene ontology, functional network, and canonical pathway analyses 
using IPA 
Gene ontology, functional networks and canonical pathways analyses were 
undertaken using the Ingenuity Pathway Analysis (IPA) tool (Ingenuity
®
 Systems, 
www.ingenuity.com). The program is a web-based application that enables the 
discovery, visualisation, and exploration of molecular interaction networks in gene 
expression or proteomic data sets. Data sets containing gene identifiers and 
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corresponding expression values of gene prob sets determined to be significantly 
expressed by at least ±1.5-fold in response to VN alone, the dimeric IGF-II:VN and 
trimeric IGF-I:IGFBP:VN complexes compared to SFM (control) were uploaded into 
the application. Each gene identifier was mapped to its corresponding gene object in 
the Ingenuity Pathways Knowledge Base. The  
structure of network knowledge base approach to analyse genome-wide 
transcriptional data in the context of known functional interrelationships among 
proteins, small molecules and phenotype has been described in details (Calvano et 
al., 2005). Functions of genes and their interaction with associated networks and 
pathways are mined from the peer-reviewed literature and encoded into ontology. 
Moreover, biological functions are assigned to whole data sets by using IPA 
knowledge base as a reference set and a propriety ontology representing over 
300,000 classes of biological objects and consisting of millions of individual 
modelled relationships between proteins, genes, complexes, cells, tissues, small 
molecules and diseases. Genes which map to the IPA knowledge base or so-called 
“focus genes” are then used as the starting point for generating biological networks. 
Networks of focus genes were then algorithmically generated based on their 
connectivity. IPA computes a score for each network according to the fit of the 
original set of significant genes. This score reflects the negative algorithm of p-value 
that indicates the likelihood of the focus genes in a network being found together due 
to random chance. A score of 3 indicates a 1 in 1000 chance that the focus genes are 
together in a network by random chance. Therefore, scores of 3 or higher have a 
99.9% chance of not being generated by random chance alone. This score was used 
as the cut-off for identifying gene networks significantly affected by VN alone, IGF-
II:VN and IGF-I:IGFBP:VN complexes. Networks are ranked and a graphical 
representation of the molecular relationships between genes/gene products is 
generated. The functional analysis also identified biological functions and/or diseases 
that were most significant to the data set. Furthermore, Fisher’s exact test score 
below 0.05 was used to calculate the p-value to determining the probability that each 
biological function and/or disease assigned to that data set is due to chance alone. 
The same statistical approach was used to determine the Canonical pathways that 
were most significant to the data set. 
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2.11 QRT-PCR ANALYSES OF DIFFERENTIAL GENE EXPRESSION 
2.11.1 Primer design 
The forward and reverse primers for qRT-PCR analyses of a number of genes 
(Table 2.1) were designed using NCBI Primer-BLAST. The parameters used to 
generate acceptable primer sets included: melting temperature of 57 °C, maximum of 
63 °C and optimal melting temperature (Tm) of 60 °C, with no more than 3 °C 
difference in Tm between forward and reverse primers; 55-70% GC content; primer 
length between 20-23 nucleotides and amplicon length between 100-200 nucleotides 
(Table 2.2). Refer to Appendix 2 for full detailed sequence information on all 
primers used.  
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Table 2.1. Target genes for qRT-PCR analysis. 
Gene 
Symbol 
Full name 
JUN Cellular oncogene JUN or c-JUN 
FOS Cellular oncogene FOS or c-FOS 
CD24 Cluster of differentiation 24 
TGFβ2 Transforming growth factor beta 2 
VAV2 vav2 guanine nucleotide exchange factor 
LAMB1 Laminin beta 1 
CTGF Connective tissue growth factor 
GABRP Gamma-aminobutyric acid receptor subunit pi 
NBPF20 Neuroblastoma breakpoint family, member 20 
FZD8 Frizzled class receptor 8 
RASGRP1 RAS guanyl releasing protein 1 
ZIC Zinc finger of the cerebellum 
HSPB8 Heat shock protein beta 
Cyr61 Cysteine-rich angiogenic inducer 61 
ANXA2 Annexin A2 
NFIB Nuclear factor 1 B-type 
H19 Imprinted maternally expressed transcript H19 
SPDEF SAM pointed domain-containing ETS transcription factor 
MTSS1 Metastasis suppressor 1 
XBP1 X-box binding protein 1 
PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 
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Table 2.2. Details of primers designed using NCBI Primer-BLAST. 
H19 NR_002196.1 
F: AAGACGCCAGGTCCGGTGGA 1365 
160 
R: TGTGCCGACTCCGTGGAGGA 1543 
     
SPDEF  NM_012391.1 
F: TCTGACCCCAGCATTTCCAGAGCA 1692 
185 
R: ATTATCCATTCCCGGGGGCACT 1876 
     
GABRP NM_014211.1 
F: GAACCTATGTTCAGGTTGCGGGT 2720 
128 
R: AACTGGAAGCCTTTACCCTGGCA 2847 
     
RASGRP1 NM_005739.2 
F: ACAGTCCAGCAAGGGCCAAAGA 4554 
129 
R: ACTAGGCTTGATAAGCCAAAGCC 4683 
     
Cyr61 NM_001554.3 
F: ATGCTACCTGGGTTTCCAGGGCA 1354 
190 
R: TTAGTGTCCATCCGCACCAGCA 1543 
     
NBPF20 NM_0010376 
F: AGGCTCAACGGCGTGCTGAT 2661 
164 
R: AGGGCGAAGCTGATGTGCTGT 2824 
     
PAK4 NM_005884.3 
F: AACCTGCACAAGGTGTCGCCAT 1844 
113 
R: TTGGCCAGGAATGGGTGCTTCA 1956 
     
LAMB1 NM_002291.1 
F: AGCAAGCAAAAGTGCAACAGATG 5073 
200 
R: TGGGACGCGTTGAACAAGGTTT 5272 
     
MTSS1 NM_014751.4 
F: GGGCACATTTCTGACCGAACCCT 4203 
200 
R: CCTTGAGCAATCGCAGCAGTGT 4402 
     
FZD8 NM_031866.1 
F: AGTGCTTGCTAAGGACGCATGG 2870 
177 
R: ACCGTCTTTGGGGAAGGTGCAAA 3046 
     
 
Gene 
Symbol 
 
RefSeq ID 
(NCBI) 
Primes 
Sequence (5’3’) Start Product 
size 
JUN NM_002228.3 
F: TTGCCAGAGCCCTGTTGCGG 967 
125 
R: TCGGACGGGAGGAACGAGGC 1108 
     
FOS  NM_005252.3 
F: CCTGTCAACGCGCAGGACTTCT 332 
174 
R: GGCGGGGACTCCGAAAGGGT 505 
     
TGFβ2 NM_003238.3 
F: ACAGCACCAGGGACTTGCTCCA 1583 
147 
R: TGGGCGGGATGGCATTTTCGG 1729 
     
VAV2 NM_003371.3 
F: CCGGTCCCCAGTGTTCACGC 2353 
167 
R: TCCGTCCGTTGGTCTCGCCC 2519 
     
CTGF NM_005080.3 
F: GTGAGCCTCGTGCTGGACGG 345 
168 
R: GGGAGCACCATCTTTGGCGGT 512 
     
HSBP8 NM_014365.2 
F: GCTGGGAGCCTGTCAGTTTATGA 1730 
179 
R: ACACACGTCCCGCCCATATACA 1908 
     
ANXA2 NM_001002857 
F: CCCGGAGAGTTTCCCGCTTGG 82 
179 
R: TGTTCAAAGCATCCCGCTCAGCA 260 
     
XBP1 NM_005080.3 
F: GACAGCGCTTGGGGATGGATGC 449 
125 
R: CTGCTGCAGAGGTGCACGTAGT 573 
     
CD24A  NM_013230.2 
F: GCACTGCTCCTACCCACGCA 159 
146 
R: CCCAGGTACCAGGACTGGCTGG 304 
     
NFIB NM_005596.3 
F: CCTCCACCTTCACCGTTGCCA 1616 
179 
R: CCCAGGTACCAGGACTGGCTGG 1794 
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2.11.2 Reverse Transcription (RT) reaction to generate cDNA for qRT-PCR  
First strand DNA synthesis was performed using the SuperScript
®
 III First-
Strand Synthesis SuperMix for qRT-PCR kit (Life Technologies) to reverse 
transcribe total RNA. One microgram of total RNA was added into 0.5 mL low 
binding tubes containing 10 μL 2X RT Reaction Mix (containing dNTPs, random 
hexamers and reaction buffer), 2 μL RT enzyme mix [Moloney Murine Leukemia 
Virus (M-MLV) RT] and made up to 20 μL with RNase-free MilliQ water. Tubes 
were then incubated at 25 °C for 10 minutes, 55 °C for 30 minutes followed by 5 
minutes incubation at 85 °C to terminate the reaction. Each reaction tube was left to 
chill on ice for 5 minutes before adding 1 μL (2 U) of E.coli RNase H and incubating 
at 37 °C for 20 minutes. The resulting cDNA was either stored at -20 °C or diluted 
1:10 with nuclease-free water to obtain a concentration of 5 ng/μL cDNA for qRT-
PCR analysis 
2.11.3 q-RT-PCR 
qRT-PCR was performed to measure relative fold expression levels of target 
genes in cells treated with VN alone, IGF-II:VN and IGF-I:IGFBP-5:VN compared 
to the cells in control treatment (SFM). All reactions were performed in triplicate in 
20 μL reaction volumes in a 96-well format using SYBR green (Life Technologies) 
chemistry and ABI Prism 7500 Sequence Detection System (Life Technologies). 
Reaction contained 1X SYBR-green PCR mix, 0.4 μM forward and reverse primers 
each and 2 μL of the cDNA dilutions (10 ng). PCR amplification followed a two-step 
protocol with an initial 10 minute denaturation step at 95 °C followed by 40 cycles of 
95 °C for 15 seconds and 60 °C for 1 minute. In addition to target genes, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal 
control for normalisation purposes. The cycle threshold (Ct) of the gene of interest 
for each reaction was obtained and directly normalised to GAPDH expression levels 
(ΔCt) and then compared with the control (ΔΔCt). The relative fold-change in 
expression of the gene of interest between the two samples was then calculated using 
the 2^(-ΔΔCt) method. To confirm the specificity of the primers and the expected 
product size the amplified PCR products were separated on a 2% agarose gel at 110 
V for 30 minutes and visualised using SYBR safe (Life Technologies) fluorescence 
probe under UV illumination (Appendix 3).  
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2.12 PROTEIN SEPARATION AND IMMUNOBLOTTING 
2.12.1 Protein isolation from cell lines maintained in cell culture 
Following desired incubation of cells, the growth medium including unattached 
cells was removed and the attached cells were washed with PBS to remove traces of 
spent medium that could interfere with any downstream applications. The cells were 
directly lysed by adding 300 µL of Radio Immuno-Precipitation Assay (RIPA) buffer 
(150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 
mM Tris, pH 8.0) (Sigma-Aldrich). In order to make the complete protein lysis 
buffer phosphatase (Thermo Fisher Scientific) (1:10) and protease (Roche 
Diagnostics) (1:10) inhibitors (inhibiting serine, cysteine, threonine, tyrosine and 
aspartic acid proteases activity) were also added to RIPA buffer. The plates were 
incubated on ice for 5 minutes and the cells were dislodged into suspension using a 
rubber policeman. The lysed cell suspension was then mixed with pellet collected 
from unattached cells. Lysates were then homogenised by passing through a 26-
gauge needle at least five times before being centrifuged at 14,000g for 20 minutes at 
4 °C. The supernatants were collected and their protein concentrations determined 
using Coomassie Plus
®
 (Thermo Fisher Scientific; VIC, Australia). Samples were 
transferred to microfuge tubes, and stored at -80 °C until further use. 
2.13 IMMUNOBLOTTING  
Proteins were resolved on pre-made NuPAGE
®
 gradient SDS-PAGE gels (4%-
12%) (Life Technologies) and transferred to BioTrace™ NT nitrocellulose transfer 
membranes (Pall Corporation; VIC, Australia) at 200 mA in transfer buffer (25mM 
Tris, 40 mM glycine and 10% methanol) for 2 hours at 4 °C. Membranes were then 
blocked with 5% non-fat skim milk powder in Tris-buffered saline (10 mM Tris, 0.5 
M NaCl; pH 7.6) with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature to 
avoid non-specific interaction of primary antibody with the membranes. The blocked 
membranes were then incubated with primary antibodies, namely, polyclonal anti-
Cyr61 (1:1000) and anti-CTGF (1:1000) (R&D Systems; MN, USA) overnight at 4 
ºC in 5% non-fat skim milk powder in TBS-T or 5% BSA in TBS-T. The membranes 
were then washed in TBS-T at least six times for 5 minutes each and incubated with 
horseradish peroxidise (HRP)-conjugated secondary IgG antibody in TBS-T+5% 
non-fat skim milk powder (1:5000) for 1 hour at room temperature. Following a 
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further six washes of 5 minutes each, the protein bands were visualised using 
enhanced chemiluminescence (ECL) as per the manufacturer’s protocol (GE 
Healthcare; Melbourne, VIC, Australia). The membranes were either exposed onto x-
ray films (Fujifilm; QLD, Australia) and developed using a film processor (AGFA 
CP 1000, Superior Radiographics; Madison, WI, USA) or were imaged directly 
using the ChemiDoc™ XRS system (BioRad; CA, USA). The same membranes were 
then stripped using restore western blot stripping buffer (Pierce) and the total levels 
of GAPDH were detected as outlined above using anti-GAPDH antibodies, 
respectively to validate equal loading of proteins onto the gel. 
2.14 IMMUNOFLUORESCENCE STAINING  
To visualise VN- and IGF-I:IGFBP:VN complex-induced expression of Cyr61 
and CTGF target proteins, MCF-7 cells grown in Nunc™ 96-well optical-bottom 
plates (Thermo Fisher Scientific; VIC, Australia) pre-bound with VN and IGF-
I+IGFBP-5+VN were stained using fluorescently labelled dyes and antibodies. All 
reactions were performed at room temperature. Cells were fixed after 48 hours with 
4% formaldehyde in phosphate buffered saline (PBS; Life Technologies) for 30 
minutes and then carefully washed twice with 400 μL PBS:Glycine (0.1M Glycine in 
PBS, pH 7.4). Cells were then permeabilised with 200 μL of 0.4% Triton-X in PBS 
for 10 minutes followed by one hour incubation with 200 μL of 5% BSA fraction-V 
(Merck-Calbiochem; VIC, Australia) to block non-specific binding. Cells were 
washed with 0.1% PBS-Tween-20 (PBS-T) and incubated for one hour with 100 µL 
primary mouse anti-Cyr61 and anti-CTGF antibodies (Santa Cruz Biotechnology; 
CA, USA) diluted in 5% BSA + PBS-T (1:100). Subsequently, cells were washed 
twice with PBS-T and incubated with 100 μL fluorophore-conjugated secondary 
AlexaFluor
®
 594 (red) or 488 (green) goat anti-mouse IgG antibodies diluted in PBS-
T (1:250) and incubated for one hour. Cells were then washed three times with 0.1% 
PBS-T and incubated for 40 minutes in the dark with 200 μL fluorescently 
conjugated AlexaFluor
®
 594 (red) or 488 (green) phalloidin (1:40, in PBS) and DAPI 
(1:500) dyes (Life Technologies). The plates were stored at 4 °C and in the dark until 
imaging by DeltaVision microscopy. 
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2.15 CLONING 
2.15.1 Eukaryotic expression vectors 
pLKO.1 lentiviral vectors with a gene specific short hairpin RNA (shRNA) 
already cloned into it (for genes Cyr61 and CTGF) were obtained from Open 
Biosystems (Thermo Fisher Scientific). pLKO.1 vector with a shRNA for firefly 
luciferase gene cloned into it (pLKO.shFF3), pLKO.1 vector containing cDNA for 
GFP (pLKO.3G) and the lentiviral packaging vectors pCMV-VSV-G (encoding the 
Vesicular stomatitis virus G-protein capsule), pCMV delta R8.2 (encoding the HIV-1 
GAG/POL, Tat and Rev elements) were from Addgene.org. For vector diagrams of 
pCMV-delta-R8.2 and pCMV-VSV-G refer to Appendix 4 and Appendix 5. 
2.16 PREPARING COMPETENT STBL3 E.COLI CELLS (CALCIUM 
CHLORIDE METHOD) 
One Shot
®
 Stbl3 competent cells (Life Technologies) were used to maintain 
lentiviral vectors as these cells reduce the frequency of unwanted homologous 
recombination of long terminal repeats (LTRs) found in lentiviral and other retroviral 
vectors. Owing to the large costs associated with purchasing these cells, contents 
from one 50 μL vial of the One Shot® Stbl3 competent cells (Life Technologies) 
were expanded to produce a working stock following methods outlined below. The 
contents from one vial of the cells (50 μL) were transferred to 100 mL antibiotic-free 
Lysogeny Broth (LB) medium. The cells were allowed to grow for 6 hours or until 
their optical density reached 0.4 to 0.6 (measured at 600 nm). The cell culture was 
centrifuged at 2,500g for 15 minutes at 4 °C and the supernatant was discarded. The 
cell pellet was resuspended, without vortexing or pipetting, in 5 mL of sterile 0.1M 
CaCl2 and incubated at 4 °C for 2 hours to obtain chemically competent Stbl3 cells. 
The cells were then mixed with 1.5 mL of sterile 80% glycerol, which was 
subsequently aliquoted and stored at -80 °C until further use. 
2.16.1 Transformation of competent Stbl3 E.coli cells 
One 50 μL aliquot of competent Stbl3 cells was thawed on ice for each 
transformation. Upon thawing, ~50 ng of each vector DNA was added to the 
competent cells, mixed gently, and incubated on ice for 30 minutes. Cells were then 
heat shocked for 45 seconds at 42 °C and then returned to ice for 5 minutes. Two 
hundred and fifty microlitres of antibiotic-free LB medium (5 g/L bactotryptone, 2.5 
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g/L yeast extract and 2.5 g/L NaCl) were added to each tube and the cells were 
allowed to recover at 37 °C for 1 hour with constant shaking at 225 rpm. For all 
vectors, 50 μL was then spread onto pre-warmed LB agar plates containing 100 
ng/mL ampicillin and incubated overnight at 37 °C. Up to 4 colonies were picked 
from each plate using a heat-sterilised inoculation loop, which was then placed into 5 
mL of LB medium containing 100 μg/mL ampicillin and incubated overnight at 37 
°C with constant shaking at 225 rpm. The following day, glycerol stocks were made 
by mixing 800 μL of each overnight culture with 200 μL of sterile 80% glycerol and 
stored at -80 °C. The remaining volume of the culture was then used to extract DNA 
using plasmid purification miniprep procedures detailed in section 2.14.4. For 
cloning that started directly from the bacterial glycerol stocks (for all pre-purchased 
vectors obtained from Open Biosystems) the inoculation loop was dipped into a 
partially thawed vial of the glycerol stock which was then streaked onto LB agar 
plates containing 100 μg/mL ampicillin and was then incubated overnight at 37 °C. 
The following day, the colony was subsequently transferred into 5 mL LB medium 
containing 100 μg/mL ampicillin and DNA extracted using plasmid miniprep 
procedures detailed below. 
2.16.2 Plasmid purification – Miniprep 
Plasmid DNA was purified from the Stbl3 bacterial cells using the QIAprep 
miniprep kit (Qiagen; VIC, AU) which contained all the solutions and spin columns 
required for plasmid purification. All steps were performed at room temperature 
following the manufacturer’s instructions. Briefly, 5 mL overnight cultures were 
centrifuged at 3000 rpm for 5 minutes to pellet the cells. The pelleted cells were 
lysed using 250 μL Buffer P1. Subsequently, two hundred and fifty microlitres of 
buffer P2 were added into each tube and mixed several times by inversion. After no 
longer than 5 minutes, 350 μL of buffer N3 was added and again mixed by inversion. 
The tubes were then centrifuged for 10 minutes at 13,000 rpm (~18,000g) in a bench-
top centrifuge and the resulting supernatants were applied to the QIAprep spin 
columns which bind the plasmid DNA. The spin columns were then centrifuged for 1 
minute (13,000 rpm) and the flow-through was discarded. The QIAprep columns 
were washed with 500 μL Buffer PB, followed by a subsequent wash with 750 μL 
Buffer PE. To elute the DNA, 30 μL of elution buffer (10 mM Tris-HCl, pH 8.5) was 
added to the centre of each column and incubated for 1 minute. The eluted DNA was 
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then collected by centrifugation for 1 minute. The quality and quantity of the 
extracted plasmid DNA was then assessed by agarose gel electrophoresis and by 
measuring the UV spectrophotometric absorbance at 260 and 280 nm, respectively. 
2.17 LENTIVIRAL VECTOR-MEDIATED GENE MANIPULATION 
To assess the functional roles of the candidate genes, namely cysteine-rich, 
angiogenic inducer 61 (Cyr61) and connective tissue growth factor (CTGF), 
lentiviral-mediated transduction of breast cells was performed to stably express the 
gene specific short hairpin RNA (shRNA) sequences against Cyr61 and CTGF to 
suppress their gene expression (gene knockdown). 
2.17.1 shRNA lentiviral vector: production and design 
pLKO.1 was the lentiviral vector of choice to perform shRNA mediated 
knockdown of Cyr61 and CTGF mRNA and protein expression. shRNA sequences 
already cloned into pLKO.1 vectors were purchased from Open Biosystems. For 
each gene five sets of shRNAs were obtained resulting in five pLKO-shRNA vectors 
for each gene. The shRNA resulting in the maximal down-regulation of its respective 
gene was chosen for further knockdown studies. The pLKO.1 vector containing the 
shRNA targeting the firefly luciferase gene (pLKO.shFF3), which is absent in 
mammalian cells, was used as a non-targeting negative control and the pLKO.1 
vector with GFP cDNA inserted (pLKO.3G) was used as a positive control for 
transfection to visually inspect the transfection efficiency under a fluorescence 
microscope. Nucleotide sequences of shRNAs targeting each gene are detailed in 
Table 2.3. For pLKO.1 vector map refer to Figure 2.2. Vectors obtained from Open 
Biosystems came in glycerol stocks of DH5α cells. To isolate the vector DNA the 
bacterial cells were streaked onto LB-agar ampicillin plates, incubated overnight, and 
single colonies were isolated and transferred to liquid culture following protocols 
outlined in the latter half of section 2.16.1. The vector DNA was isolated using the 
miniprep procedures described in section 2.16.2. 
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Table 2.3. shRNA sequence information. 
shRNA sets cloned into pLKO.1 lentiviral vectors for genes Cyr61 and CTGF were purchased from 
Open Biosystems. The sequence for each shRNA (sense-loop-antisense) within the pLKO.1 vector is 
depicted in this table. 
Description Hairpin Sequence 
Cyr61-1 5'CCGGGCAAACAGAAATCAGGTGTTTCTCGAGAAACACCTGATTTCTGTTTGCTTTTTG3' 
Cyr61-2 5'CCGGCGCATCCTATACAACCCTTTACTCGAGTAAAGGGTTGTATAGGATGCGTTTTTG3' 
Cyr61-3 5'CCGGCCGAACCAGTCAGGTTTACTTCTCGAGAAGTAAACCTGACTGGTTCGGTTTTTG3' 
Cyr61-4 5'CCGGCCCTTCTACAGGCTGTTCAATCTCGAGATTGAACAGCCTGTAGAAGGGTTTTTG3' 
Cyr61-5 5'CCGGCGAACCAGTCAGGTTTACTTACTCGAGTAAGTAAACCTGACTGGTTCGTTTTTG3' 
 
CTGF-1 5'CCGGGAGAACATTAAGAAGGGCAAACTCGAGTTTGCCCTTCTTAATGTTCTCTTTTTG3 
CTGF-2 5'CCGGCGCATCCTATACAACCCTTTACTCGAGTAAAGGGTTGTATAGGATGCGTTTTTG3' 
CTGF-3 5'CCGGCATCTTTGAATCGCTGTACTACTCGAGTAGTACAGCGATTCAAAGATGTTTTTG3' 
CTGF-4 5'CCGGGCATGAAGACATACCGAGCTACTCGAGTAGCTCGGTATGTCTTCATGCTTTTTG3' 
CTGF-5 5'CCGGCCCAAGGACCAAACCGTGGTTCTCGAGAACCACGGTTTGGTCCTTGGGTTTTTG3' 
Colour Codes: sense (target sequence)-loop-antisense 
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Description  Vector Element  
U6  
Human U6 promoter drives RNA Polymerase III transcription for 
generation of shRNA transcripts.  
cPPT  
Central polypurine tract, cPPT, improves transduction efficiency by 
facilitating nuclear import of the vector’s preintegration complex in the 
transduced cells.  
hPGK  Human phosphoglycerate kinase promoter drives expression of puromycin.  
Puro R  
Puromycin resistance gene for selection of pLKO.1 plasmid in mammalian 
cells.  
sin 3’LTR  3’ Self-inactivating long terminal repeat.  
f1 ori  f1 bacterial origin of replication.  
Amp R  
Ampicillin resistance gene for selection of pLKO.1 plasmid in bacterial 
cells  
pUC ori  pUC bacterial origin of replication.  
5’LTR  5’ long terminal repeat.  
RRE  Rev response element.  
Figure 2.2: Map of pLKO.1 containing a shRNA insert. Adapted from addegene.org 
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2.17.2 Virus production in HEK293T packaging cells  
The pLKO.1 vector containing the shRNA of interest and the viral packaging 
plasmids, pCMV-VSV-G and pCMV delta R8.2, were transiently transfected into 
HEK293T packaging cells to produce lentiviral particles. The day before the 
transfection, 1.5 x 10
6
 cells suspended in 10 mL DMEM+10% iFBS were seeded 
onto 10 cm dishes. The following day, a transfection mix was prepared in 
DNase/RNase free tubes containing 185 μL serum-free and antibiotics-free DMEM, 
12 μL FuGENE-6 transfection reagent (Promega), 1.8 μg pCMV delta R8.2, 0.2 μg 
pCMV-VSV-G and 2 μg of the shRNA-containing pLKO.1 vector. This mix was 
incubated for 15 minutes at room temperature, following which the mixture was 
added drop wise to the pre-plated HEK293T cells (50-60% confluent at the time of 
transfection). These plates were incubated overnight at 37 °C, 5% CO2. The 
following day, the transfection mix-containing medium was replaced with 7 mL of 
fresh DMEM+10% iFBS medium or with medium used for the target cells and 
incubated overnight at 37 °C, 5% CO2. The viral supernatants were harvested at 48 
and 72 hours post-transfection. These viral supernatants from both 48 and 72 hours 
were pooled, centrifuged at 1000 rpm for 5 minutes to remove any cellular debris, 
filtered using a 0.45 μm cut-off filter and stored at -80 °C until further use. Prior to 
harvesting, the viral supernatants from HEK293T cells transfected with the 
pLKO.3G control were visually inspected for green fluorescence under a 
fluorescence microscope to confirm DNA transfection. 
2.17.3 Transfection of target cell lines 
Target cell lines used in this project for transduction of lentiviruses were MCF-
7 and MDA-MB-231. Target cells were seeded onto a 6-well plate at a density such 
that they were 30-50% confluent at the time of infection. Two hundred thousand 
cells for MCF-7 and 150,000 cells for MDA-MB-231 suspended in 2 mL target cell 
medium were seeded onto each well of a 6-well plate. The following day the spent 
medium was removed and 2 mL of the lentiviral particles-containing medium 
obtained in section 2.15.2 was added onto the target cells. Simultaneously, 6 μg/mL 
protamine sulphate was also added to the well to facilitate virus uptake by the cells. 
After overnight incubation at 37 °C, 5% CO2, the viral supernatant was removed and 
the cells were allowed to recover overnight in the target cell medium. The following 
day, target cells containing the viral DNA inserted within their genome were selected 
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using 2 μg/mL puromycin. This high concentration of puromycin was maintained 
until all the un-transfected negative control cells died, after which the concentration 
of puromycin was halved to 1 μg/mL, with transfected cells constantly being 
maintained in puromycin-containing medium. The cells were observed for any 
changes in morphology compared to the shFF3-containing control cells (shCntrl). 
RNA and protein was isolated following the protocols outlined in sections 2.8.2 and 
sections 2.12.1, respectively to analyse shRNA-mediated knockdown of the gene of 
interest through qRT-PCR and western immunoblotting. Figure 2.3 depicts the 
overall schema for lentiviral production and transduction of target cells. 
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Figure 2.3. Schematic depiction of lentiviral shRNA-mediated suppression of target cells. 
pLKO-shRNA vector along with delta R8.2 and VSV-G packaging vectors are transfected into 
HEK293T cells. These packaging cells secrete into the medium the lentiviral particles harbouring the 
shRNA. Incubation of the target cells with the viral supernatant results in the shRNA being expressed 
by the target cells.  
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2.17.4 Statistical Analyses 
Data were pooled from multiple experiments (two being the minimum) with 
each treatment tested in three wells (two wells for Matrigel™ experiments) in each 
replicate experiment. The only exceptions were the studies screening for shRNA 
with maximal down-regulation of target gens as well as cell signalling and receptor 
studies where the data were pooled only from one biological replicate with each 
treatment tested in three wells. Data are expressed as percentage of the response 
observed in wells treated with SFM (control) or as fold change in gene expression 
observed in wells treated with SFM, unless otherwise stated. For functional assays 
and qRT-PCR analysis the data analyses was performed using two-tailed student’s t-
test utilising InerSTAT-a version 1.3. For microarray analysis the data were analysed 
using two-way ANOVA (parametric test, assuming unequal variances) with 
‘Benjamini and Hochberg false discovery rate’ (BHFDR) tests. Differences of 
p<0.05 (95% confidence interval) were considered to be statistically significant.  
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3.1 INTRODUCTION  
The metastatic spread of cancer cells to distant sites of the body and the 
subsequent establishment of secondary tumours in critical organs of the body is the 
major cause of death among breast cancer patients. A lack of a clear understanding of 
how cancer cells attain the ability to survive and promote metastasis within 
surrounding tissue microenvironments is one of the most challenging aspects in the 
treatment of patients with aggressive disease. Altered interactions between the 
malignant cells and extracellular matrix (ECM) proteins within the tumour 
microenvironment are considered to be a major driver of cancer progression (Lochter 
& Bissell, 1995; Muschler & Streuli, 2010; Quail & Joyce, 2013). These interactions 
have been reported to alter biological phenotypes manifested at most stages during 
cancer progression, from pre-malignancy to proliferative dysregulation, 
dissemination, survival in foreign tissues and subsequent metastasis formation.  
As outlined in chapter one, the multi-functional ECM glycoprotein vitronectin 
(VN) plays a key role in the regulation of diverse cellular functions during normal 
and pathological conditions (Preissner & Reuning, 2011). In breast carcinoma, VN 
was identified to be present in the peritumoral stroma, blood vessel walls and in 
ECM surrounding cancer cells (Carriero et al., 1997; Aaboe et al., 2003; Kadowaki et 
al., 2011). VN has been shown to modulate cancer metastasis by providing traction 
and direction to migrating tumor cells during invasion (Aaboe et al., 2003), while 
also conferring a survival advantage to advancing tumour cells (Uhm et al., 1999; 
Leavesley et al., 2013). The effects of VN are predominantly mediated through its 
specific interactions with cell surface integrins and the urokinase plasminogen 
activator system (Felding-Habermann & Cheresh, 1993), both of which are 
frequently overexpressed in tumour cells (Andreasen et al., 1997; Mizejewski, 1999). 
Upon integrin ligation, VN triggers intracellular signalling cascades, controlling 
critical cellular events contributing to cancer progression (Hapke et al., 2003; Hurt et 
al., 2010).  
In addition, VN ligation of integrins causes integrins to become clustered in the 
plane of the cell membrane, to facilitate the formation of focal adhesion contacts that 
link the cells to the ECM (Giancotti & Ruoslahti, 1999). Interestingly, present within 
these focal adhesion contacts are growth factors (GFs) (Taipale & Keski-Oja, 1997). 
Integrin clustering and its association with focal adhesions in turn facilitate the 
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formation of integrin-GF complexes that regulate cell behaviour. In this regard, 
studies from the last two decades indicate that several GFs and cytokines interact 
with VN-binding integrins, and this integrin-GF cooperation regulates diverse 
biological processes (Eliceiri, 2001; Schwartz & Ginsberg, 2002; Beattie et al., 
2010). In view of this, studies within our laboratory are only among the few that have 
investigated the effects of such GF-ECM interactions, in particular, interactions 
between VN and IGF ligands on cellular functions (Upton et al., 1999; Noble et al., 
2003; Hollier et al., 2005; Hollier et al., 2008; Kricker et al., 2010; Kashyap et al., 
2011). These studies have revealed that IGF ligands bind to VN forming dimeric 
IGF-II:VN and trimeric IGF-I:IGFBP:VN complexes (Upton et al., 1999; Kricker et 
al., 2003) stimulating breast cancer cell migration (Noble et al., 2003; Hollier et al., 
2008) and inhibiting drug-induced apoptosis (Kashyap et al., 2011). Moreover, 
microarray analysis of non-tumorigenic MCF10A breast cells that migrated in 
response to the trimeric IGF-I:IGFBP-5:VN complex revealed genes specific to cell 
movement to be uniquely deregulated in cells that migrated in response to the 
complex. These studies provide mechanistic as well as molecular insight into the 
functional effects of the IGF:VN complexes and provide further evidence for the 
important role these novel complexes play in regulating biological functions relevant 
to cancer progression.  
The emergence of global gene expression profiling using DNA microarrays has 
added valuable new information to our understanding of the molecular events 
underpinning ECM component-mediated biological functions. The studies to date 
have focused on identifying gene expression changes across a variety of cell types, 
largely in response to the ECM proteins FN and collagen (Thornton et al., 2002; 
Chen et al., 2004; Charoenpanich et al., 2011). However, there exists no global 
expression studies investigating the changes in gene expression associated with VN-
stimulated breast cell survival and metastasis, especially since we and others have 
shown that VN is able to stimulate cell survival in variety of cell types (Uhm et al., 
1999; Kashyap et al., 2011; Hazawa et al., 2012). Additionally, considering the 
important roles of the IGF in the transformation and progression of breast cancer and 
its association with VN, the molecular mechanisms underlying the IGF:VN-induced 
responses in breast cancer cells remains to be investigated.  
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Based on the evidence outlined above it was hypothesised that VN and the 
IGF:VN complexes would induce differential expression of genes critical to breast 
cell survival. Identification of these transcriptional programs will not only increase 
our understanding of the mechanisms responsible for VN- and IGF:VN-stimulated 
survival, but may also provide insights into the early molecular events promoting 
breast cell metastasis. To identify changes in gene expression patterns induced by 
VN and the IGF:VN complexes, DNA microarrays were performed on RNA samples 
isolated from cells which had survived in response to VN with or without IGF-
I+IGFBP-5 and IGF-II pre-bound to polystyrene multi-well cell culture plates. This 
“pre-bound” strategy was adopted in an effort to more accurately mimic the in vivo 
cellular environment in which cells are not constantly exposed to growth factors in 
solution but rather interact with components of the ECM. Hence, the genes identified 
would more accurately represent the actual cellular and molecular processes involved 
in cell survival in comparison to the more common and relatively static pre-plated 
culture methodologies previously adopted by others.  
In summary, this chapter builds on the previous studies performed within our 
laboratory and reveals for the first time the global transcription programs induced by 
VN and the IGF:VN complexes relevant to breast cancer cell survival. In particular, 
we have identified enriched biological networks and intracellular signalling pathways 
highly enriched in these transcriptional responses. These datasets not only shed new 
light on ECM-induced cancer cell survival, but will also guide the selection of 
candidate genes for functional validation studies in subsequent chapters.  
3.2 EXPERIMENTAL METHODS 
The following is a brief summary of the materials and procedures used to 
generate the data presented in this chapter. Full details of materials and methods used 
herein are described in Chapter 2. 
3.2.1 Cell lines  
MCF-7 adenocarcinoma breast cancer cell line was the model of choice for the 
studies performed in this chapter. MCF-7 are epithelial breast cancer cells that 
express relatively high levels of the IGF-IR, display a number of VN-binding 
integrins and are poorly metastatic (Meyer et al., 1998; Bartucci et al., 2001), making 
them an ideal cell line to investigate the transcriptional changes in response to VN 
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alone and the IGF:VN complexes. For details on maintenance of these cells please 
refer section 2.3. 
3.2.2 Treatment strategy for in vitro viability assay 
In an effort to more accurately mimic the in vivo cellular environment this 
study adopted the strategy of “pre-binding” VN with or without growth factors to 
polystyrene multi-well cell culture plates prior to seeding cells. These “pre-bound” 
studies have been implemented to reflect the in vivo microenvironment in which 
these breast cancer cells normally encounter to maintain their survival. The protocol 
to pre-bind VN and IGFs to the tissue culture plastic and the full details of this 
method is outline in section 2.4.  
3.2.3 Cell viability measurement 
To measure the relative viability, cells were incubated for 72 hours and cellular 
metabolic activity was assessed using the CellTitre 96
®
 AQueous One Solution Cell 
Proliferation Assay (MTS). After 72 hours, 20 µL MTS reagent was added into each 
well and the absorbance recorded at 490 nm using a 96-well plate reader (Benchmark 
Plus, Bio-Rad). Furthermore, as a complementary approach Trypan blue exclusion 
assay was also employed to determine cell viability. MCF-7 cells were serum-starved 
for 4 hours before seeding 5 x 10
4
 cells suspended in 2 mL SFM + 0.05% BSA into 
6-well plates pre-coated with proteins treatments outlined above (section 3.2.2). 
Treatments with only SFM served as negative controls. After 72 hours incubation 
attached cells were harvested, centrifuged at 1000 rpm for 5 minutes and the 
resulting pellet was resuspended in SFM. Trypan blue 4% solution was then mixed 
with cell suspension by preparing a 1:10 dilution and the number of viable cells was 
assessed using a hemocytometer.  
3.2.4 Optimisation of MCF-7 cell density for seeding onto 6-well plates 
To optimise seeding density for time course microarray experiments, MCF-7 
cells were seeded onto 6-well plates pre-bound with either VN alone or the IGF:VN 
complex over a period of 48 hours. Three different cell densities including 2.5 x 10
5
, 
5 x 10
5 
and 7.5 x 10
5
 cells per well were tested for confluency using phase contrast 
microscopy (Eclipse TE 2000-U, Nikon).  
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3.2.5 Microarray analysis of differential gene expression 
Experimental set up 
MCF-7 cells were spilt 1:1 24 hours prior to performing the experiment. Cells 
were serum-starved for 4 hours and a cell suspension containing 5 x 10
5
 cells in 2.5 
mL SFM + 0.05% BSA was seeded onto each well of the 6-well plates pre-bound 
with either VN only, IGF-II:VN or IGF-I:IGFBP-5:VN treatments. Cells seeded in 
wells containing only SFM served as the control treatment. Plates were incubated for 
12 and 48 hours at 37 °C, 5% CO2. These time points were selected to account for 
changes in the gene expression patterns induced by VN and the IGF:VN complexes 
at both the early (12 hours) as well as the late (48 hours) stages. For each treatment 
and time point three wells were used for RNA and three wells for protein extraction 
according to protocols outlined in sections 2.8.1 and 2.12.1, respectively. MCF-7 
cells attach weakly to the tissue culture plate in the absence of any adhesive ECM 
proteins. This was also the case for MCF-7 cells grown in untreated wells (control 
wells) in this study. Hence, to more fairly compare chenges in gene expression 
profiles induced in MCF-7 cells in response to VN alone or in combination with 
IGF-I+IGFBP or IGF-II tretaments compare to the control treatment (untreated cells) 
in all experiments reported throughout this study both attached and floating cells 
were collected for RNA and protein extraction. 
Total RNA isolation and concentration, purity and integrity check 
 For full details on this method refer to section 2.8.2. RNA was extracted from 
cell lysates using the Direct-zol™ MiniPrep Kit (Zymo Research) following the 
manufacturer’s protocol and concentration, purity and integrity of samples were 
checked as outlined in section 2.8.3.  
Microarray analysis  
The Illumina
®
 HumanHT-12 v4.0 BeadChip array technology (Australian 
Genome Research Facility; VIC, AU) used in this study to identify changes in gene 
expression patterns induced by VN alone, dimeric IGF-II:VN and trimeric IGF-
I:IGFBP:VN complexes in MCF-7 breast cancer cells. This technology provides 
genome-wide transcriptional coverage of well-characterised genes, including both 
coding and non-coding genes. The majority of probes used in the array were 
designed to cover content form National Centre Biotechnology Information (NCBI) 
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Reference Sequence (RefSeq) release 38 (November 7, 2009). Sequence clusters are 
created from UniGene and are refined by analysis and comparison with a number of 
publicly available human genome databases. Oligonucleotide probes are synthesised 
in situ complementary to each corresponding sequence Additional feature of the 
Illumina
®
 HumanHT-12 v4.0 array includes hybridisation-based quality control of 
each array feature, allowing consistent production of high-quality, reproducible 
arrays.  
RNA samples were used for in vitro transcription to synthesise biotin-labelled 
anti-sense RNA (aRNA), aRNA purification and quantification using procedures 
outlined in sections 2.9.1 to 2.9.3. The biotin-labelled aRNA was further used for 
hybridisation to BeadChip
®
 Arrays using direct hybridisation assay and then 
scanned. The scanner operating software, GenomeStudio
®
, converts the signal on the 
array into a TXT file for analysis. For full details of hybridisation assay and scanning 
procedures refer to sections 2.9.4 and 2.9.5. The Illumina
®
 Whole-Genome Gene 
Expression Direct Hybridisation assay control system covers every aspect of the 
array experiment, from the biological specimen, sample integrity to sample labelling, 
hybridisation, and signal generation. For full details on samples and system Quality 
Control (QC) refer to section 2.9.6.  
Microarray data analysis 
The data files containing individual raw array data (probe intensities) were 
imported to GeneSpring GX 11 and pre-processed using Robust Multi-array Average 
with GC-content background correction. This (GC-RMA) normalise data were then 
further normalised using the ‘per gene normalisation’ step in which all the samples 
were normalised against the median of the control samples (SFM being the control). 
Statistically significant differentially expressed genes were then identified using a 
fold change threshold of 1.5 and two-way ANOVA (parametric test, assuming 
unequal variances) with Benjamini and Hochberg false discovery rate (BHFDR) as 
the multiple testing correction (p<0.05). Together, this generated a list of gene probe 
sets whose expression was significantly increased or decreased by at least 1.5-fold in 
response to VN, IGF-I:IGFBP:VN and IGF-II:VN when compared to the SFM 
treatment. To get a visual representation of the global changes in the gene expression 
patterns induced by VN and the IGF:VN complexes, the data containing normalised 
gene values were imported into R 3.0.2 language to generate and plot the heatmaps, 
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using the “gplots” version 2.12.1 package. The genes and treatments were clustered 
using hierarchical cluster analysis based on ‘similarity in expression’ using 
algorithms applying Ward's minimum variance method within the R package 
“gplots” and results were added to the heatmap as dendrograms (hierarchical tree). 
Furthermore, Ingenuity Pathway Analysis tool (Ingenuity
®
 Systems, 
www.ingenuity.com) was used to investigate gene ontology, canonical pathway, and 
network enrichment associated with differentially expressed genes in response to 
each treatment. For full details on microarray data analysis refer to section 2.10. 
3.2.6 Confirmation of differential gene expression using quantitative Real-Time 
PCR (qRT-PCR)  
qRT-PCR was used to validate microarray data by measuring absolute 
expression levels of selected differentially expressed genes of interest. The total 
RNA used for qRT-PCR was from the original samples isolated and used for 
microarray analysis. For full details of primer design for target genes, Reverse 
transcription of RNA to produce cDNA and qRT-PCR analysis refer to section 2.11.  
3.3 RESULTS 
3.3.1 VN, dimeric IGF-II:VN and trimeric IGF-I:IGFBP:VN complexes 
increase cellular viability of MCF-7 breast cancer cells 
Previous studies have shown that VN and the IGF:VN complexes stimulate 
breast cancer cell survival in 2D in vitro assays (Kashyap et al., 2011). To confirm 
these results, the viability of MCF-7 breast cancer cells in response to the dimeric 
IGF-II:VN and trimeric IGF-I:IGFBP:VN complexes and VN alone was assessed 
using MTS and trypan blue viability assays (Figure 3.1). The responses of serum-
starved cells were investigated over 72 hours after seeding the cells into culture 
plates pre-coated with either 1 μg/mL of VN alone or in combination with 30 ng/mL 
of IGF-I, 90 ng/mL of IGFBP-5 and 100 ng/mL of IGF-II.  
The treatment of MCF-7 cells with VN alone, dimeric and trimeric complexes 
showed significant increases (p<0.01) in viability compared to SFM alone (control 
treatment) (Figure 3.1 A). The trimeric complex-stimulated cell viability was higher 
(p<0.05) than that recorded for VN only treatment. Similar findings were observed 
when the actual number of viable cells was counted using the trypan blue assay 
(Figure 3.1 B). All treatments showed a significant increase (p<0.01) in the number 
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of viable cells compared to the SFM control treatment. The number of viable cells in 
wells treated with the trimeric complex was also significantly (p<0.05) greater than 
the viable cell count from VN only treated wells. These results confirm those our 
laboratory has reported previously and validates our experimental set-up for 
subsequent RNA isolation and microarray analysis. Taken together, these data 
indicate that substrate-bound VN and the IGF:VN complexes are capable of 
stimulating MCF-7 breast cancer cell viability over 72 hours. These data also show 
that presence of IGF-I and IGFBP-5 in combination with VN (IGF-I:IGFBP-5:VN) is 
providing substantially greater viability responses than those obtained with VN. This 
data fits well with our previous findings showing that substrate-bound IGF-I:IGFBP-
5:VN complex stimulates breast cancer cell survival significantly greater than cells 
exposed to VN alone (Kashyap et al., 2011). 
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Figure 3.1: Effect of VN, the IGF-II:VN and IGF-I:IGFBP:VN complexes on MCF-7 cellular 
viability. 
Viability of MCF-7 cells seeded for 72 hours into 96-well (for MTS assay) and 6-well (for trypan blue 
assay) plates pre-coated with VN alone or dimeric IGF-II:VN and trimeric IGF-I:IGFBP:VN 
complexes (TRI) was assessed using MTS (A) and trypan blue (B) viability assays. The data are 
pooled from three experiments with treatments tested in at least six and two wells in each replicate 
experiment for MTS and trypan blue assays, respectively. The data for MTS assay are expressed as 
the average percent stimulation of control wells containing only SFM (A) and for trypan blue assay 
the data are presented as the number of viable cells number for each treatment (B). The asterisks 
indicate treatments which significantly increased viability compared to the respective control 
treatments (for TRI vs VN (*p<0.05) and for VN vs SFM, TRI vs SFM and IGF-II+VN vs VN 
(**p<0.01), two-tailed student’s t-test). Both VN alone and the IGF:VN complexes significantly 
(p<0.01) increased MCF-7 cell viability compared to SFM control treatment. TRI complex-stimulated 
MCF-7 viability was significantly (p<0.05) greater than VN-stimulated viability. Error bars indicate 
SEM. SFM = Serum Free Media, VN = Vitronectin and TRI = trimeric IGF-I:IGFBP-5:VN complex. 
A 
B 
                MTS 
                Trypan blue 
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3.3.2 Optimal MCF-7 cell seeding density for studies in 6-well plates  
Previous studies have shown that high-density cell cultures result in 
morphological changes and influences endogenous gene expression (Wang & 
Adamo, 2000; Schmitt-Ney & Habener, 2004). Prior to performing microarray 
analysis, MCF-7 cell seeding density was optimised to avoid changes associated with 
cell confluency while allowing the cells to multiply to a sufficient number to 
facilitate efficient RNA extraction and yields. Since the maximum cell viability 
observed was in response to the IGF-I:IGFBP-5:VN complex, this treatment was 
used as the determinant to optimise the cell density. Cells treated with VN alone 
were also used in parallel for comparative purposes. Comparison of different cell 
densities grown in 6-well plates pre-coated with the IGF-I:IGFBP-5:VN complex 
over a 48 hour period showed that 5 x 10
5
 cells per well is the optimal seeding 
density for MCF-7 cells (Figure 3.2). This was clearly demonstrated in microscopic 
images wherein wells with 5 x 10
5
 cells reached an optimal sub-confluent density 
whereas wells with 7.5 x 10
5
 seeded cells reached an undesirable overly confluent 
state. In addition, 2.5 x 10
5
 cells per wells were not sufficient to obtain reliable 
amounts of RNA for downstream molecular analyses.  
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Figure 3.2: Optimisation of MCF-7 cell density for microarray analysis.  
Three different densities of MCF-7 cells, including 2.5 x 105, 5 x 105 and 7.5 x 105 cells per well were 
seeded into each well of 6-well plates pre-coated either with VN only or trimeric IGF-I:IGFBP:VN 
complex and allowed to grow for 48 hours. Cell confluency was observed and recorded using light 
microscopy. Scale bars indicate 100 μm. TRI = trimeric IGF-I:IGFBP:VN complex.  
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3.3.3 RNA Quality Control (QC) 
The quality and integrity of RNA can significantly impact the performance of 
microarray experiments. To confirm whether the total RNA samples extracted from 
MCF-7 breast cancer cells were intact and free of DNA contamination, 1 μL of the 
RNA sample was loaded onto a 2% agarose gel. The total RNA separated into two 
distinct 28S rRNA and 18S rRNA bands with an intensity ratio of 2:1, respectively 
(Figure 3.3). No smearing within the samples was observed, indicating the RNA was 
intact and free of any contaminating DNA.  
In addition, integrity, purity and the quantity of extracted RNA samples was 
determined by A260/A280 ratios (ideal A260/A280 and A230/A260 ratio for RNA is ~2.0) 
using UV spectroscopy. All isolated total RNA samples had A260/A280 and 
A230/A260 ratios of 2.00-2.15, indicating purity of the samples and yielded a 
sufficient quantity of RNA (Table 3.1). In addition, all samples demonstrated 
A260/A230 ratios above 2.0 indicating minimal solvent carry over. Taken together, 
these results indicated that all isolated total RNA samples were of sufficient quality 
to be used for downstream applications.  
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Figure 3.3: Integrity and quality check of RNA samples extracted from MCF-7 cells. 
MCF-7 cells were seeded into 6-well plates pre-coated with either VN alone or in combination with 
IGF-I+IGFBP-5 (TRI) and IGF-II. Cells were incubated for 12 and 48 hours, lysed and RNA was 
extracted using the Direct-zolTM RNA MiniPrepkit (Zymo Research). One µL RNA sample was 
loaded onto a 2% agarose gel, run for 30 minutes at 110 volts and visualised under UV light. Hundred 
base pair DNA molecular marker XIV (Roche) was run in parallel. SFM = Serum Free Media and TRI 
= trimeric IGF-I:IGFBP:VN complex. 
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Table 3.1. QC of isolated total RNA samples for microarray analysis.  
Purity and concentration of extracted RNA samples was measured using Nanodrop® ND-1000 
spectrophotometer. RNA samples with A260/A230 and A260/A280 ratios of 2.00 - 2.2 were considered 
valid for further downstream applications.  
RNA Conc (ng/µL) A260/A280 A260/A230 
SFM 12hrs (Exp-1) 166.6 2.03 2.04 
VN 12hrs (Exp-1) 267.9 2.02 2.10 
TRI 12hrs (Exp-1) 254.7 2.03 2.10 
IGF-II+VN 12hrs (Exp-1) 313.6 2.03 2.08 
SFM 48hrs (Exp-1) 157.0 2.03 2.01 
VN 48hrs (Exp-1) 347.5 2.00 2.12 
TRI 48hrs (Exp-1) 773.1 2.04 2.14 
IGF-II+VN 48hrs (Exp-1) 337.1 2.02 2.12 
SFM 12hrs (Exp-2) 377.5 2.03 2.15 
VN 12hrs (Exp-2) 404.4 2.00 2.15 
TRI 12hrs (Exp-2) 567.1 2.02 2.18 
IGF-II+VN 12hrs (Exp-2) 426.0 2.04 2.13 
SFM 48hrs (Exp-2) 508.8 2.07 2.13 
VN 48hrs (Exp-2) 444.4 2.03 2.13 
TRI 48hrs (Exp-2) 737.1 2.08 2.17 
IGF-II+VN 48hrs (Exp-2) 678.2 2.08 2.16 
SFM 12hrs (Exp-3) 250.4 2.04 2.06 
VN 12hrs (Exp-3) 546.0 2.13 2.07 
TRI 12hrs (Exp-3) 422.4 2.03 2.09 
IGF-II+VN 12hrs (Exp-3) 822.3 2.12 2.10 
SFM 48hrs (Exp-3) 475.0 2.01 2.09 
VN 48hrs (Exp-3) 532.1 2.14 2.05 
TRI 48hrs (Exp-3) 646.0 2.13 2.05 
IGF-II+VN 48hrs (Exp-3) 457.5 2.03 2.10 
SFM = Serum Free Media and TRI = trimeric IGF-I:IGFBP-5:VN complex. 
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3.3.4 Global gene expression patterns induced by VN and IGF:VN complexes 
Text files containing the individual raw array data (probe intensities) were 
generated using Illumina’s GenomeStudio® data analysis software (AGRF), imported 
into GeneSpring GX 11 software and pre-processed using Robust Multi-chip 
Average (RMA). Statistically significantly expressed gene across treatment groups, 
taking into account the variability within the three biological replicates per group 
were then identified using two-way ANOVA with BHFDR as the multiple testing 
correction (p<0.05). A data set containing probe intensities of 3650 gene identifiersas 
being significantly expressed (across the conditions for all biological replicates) in 
cells were then imported into R program to generate and plot a heatmap, using the 
“gplots” package. The heatmap provided a graphical representation of changes in 
global gene expression patterns in MCF-7 cells in response to VN alone, the IGF-
II:VN and IGF-I:IGFBP-5:VN in addition to control treatment (cells in SFM) (Figure 
3.4). The genes and treatments were clustered using hierarchical cluster analysis 
based on ‘similarity in expression’ using algorithms (Ward's minimum variance 
method) within the R package “gplots”. This method was also used to measure 
Euclidean distance between two treatments. The resulting analysis was graphed as 
dendrograms within the heatmaps and Euclidean distance maps.  
The clustering evident within the upper dendrogram (hierarchical tree) 
demonstrated that the largest difference in gene expression patterns is evident 
between the 12 and 48 hour time point samples (Figure 3.4). It is also seen that VN 
and the IGF-I:IGFBP:VN treatments among all treatments shared the most common 
pattern of gene expression changes at both 12 and 48 hour time points indicated by 
the homogenous shading and the strong clustering observed for these treatments. 
Moreover, very similar expression patterns were observed for VN, IGF-II:VN and 
IGF-I:IGFBP:VN treatments for the 48 hour time point. Furthermore, changes in 
gene expression induced by VN, IGF-II:VN and IGF-I:IGFBP:VN treatments in 
comparison with control SFM treatment were observed to be larger at 48 hours 
compared to those seen at the earlier 12 hour time point (Figure 3.4).  
These results can also be deduced from Euclidean distance map analysis 
(Figure 3.5). VN and IGF-I:IGFBP:VN treatments induced the most similar patterns 
of gene expression changes at 12 and 48 hour time points, indicated by the similar 
shading and the smaller Euclidean distances (between 16 to 18) and the late 
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branching of the dendrogram compared to other treatments (Figure 3.5). The IGF-
II:VN treatment was also found to have the most similar patterns of gene expression 
to VN and IGF-I:IGFBP:VN treatments with 18.9 and 19.3 Euclidean distance at 48 
hour time point, respectively.  
Taken together, these data suggest that changes in global gene expression 
patterns induced by VN alone, dimeric IGF-II:VN and trimeric IGF-I:IGFBP:VN 
complexes are greater at the longer (48 hours) time point compared to the early (12 
hours) time point when compared to cells grown in SFM control treatment. The 
clustering analysis also suggests that changes in gene expression patterns are strongly 
influenced by VN which is presented in all three treatments.  
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Figure 3.4: Heatmap of changes in global gene expression patterns.  
The heatmap was generated using the heatmap function in the “gplots” package of the R program. 
Statistically significant (p<0.05) gene identifiers across all three biological replicates in response to 
each tretament and time point were identified using GeneSpring GX 11 software. The clusters 
(hierarchical tree) were generated using hierarchical cluster algorithms based on Ward's minimum 
variance method within the R package “gplots”. The left and top dendrograms are clustering of genes 
and treatments, respectively based on similarity in expression levels. The expression of the gene is 
compared across all treatments, where low expression is indicated by green, while high expression is 
indicated in red. SFM = Serum Free Media and TRI = trimeric IGF-I:IGFBP:VN complex.  
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Figure 3.5: Euclidean distance map of changes in global gene expression patterns.  
Euclidean distance map produced by the R package “gplots”. The numerals signify the Euclidean 
distance between the treatments, with regards to their gene expression profiles. Statistically significant 
gene identifiersacross all three biological replicates were identified using GeneSpring GX 11 prior to 
Euclidean distance analysis. The Euclidean distance between two treatments and clustering was 
analysed using hierarchical cluster algorithms based on Ward's minimum variance method within the 
R package “gplots”. The closer the Euclidean distance is to zero indicates increasing similarity 
between the two treatments, with regards to their profiles. This is also demonstrated by the shading of 
the coloured square, where an increase in shading is proportional to increased similarity between the 
two treatments. Likewise, the dendrogram (hierarchical tree) on either side of the map clusters the 
treatments based on their similarity, with late branching indicating treatments which are more similar 
to each other. For example, the largest difference when comparing the treatments is IGF-II:VN (12 
hours) and TRI (48 hours) with Euclidean distance value of 59.54. SFM = Serum Free Media and TRI 
= trimeric IGF-I:IGFBP:VN complex. 
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3.3.5 Identification of differential gene expression 
Using GeneSpring GX 11 software, a number genes were identified to be 
significantly (p<0.05) expressed in response to each treatment compared to the 
control treatment at 12 and 48 hour time points. An additional ‘per gene 
normalisation’ step was performed in which the expression of each gene identifier 
across treatments was normalised against the median expression of the corresponding 
gene identifier on the control arrays. This ensured that genes which did not change 
across the treatments received a normalised expression value of one. Replicates for 
each sample array were obtained by “Treatment type”, effectively forming eight 
treatment groups, each containing the combined normalised data generated from the 
hybridisation of the 3 biological replicates. The 8 treatment groups were as follow 1) 
Control or no treatment at 12 hours (SFM at 12 hours), 2) VN alone at 12 hours, 3) 
IGF-I+IGFBP-5+VN at 12 hours, 4) IGF-II+VN at 12 hours, 5) no treatment at 48 
hours (SFM at 48 hours), 6) VN alone at 48 hours, 7) IGF-I+IGFBP-5+VN at 48 
hours and 8) IGF-II+VN at 48 hours.  
In order to identify differentially expressed genes in response to each treatment 
at 12 and 48 hours, pair-wise comparisons between each “treatment” group and the 
“control” group were performed. In addition, pair-wise comparisons between each 
“treatment” group and “VN alone” were also performed to identify IGF-I+IGFBP-5- 
and IGF-II-induced changes from those induced by VN. Statistically significant 
differentially expressed genes were then identified using two-way ANOVA with 
BHFDR as the multiple testing correction (p<0.05). The selection criteria of ±1.5-
fold were used to ensure critical genes which may not have a large magnitude of 
change was identified, while also keeping the data set to a manageable size.  
Table 3.2. Number of gene identifiers differentially regulated in pair-wise comparisons.  
The table shows the number of gene identifiers identified to be at least ±1.5-fold differentially 
expressed in each pairwise comparison (p<0.05). SFM = Serum Free Media and TRI = trimeric IGF-
I:IGFBP:VN complex. 
12 hours VN TRI IGF-II+VN 
Control (SFM) 245 263 362 
VN - 104 216 
  48 hours  
Control (SFM) 568 594 595 
VN - 147 164 
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Since the control arrays (SFM treatments) represented RNA isolated from cells 
grown in un-coated wells, the number of transcripts differentially regulated by VN 
only, IGF-II:VN and IGF-I:IGFBP:VN treatments were compared to the control 
arrays. A number of transcripts were identified to be differentially expressed in 
MCF-7 cells by VN alone (245 at 12 hours and 568 at 48 hours), IGF-I:IGFBP:VN 
(263 at 12 hours and 594 at 48 hours) and IGF-II:VN (362 at 12 hours and 595 at 48 
hours) treatments when compared to the control arrays (Table 3.2). As expected in 
view of enhanced survival observed in MCF-7 cells in response to IGF-I:IGFBP:VN 
compared to VN alone treatments (Figure 3.1), a substantial number of IGF-
I:IGFBP:VN-unique transcripts were identified. Cells treated with IGF-I:IGFBP:VN 
were seen to have 104 and 147 uniquely regulated genes at the 12 and 48 hour time 
points compared to cells treated with VN only, respectively. Similarly, 216 genes at 
12 hours and 164 genes at 48 hours were uniquely regulated in these cells by the 
IGF-II:VN treatment when compared to cells treated with VN alone.  
Direct pair-wise comparison of treatments also demonstrated a considerable 
overlap in probes differentially expressed in response to VN alone, IGF-I:IGFBP:VN 
and IGF-II:VN treatments compared to the control treatment with 97 and 378 genes 
at 12 and 48 hour time points, respectively (Figure 3.6). Specifically, 40% (146 out 
of 362) and 60% (159 out of 263) of differentially expressed genes in response to 
IGF-II:VN and IGF-I:IGFBP:VN treatments were in common with VN treatment at 
12 hour time point, respectively. Similarly, the IGF-II:VN and IGF-I:IGFBP:VN 
treatment groups were shared 72 % (428 out of  595) and 80% (447 out of 594) of 
differentially expressed genes at 48 hours with VN treatment group (Figure 3.6). 
This indicates that the majority of transcripts differentially regulated by these three 
treatments, in comparison to the control cells, are most likely due to the effect of VN 
which is present in all treatments. This implies that VN is potentially responsible for 
the majority of changes in the gene expression identified in these treatments. Since 
VN was observed to be a significant contributor to the functional responses induced 
by IGF:VN treatments, it was no surprise that VN was observed to induce the bulk of 
the changes in gene expression stimulated by IGF-II:VN and IGF-I:IGFBP:VN 
treatments. This will be discussed in further detail in the following chapter.  
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Figure 3.6: Pair-wise comparisons of gene identifiers differentially expressed. 
All gene identifiers passed a ±1.5-fold change threshold compared to the control samples and two-way 
ANOVA with BHFDR, p<0.05. The venn diagram shows the number of gene identifiers in common 
or uniquely expressed by each treatment when compared to the expression of the control group 
(SFM). SFM = Serum Free Media and TRI = trimeric IGF-I:IGFBP-5:VN complex. 
  
12 hour 48 hour 
hour 
VN vs SFM 
(245 probes) 
TRI vs SFM 
(263 probes) 
IGF-II+VN vs SFM 
(362 probes) 
IGF-II+VN vs SFM 
(595 probes) 
VN vs SFM 
(568 probes) 
TRI vs SFM 
(594 probes) 
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3.3.6 Gene ontology analysis of differentially regulated genes by VN and the 
IGF:VN complexes 
The microarray analysis produced large data sets of genes differentially 
expressed in response to VN alone, dimeric IGF-II:VN and trimeric IGF-I:IGFBP-
5:VN complexes at 12 and 48 hour time points. Such differentially expressed genes 
are often from a diverse range of gene families associated with a variety of biological 
functions. Ingenuity Pathway Analysis (IPA) software was used to interpret and 
place differentially regulated genes in the context of biological processes and 
networks. Data sets containing genes identified as being significantly differentially 
expressed in MCF-7 cells by at least ±1.5-fold compared to the control SFM 
treatment at both 12 and 48 hours were uploaded into IPA. Out of the probe 
identifiers uploaded for each data set, > 90% were identified and mapped to 
corresponding gene objects in the Ingenuity Knowledge Base (termed focus genes).  
Biological functions were assigned to the whole data set using IPA knowledge 
base reference database. A propriety ontology representing over 300,000 classes of 
biological objects and millions of individual modelled relationships between 
proteins, genes, complexes, cells, tissues, small molecules and diseases was used to 
identify enriched biological functions associated with differentially expressed genes 
in response to each treatment. Molecular and cellular functions with a Fischer’s exact 
test score below 0.05 and containing at least 3 focus genes were considered 
significant. IPA analysis identified a number of biological functions associated with 
genes differentially regulated. For full details of biological processes associated with 
genes differentially regulated at 12 hour and 48 hour time points, refer to 
(Appendices 6 to 8). Ranked in order of significance, Figures 3.7 and 3.8 display the 
top ten biological functions associated with genes differentially expressed in 
response to VN, IGF-II:VN and IGF-I:IGFBP:VN treatments at 12 and 48 hour time 
points.  
Biological processes involved in “cellular development” followed by “cellular 
growth and proliferation” were found to be the most significant functions associated 
with genes differentially expressed at 12 hours among all three treatments (Figure 
3.7). Similarly, “cellular growth and proliferation” was identified as one of the 
highest ranking functional categories associated with differentially expressed genes 
at 48 hours in response to VN, IGF-II:VN and IGF-I:IGFBP:VN treatments, 
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containing 153, 113 and 171 focused genes, respectively (Figure 3.8). “Cellular 
movement” was also found as one of the most significant functional categories 
associated with differentially expressed genes at 48 hours. Importantly, “cell death 
and survival” was identified as one of the most significant functional categories at 
both 12 hour (42, 83 and 57 focus genes) and 48 hour time points (130, 102 and 149 
focus genes) for cells treated with VN, IGF-II:VN and IGF-I:IGFBP:VN, 
respectively (Figure 3.8).   
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Figure 3.7: Top ten molecular and cellular functions associated with differentially expressed genes at 
12 hours. 
Out of all differentially expressed genes at 12 hours in response to VN, IGF-II:VN and IGF-I:IGFBP-
5:VN treatments, 196, 304 and 220 genes, respectively, were identified and mapped as gene objects in 
Ingenuity Pathway Knowledge for molecular and cellular function analysis. Molecular and cellular 
functions were ranked in the order of significance with a Fischer’s exact test score below 0.05 and 
containing at least 4 focus genes. Number of involved genes associated with each biological function 
is also represented within the columns of the bar graph. SFM = Serum Free Media.  
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Figure 3.8: Top ten molecular and cellular functions associated with differentially expressed genes at 
48 hours. 
Out of all differentially expressed genes at 48 hours in response to VN, IGF-II:VN and IGF-I:IGFBP-
5:VN treatments, 507, 530 and 519 genes, respectively, were identified and mapped as gene objects in 
Ingenuity Pathway Knowledge for molecular and cellular function analysis. Molecular and cellular 
functions were ranked in the order of significance with a Fischer’s exact test score below 0.05 and 
containing at least 4 focus genes. Number of involved genes associated with each biological function 
is also represented within the columns of the bar graph. SFM = Serum Free Media.   
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3.3.7 Pathway analysis 
Canonical pathway analysis was performed to relate the differentially 
expressed genes to well documented biological pathways. This analysis identified the 
pathways from the IPA library of canonical pathways that were most significant to 
the genes expressed differentially in cells treated with VN, IGF-II:VN and IGF-
I:IGFBP-5:VN treatments. To assign canonical pathways to the dataset the 
significance p-value as well as the ratio of focus genes to overall genes in each 
pathway was used. Since the number of differentially expressed genes with roles in 
cell survival at 48 hours was substantially more than those detected at12 hours, the 
48 time point was chosen to report the data obtained from the canonical pathway 
analysis. 
Table 3.3 depicts the top ten canonical pathways associated with differential 
gene expression for each treatment at 48 hours. When ranked according to p-value, 
the Aryl Hydrocarbon Receptor (AHR) pathway was identified as the most 
significant canonical pathway in response to VN (p = 1.37 x 10
-3
), IGF-II:VN (p = 
2.03 x 10
-3
) and IGF-I:IGFBP-5:VN (p = 9.82 x 10
-5
) treatments (Table 3.3). The 
transforming Growth Factor beta (TGFβ) signalling pathway with previously 
reported roles in breast cancer progression (Buck & Knabbe, 2006) was ranked as the 
second highest (P = 1.25 x 10
-3
) canonical pathway associated with IGF-I:IGFBP-
5:VN treatment. This pathway was also found to be one of the most significant 
pathways in response to VN alone (P = 1.81 x 10
-2
) and IGF-II:VN (P = 6.44 x 10
-3
) 
treatments. Interestingly, molecular mechanism of cancer was one the highest 
ranking canonical pathways associated with IGF-II:VN (P = 5.22 x 10
-3
) and IGF-
I:IGFBP-5:VN (P = 1.48 x 10
-3
) complexes at 48 hours (Table 3.3).  
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Table 3: Top ten canonical pathways associated with differentially expressed genes at 48 hours. 
Top ten canonical pathways identified by IPA as being associated with genes differentially expressed 
(±1.5-fold) at 48 hours in response to VN, IGF-II:VN and IGF-I:IGFBP-5:VN treatments (p<0.05). 
VN vs SFM 
Canonical pathway Significance        
p-value 
Ratio
* 
AHR signalling 1.37 x 10-3 10/141 (0.071) 
RAR activation 2.93 x 10-3 11/179 (0.061) 
NRF2-mediated oxidative stress response 3.65 x 10-3 11/187 (0.059) 
GDP-glucose biosynthesis 5.45 x 10-3 2/5 (0.4) 
GDNF family ligand-receptor interactions 5.7 x 10-3 6/70 (0.086) 
Glucose and glucose-1-phosphate degradation 8.05 x 10-3 2/6 (0.333) 
Thyroid cancer signalling 1.5 x 10-2 4/4 (0.098) 
UVC-Induced MAPK Signalling 1.72 x 10-2 4/42 (0.095) 
TGF-β signalling 1.81 x 10-2 6/93 (0.065) 
Glycogen degradation II 1.84 x 10-2 2/9 (0.222) 
IGF-II+VN vs SFM 
AHR signalling 2.03 x 10-3 10/141 (0.071) 
Hereditary breast cancer signalling 2.13 x 10-3 9/119 (0.076) 
Role of CHK proteins in cell cycle checkpoint control 2.56 x 10-3 6/57 (0.105) 
ATM signalling 3.65 x 10-3 6/61 (0.098) 
Cell cycle: G2/M DNA damage checkpoint regulation 4.39 x 10-3 5/48 (0.104) 
Mitotic roles of polo-like kinase 4.68 x 10-3 6/64 (0.094) 
Molecular mechanisms of cancer 5.22 x 10-3 17/363 (0.047) 
NRF2-mediated oxidative stress response 5.42 x 10-3 11/187 (0.059) 
GPD-glucose biosynthesis 6.05 x 10-3 2/5 (0.4) 
TGF-β signalling 6.44 x 10-3 7/93 (0.075) 
IGF-I+IGFBP-5+VN vs SFM 
AHR signalling 9.82x 10-5 12/141 (0.085) 
TGF-β signalling 1.25 x 10-3 8/93 (0.086) 
Molecular mechanisms of cancer 1.48 x 10-3 18/363 (0.05) 
LPS/IL-1 mediated inhibition of RXR function 1.93 x 10-3 13/222 (0.083) 
Regulation of IL-2 expression in activated and anergic 
T lymphocytes 
2.47 x 10-3 7/84 (0.069) 
Epithelial adherens junction signalling 2.75 x 10-3 10/144 (0.119) 
UVC-induced MAPK signalling 3.36 x 10-3 5/42 (0.5) 
Tight junction signalling 4.06 x 10-3 10/157 (0.064) 
NRF2-mediated oxidative stress response 4.07 x 10-3 11/187 (0.059) 
ILK signalling 4.82 x 10-3 11/185 (0.059) 
* Ratio of focus genes present in each pathway 
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3.3.8 Network analysis 
The IPA network analysis was further performed to investigate regulatory 
networks associated with the differentially expressed genes in cells treated with VN, 
IGF-II:VN and IGF-I:IGFBP-5:VN. To start generating networks, IPA queries the 
IPA Knowledge Base for interactions between focus genes and all other gene objects 
stored in the knowledge base, and generates a set of networks to describe the 
functional relationships between gene products based on known interactions in the 
literature. The output, displayed graphically as nodes (genes) and edges (the 
biological relationship between the nodes), provides a detailed representation of a 
number of biological pathways and functions implicated by the data set. The tool 
then associates these networks with known biological pathways. Using a 99.9% 
confidence level (score ≥ 3) that the genes present in a particular network are not due 
to random chance, the tool identified and mapped 15 and 25 networks significantly 
associated with differential gene expression in response to each treatment at 12 and 
48 hour time points, respectively. The networks generated ranged in score depending 
of their significance and number of focus genes. Differentially expressed genes 
associated with the top five functional networks are reported in (Appendices 9 to 11). 
Network analysis indicated that a number of networks, including the top two 
significant networks associated with genes differentially expressed at 12 and 48 
hours in response to VN and the IGF:VN complexes, contained PI3-K, AKT, ERK 
and MAPK signalling pathways primarily as central nodes in these networks. This is 
in alignment with previous reports from our laboratory and others showing activation 
of PI3/K/AKT and MAPK/ERK pathways by VN and the IGF:VN complexes 
(Salasznyk et al., 2004; Hollier et al., 2008; Kashyap et al., 2011; Bae et al., 2012). 
Specifically, differentially expressed genes at 12 hours in response to each treatment 
were found to be significantly associated with 5 networks out of 15 mapped networks 
containing PI3K, AKT and ERK signalling pathways (data not shown). Although not 
differentially regulated, these pathways mapped primarily to the core of associated 
networks. Interestingly, all three pathways were found to be involved in the top two 
ranking networks associated with VN, IGF-II:VN and IGF-I:IGFBP:VN treatments 
at 12 hours (Figure 3.9). This indicates the possibility that VN and the IGF:VN 
complexes may regulate the activity of a number of genes present in these networks 
via PI3K, AKT and ERK pathways.   
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Figure 3.9: Top two functional networks associated with differentially expressed genes at 12 hour.  
The top two ranking networks significantly associated with genes differentially expressed by VN, 
IGF-II:VN and IGF-I:IGFBP-5:VN treatments at 12 hours. These pathways were found to contain key 
survival signalling pathways including, PI3K, AKT and ERK pathways (bold letters and colour coded 
in yellow). Nodes are colour coded according to their gene expression determined by the microarray 
analysis (red, up-regulated; green, down-regulated). Unshaded nodes or presented in yellow colour 
were either not on the expression array or not significantly regulated. Number of focus genes in each 
network and the score are also shown for each network. The score reflects the negative algorithm of p-
value that indicates the likelihood of the focus genes in a network being found together due to random 
chance. Scores of 3 or higher have a 99.9% chance of not being generated by random chance alone.  
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Functional network analysis of genes at 48 hours also identified 5 networks 
containing PI3K, AKT and ERK pathways out of the 25 mapped networks. Similar to 
networks identified at 12 hours, the two highest ranking networks associated with 
genes at 48 hours were found to contain PI3-K and AKT within the networks (Figure 
3.10). The ERK pathway also mapped to the third most significant network 
(Appendices 9 to 11). Furthermore, members of Nuclear Factor kappa-light-chain-
enhancer of activated B cells (NF-κB) family were found to map to the core of the 
top two networks in response to all treatments tested at 48 hours (Figure 3.10). In 
addition, this pathway mapped to the core of the highest ranking pathways for both 
12 and 48 hours in response to the IGF-II:VN treatment (Figures 3.9 & Figure 3.10). 
This suggests that NF-κB pathway may play an important role in IGF-II:VN 
complex-induced changes in gene expression. With regards to the IGF-I:IGFBP-
5:VN treatment, the oncogene FOS was seen to map to the core of the most 
significant network at 48 hours (Figure 3.10).  
VN via ligation of cell surface integrins can also trigger intracellular signalling 
cascades via FAK and the Src tyrosine kinase pathways, which affect critical cellular 
events contributing to cancer progression, including cell attachment, cell 
proliferation and cell survival (Hapke et al., 2003; Hurt et al., 2010). Interestingly, 
genes differentially expressed in cells treated with VN or the IGF:VN complexes at 
both time points were found to be associated with networks containing FAK and Src 
signalling pathways. Networks containing the FAK pathway were found to include 
other associated intracellular signalling intermediates including, Src, MAPK, P38 
MAPK, MAP2K 1/2, PI3K and ERK pathways in addition to the integrin receptors 
being mapped as the major core nodes to these FAK containing networks (Figure 
3.11). This is likely due to the effect of VN-binding integrins activating FAK 
phosphorylation (Hurt et al., 2010) which subsequently triggers other signalling 
pathways downstream, such as AKT and MAPK (McLean et al., 2005). Taken 
together, these data suggest the involvement of intracellular MAPK/ERK, 
PI3K/AKT, FAK, Src and NF-κB pathways in VN- and IGF:VN complex-stimulated 
MCF-7 breast cancer cell survival. In addition, these results suggest the possibility 
that the differential expression of genes involved in these networks may play an 
important role in VN- and IGF:VN-induced cell survival. These data also provide 
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further insights into the selection of critical pathways for identification of the 
mechanisms underlying VN- and IGF:VN- complex-induced cell survival.  
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Figure 3.10: Top two functional networks associated with differentially expressed genes at 48 hours. 
The top two ranking networks significantly associated with genes differentially expressed in response 
to VN, IGF-II:VN and IGF-I:IGFBP-5:VN at 48 hours. These pathways were found to contain key 
survival signalling pathways including, PI3K, AKT, ERK and NF-κB pathways (bold letters and 
colour coded in yellow). Nodes are colour coded according to their gene expression determined by the 
microarray analysis (red, up-regulated; green, down-regulated). Unshaded nodes or presented in 
yellow colour were either not on the expression array or not significantly regulated. Number of focus 
genes in each network and the score are also shown for each network. The score reflects the negative 
algorithm of p-value that indicates the likelihood of the focus genes in a network being found together 
due to random chance. Scores of 3 or higher have a 99.9% chance of not being generated by random 
chance alone.  
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Figure 3.11: FAK-containing networks associated with differentially expressed genes at 12 hours and 
48 hours. 
Networks containing FAK signalling pathways significantly associated with genes differentially 
expressed in response to VN, IGF-II:VN and IGF-I:IGFBP-5:VN treatments at 12 hour and 48 hour 
time points. These pathways were found to contain other key members of intracellular signals 
including, MAPK, P38 MAPK, MAP2K 1/2, ERK and PI3K pathways as well as integrin receptors 
(colour coded in orange). Nodes are colour coded according to their gene expression determined by 
the microarray analysis (red, up-regulated; green, down-regulated). Unshaded nodes or presented in 
yellow and orange colours (except integrin which are up-regulated) were either not on the expression 
array or not significantly regulated. Number of focus genes in each network and the score are also 
shown for each network.   
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3.3.9 qRT-PCR validation of differentially expressed genes 
A number of genes determined by microarray analysis to be differentially 
regulated and deemed biologically interesting because of their IPA classification into 
relevant cell survival categories were selected for validation using qRT-PCR. In 
addition, among these genes, several genes were observed to be regulated by 
members of key intracellular singling pathways such as FAK, Src, MAPK/ERK and 
PI3-K/AKT pathways. Hence, to validate the microarray data, the expression of 21 
genes with roles in cell survival and/or involvement in key signalling pathways was 
assessed using qRT-PCR analysis (Table 3.4).  
 The differential expression of 16 up-regulated (Figure 3.12 A, B, C & D) and 
5 down regulated (Figure 3.13 A & B) target genes were confirmed. The IGF-
I:IGFBP-5:VN treatment was found to change the expression of genes namely, 
LAMB1, GABRP, NBPF20, FZD8, NFIB, HSPB8, PAK4 and MTSS1 above the 
IGF-II:VN- or VN-induced levels, although the expression of the majority of target 
genes remained relatively unchanged across all three treatments. This likely suggests 
that although the IGF-I:IGFBP:VN complex increases the expression of a few 
candidate genes, overall the gene expression profiles of target genes are strongly 
influenced by VN which is present in all treatment groups. This was also suggested 
by the microarray data wherein the majority of genes differentially expressed in these 
treatments were seen to be commonly regulated by VN.  
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Table 3.3. Target genes for qRT-PCR analysis. 
Gene 
Symbol 
Full name Regulation 
Fold change identified by 
Microarray analysis 
VN IGF-
II:VN 
TRI 
JUN Cellular oncogene JUN or c-JUN Up 2.00 1.83 1.68 
FOS Cellular oncogene FOS or c-FOS Up 3.40 2.70 2.52 
CD24 Cluster of Differentiation 24 Up 1.40 1.64 1.52 
TGFβ2 Transforming Growth Factor beta 2 Up 5.30 5.32 6.60 
VAV2 vav2 guanine nucleotide 
exchange factor 
Up 1.28 1.11 1.59 
LAMB1 Laminin beta Up 1.90 2.2 2.87 
CTGF Connective Tissue Growth Factor Up 7.96 6.055 6.32 
GABRP Gamma-aminobutyric acid 
receptor subunit pi 
Up 21.59 27.70 28.76 
NBPF20 Neuroblastoma Breakpoint Family, 
Member 20 
Up 1.01 1.04 1.95 
FZD8 Frizzled class receptor 8 Up 1.30 1.51 1.65 
RASGRP1 RAS guanyl releasing protein 1 Up 5.76 5.04 5.33 
ZIC Zinc finger of the cerebellum Up 1.24 1.52 1.86 
HSPB8 Heat shock protein beta Up 1.98 1.76 1.62 
Cyr61 Cysteine-rich angiogenic inducer 61 Up 5.76 4.54 5.44 
ANXA2 Annexin A2 Up 1.34 1.62 1.79 
NFIB Nuclear factor 1 B-type Up 1.35 1.21 1.56 
H19 Imprinted maternally expressed 
transcript H19 
Down 4.98 2.40 2.58 
SPDEF SAM pointed domain-containing 
ETS transcription factor 
Down 1.60 1.52 1.811 
MTSS1 Metastasis suppressor 1 Down 1.60 1.55 1.77 
XBP1 X-box binding protein 1 Down 1.59 1.59 1.51 
PAK4 p21 protein (Cdc42/Rac)- 
activated kinase 4 
Down 1.30 1.57 1.78 
VN = Vitronectin and TRI = trimeric IGF-I:IGFBP-5:VN complex.  
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Figure 3.12: qRT-PCR validation of up-regulated target genes identified by microarray analysis. 
(A, B, C & D) mRNA expression of each target gene was normalised to GAPDH and data from each 
treatment were expressed as the fold change to control treatment (SFM). The asterisks indicate 
treatments with significant increase in gene expression compared to SFM (*p<0.05, **p<0.01, two-
tailed student’s t-test). The data are pooled from three experiments with treatments tested in at least 
three wells in each replicate experiment. Error bars indicate SEM. SFM = Serum Free Media and TRI 
= trimeric IGF-I:IGFBP-5:VN complex.  
D 
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Figure 3.13: qRT-PCR validation of down-regulated target genes identified by microarray analysis. 
(A & B) mRNA expression of each target gene was normalised to GAPDH and data from each 
treatment were expressed as the fold change to control treatment (SFM). The asterisks indicate 
treatments with significant decrease in expression compared to SFM (*p<0.05, **p<0.01, two-tailed 
student’s t-test). The data are pooled from three experiments with treatments tested in at least three 
wells in each replicate experiment. Error bars indicate SEM. SFM = Serum Free Media and TRI = 
trimeric IGF-I:IGFBP-5:VN complex.  
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To fully validate the microarray data, the relative mRNA levels for target genes 
were assessed across SFM (control), VN alone, IGF-I+IGFBP-5+VN and IGF-
II+VN treatments. The expression levels for each candidate gene was then 
normalised to GAPDH and fold expression relative to control samples determined. 
This was then compared to the fold change values identified by microarray analysis 
in response to each treatment compared to the control SFM treatment. Correlation of 
relative fold change values were then analysed using the Pearson product-moment 
correlation coefficient in GraphPad Prism 6 software. The results indicated a 
significant (p<0.0001) correlation between the differential expression determined by 
microarray analysis and the relative gene expression assessed by qRT-PCR (Figure 
3.14). This, therefore aids in validating the data set of genes identified to be 
differentially regulated in response to VN alone, the dimeric IGF-II:VN and trimeric 
IGF-I:IGFBP-5:VN complexes.  
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Figure 3.14: Correlation of gene expression levels of 21 target genes determined by microarray 
analysis with qRT-PCR analysis. 
Correlations of relative fold change of 21 genes differentially expressed in response to VN alone, the 
dimeric IGF-II:VN and trimeric IGF-I:IGFBP-5:VN complexes compared to the control treatment 
(SFM) for 48 hour time point samples as determined by microarray analysis vs qRT-PCR analysis 
using the Pearson product-moment correlation coefficient analysis in GraphPad Prism 6 software.  
  
Microarray vs qRT-PCR 
Microarray  
qRT-PCR  
Coefficient correlation: 0.8997 
P<0.0001 
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3.4 DISCUSSION 
It is widely accepted that the development, progression and subsequent 
metastasis of breast cancer is largely influenced by constituents of the ECM (Lochter 
& Bissell, 1995; Bissell & Radisky, 2001; Muschler & Streuli, 2010). Less well 
established is the extent to which these ECM components actually enhance cancer, 
and the involvement of the downstream mediators of such functions. In this regard, 
VN, an ECM glycoprotein, has been shown to induce cell survival, differentiation 
and tumour formation in a number of cancers, including breast cancer (Aaboe et al., 
2003; Hurt et al., 2010). Moreover, altered interactions between mitogenic hormones 
and growth factors (GFs) such as IGFs are amongst the most important factors 
promoting breast cancer progression (Beattie et al., 2010). In view of this, previous 
work within our laboratory has demonstrated that IGF-I can associate with the ECM 
protein VN through IGFBP-2, -3, -4 and -5, forming multiprotein IGF-I:IGFBP:VN 
complexes (Kricker et al., 2003) that are capable of stimulating increased breast 
cancer cell migration and survival and inhibiting drug-induced apoptosis (Hollier et 
al., 2008; Kashyap et al., 2011). IGF-II was also shown to bind directly to VN 
forming dimeric IGF-II:VN complexes (Upton et al., 1999), which were shown to 
stimulate increased breast cancer cell proliferation and migration (Noble et al., 
2003).  
Previous studies within our laboratory have largely focused on complex-
induced migration. Using microarray analysis, a number of unique differentially 
expressed genes were identified in non-tumorigenic MCF10A breast cells that had 
migrated in response to the trimeric IGF-I:IGFBP:VN complex. Some of these genes 
are known to be involved in cell movement, growth and survival, including Tissue 
Factor (TF), Stratifin (SFN), Ephrin-B2 (EFNB2), Plasminogen Activator Inhibitor-1 
(PAI-I), and Basic helix-loop-helix B2 (BHLHB2). The role of TF and SFN in 
IGF:VN-induced migration were also investigated and confirmed using gene knock-
down and overexpression techniques. However, such downstream molecular 
mediators of IGF-I:IGFBP:VN- and IGF-II:VN-stimulated cell survival have not yet 
been investigated. In addition, the identity of molecular mediators responsible for 
VN-induced cell survival remains to be resolved. Hence, the studies reported in this 
chapter attempted to identify differentially expressed genes involved in cell survival 
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stimulated by VN alone, the dimeric IGF-II:VN and trimeric IGF-I:IGFBP-5:VN 
complexes. 
To study the changes in gene expression accompanying the VN and IGF:VN 
complex-induced cell survival, the strategy adopted was to culture cells in tissue 
culture plastic wells pre-coated with VN bound to IGF-I+IGFBP-5 or IGF-II. This 
substrate-bound strategy was adopted to identify genes more accurately representing 
the molecular and cellular mediators involved in cell survival stimulated by VN and 
the IGF:VN complexes. In vivo, ECM proteins bind soluble growth factors and 
regulate their activation, distribution and presentation to cells (Hynes, 2009). In 
addition, the binding of growth factors and ECM proteins can result in maintenance 
of local growth factor concentrations, modulate growth factor receptor interactions 
and signalling, and also alter the diffusion of growth factors through the matrix 
(Taipale & Keski-Oja, 1997). Indeed, ECM-bound IGFBP-5 has been shown to 
enhance the effects of IGF-I on smooth muscle cell DNA synthesis, whereas IGFBP-
5 added in solution had no effect on IGF-I-mediated effects (Jones et al., 1993). To 
accommodate the influence of ECM on growth factor responses, substrate-bound 
approaches were adopted in the hope that the genes identified would more accurately 
represent the actual cellular and molecular processes involved in stimulated cell 
survival in comparison to the more common and relatively static pre-plated culture 
methodologies previously adopted by others. It was envisioned our approach would 
also reduce the number of genes identified that may be irrelevant to our phenotype of 
interest, thus making the data sets obtained more manageable for further analysis. 
Using genome-wide microarray analysis the changes in gene expression 
patterns were identified in MCF-7 breast cancer cells treated with substrate-bound 
VN alone, the IGF-II:VN and IGF-I:IGFBP-5:VN complexes when compared to the 
cells in the control SFM treatment. Furthermore, using a threshold of ±1.5-fold (two-
way ANOVA with BHFDR, p<0.05), a substantial number of genes were identified 
to be up- or down-regulated in response to each treatment (Figure 3.6). It was also 
found that VN is the component responsible for the majority of changes in global 
gene expression patterns induced by the IGF:VN complex. This was represented by 
the high degree of commonality in genes differentially regulated by VN alone, IGF-
II:VN and IGF-I:IGFBP-5:VN treatments. IGF-I and IGF-II were seen in our current 
and previous studies (Noble et al., 2003; Hollier et al., 2008; Kashyap et al., 2011) to 
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stimulate cell migration and survival responses above those responses observed in 
VN alone. However, cell migration and survival responses induced by VN were still 
significantly higher than that observed in SFM controls (Upton et al., 2008; Kashyap 
et al., 2011). This suggests that VN was the key component in IGF-mediated cell 
responses, including migration and survival. Thus, it was no surprise that VN was 
also the component which induced the majority of differential gene expression 
stimulated by IGF-II:VN and IGF-I:IGFBP-5:VN treatments. Moreover, there were a 
significantly larger number of differentially expressed genes at 48 hours compared to 
12 hours, suggesting a more predominant effect of VN and the IGF:VN complexes at 
longer time points. Nevertheless, we have also identified a subset of differentially 
expressed genes uniquely regulated by IGF-II:VN and IGF-I:IGFBP-5:VN 
complexes, most likely acting via direct action of IGF-II and IGF-I presented in these 
complexes, respectively. Further studies using non-receptor binding IGF-I and IGF-II 
analogues, such as [L24][A31]-IGF-I and [Leu27]IGF-II would be required to 
confirm this direct action on cells. 
The microarray analysis allowed for a global view of treatment induced 
transcriptional responses across time points. Providing us with the first ever insight 
into downstream molecular events underpinning these ECM:GF complexes. 
However, to place the differentially expressed genes in a biological context, pathway 
and network analysis was performed using the IPA knowledge base. Overall, the 
entire data set of differentially expressed genes were determined to be highly 
associated with a number of important molecular and cellular functions, the most 
significant of which included functions such as “cell development”, “cell growth and 
proliferation”, “cell assembly and organisation”, “cell cycle”, “cell movement” and 
“cell death and survival” (Figures 3.7 and 3.8). This is in accordance with well 
documented effects of VN and IGF family members on cell growth, proliferation, 
migration, inhibition of cell cycle arrest and cell survival (Annunziata et al., 2011; 
Preissner & Reuning, 2011; Hazawa et al., 2012; Leavesley et al., 2013). 
Importantly, biological functions related to cell survival, namely “cell growth and 
proliferation” and “cell death and survival” were ranked as one of the most 
significant biological functions, adding further evidence for prosurvival effects on 
VN and IGF:VN complexes on MCF-7 breast cancer cells confirming the prosurvival 
effect of VN and the IGF:VN complexes on MCF-7 breast cancer cells. 
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Comparing and contrasting treatments and time points, there were a substantially 
larger number of differentially expressed genes with roles in the “cell growth and 
proliferation” and “cell death and survival” at the 48 hour compared to the 12 hour 
time-point. This suggests that VN and the IGF:VN complexes, in particular IGF-
I:IGFBP:VN complex augment their prosurvival effects at longer time points by 
stimulating cell survival genes at later time points. Moreover, further VN- and 
IGF:VN-induced induction and expression of a larger number of genes with roles in 
cell growth and proliferation at 48 hours. This suggests that differential expression of 
these genes may be critical for cells progressing through the lag phase of 
growth/proliferative and subsequently entering the exponential phase. This in turn 
may be potentially responsible for the concomitant increase in cell survival as 
measured over a longer 72 hour time period (Figure 3.1). This also fits in well with 
our previous observations wherein cell viability assessed over 24, 48 and 72 hours in 
response to these treatments demonstrated significant changes only at 48 and 72 
hours, with no changes observed at 24 hours (Kashyap et al., 2011). Moreover, 
differentially expressed genes in response to the IGF-I:IGFBP-5:VN complex at 48 
hours were found to contain more genes involved in the “cell growth and 
proliferation” biological function (171 focus genes) compared to VN (153 focus 
gene) and IGF-II:VN (113 focus gene) treatments. A similar result was also observed 
for differentially expressed genes involved in the “cell death and survival” biological 
function (Figures 3.7 & 3.8). This can also be reflected in the greater levels of cell 
viability stimulated by IGF-I:IGFBP-5:VN treatment compared to VN and IGF-
II:VN treatments (Figure 3.1). In addition, “cellular movement” was identified as one 
of the highest ranking biological functions associated with differentially expressed 
genes at 48 hours in response to VN, IGF-II:VN and IGF-I:IGBP-5:VN treatments. 
This is in concordance with our previous reports of these treatments stimulating 
MCF-7 transwell migration (Kricker et al., 2003; Noble et al., 2003; Hollier et al., 
2008; Kashyap et al., 2011). 
It is well documented that ECM proteins through binding cell surface integrin 
receptors trigger FAK, Src, PI3-K/AKT, MAPK/ERK and NF-κB signalling 
pathways promoting survival (Stupack & Cheresh, 2002). Using the IPA knowledge 
base a number of networks and functional pathways were identified to be 
significantly associated with the differentially expressed genes within our dataset. 
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Interestingly, out of all mapped networks at each time point, 5 networks were 
identified to include the intracellular PI3-K/AKT and MAPK/ERK pathways mapped 
to the core of the network. Importantly, these networks were found to be among the 
highest ranking networks associated with genes differentially expressed in response 
to VN and the IGF:VN complexes (Figures 3.9 and 3.10). This is in accordance with 
our previous results demonstrating that VN- and IGF:VN complex-stimulated breast 
cancer cell survival is mediated via the PI3-K/AKT and MAPK/ERK pathways 
(Hollier et al., 2008; Kashyap et al., 2011).  
Genes differentially expressed in cells treated with VN and the IGF:VN 
complexes were also identified to be associated with networks containing FAK and 
Src signalling pathway intermediates. This is consistent with previous findings 
indicating that FAK and Src are involved in VN stimulated cell adhesion, cell 
migration and cell survival (Hapke et al., 2003; Hurt et al., 2010). FAK also acts as a 
receptor-proximal bridging protein that links growth factor receptor and integrin 
signalling pathways to promote both growth factor and integrin-mediated 
downstream effects (Sieg et al., 2000). Upon ligation of integrins with VN, FAK is 
autophosphorylated, creating a high affinity binding site for proteins containing the 
Src homology 2 (SH2) domain, namely proteins including the upstream Src kinase 
itself, proto-oncogene Crk (p38) and lymphocyte-specific tyrosine kinase (Lck) 
(McLean et al., 2005; Hurt et al., 2010). The association of Src and FAK leads to 
conformational change and activation of the kinase activity of Src which 
subsequently activates other critical downstream signalling pathways such as AKT 
and MAPK to promote cellular functions such as cell motility, cell cycle progression 
and cell survival (Mitra & Schlaepfer, 2006). Indeed, FAK-Src complex activation 
has been shown to promote cell survival by enhancing activation of both PI3-K/AKT 
and MAPK/ERK pathways (Schlaepfer et al., 2004; Benlimame et al., 2005). These 
findings can also be observed in the network analysis data, wherein networks 
containing FAK also displayed interactions with other key signalling pathways 
including Src (not shown in the figure), PI3K, AKT, MAPK/ERK, and P38 MAPK 
pathways as well as integrin receptors (Figure 3.11). This suggest that VN and the 
IGF:VN complexes via activation of the FAK-Src complex, PI3-K/AKT and 
MAPK/ERK pathways may regulate a number of genes presented in these networks 
capable of mediating the observed cell survival responses.  
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Network analysis also demonstrated that the NF-κB pathway mapped to the 
core of the most significant networks associated with differentially expressed genes 
at 48 hours (Figure 3.10). NF-κB protein is one of the most investigated transcription 
factors found to control transcription of a number of genes that regulate cancer 
progression (Chaturvedi et al., 2011). Involvement of NF-κB signalling has been 
implicated in maintaining self-sufficiency in growth signals, evasion of apoptosis, 
promoting survival, tissue invasion and metastasis (Naugler & Karin, 2008). 
Moreover, it has been shown that the activation of NF-κB occurs via the PI3-K/AKT 
and /MAPK/ERK signalling pathways (Takahashi et al., 2005; Sun et al., 2010). This 
suggests the possibility that VN- and IGF:VN complex-stimulated activation of the 
PI3-K-AKT and MAPK/ERK pathways may also lead to the subsequent activation of 
the NF-κB signalling pathway. Furthermore, the NF-κB pathway was found to be 
included in the highest ranking networks associated with differentially expressed 
genes in response to IGF-II:VN complexes at both 12 hour and 48 hour time points 
(Figures 3.9 and 3.10). This is most likely due to the presence of IGF-II which is 
known to induce NF-κB activity downstream of the PI3-K/AKT pathway (Kaliman 
et al., 1999).  
The FOS oncogene was found to be mapped to the core of the highest ranking 
network associated with genes differentially expressed in response to the IGF-
I:IGFBP-5:VN complex at 48 hours (Figure 3.10). It is well established that the 
MAPK/ERK pathway, in the presence of growth factors, is involved in the activation 
of the members of the FOS family and also mediates its downstream signalling and 
transcriptional activity (Murphy et al., 2002; Murphy et al., 2004). Moreover, GF 
activation of the MAPK/ERK pathway regulates cell cycle and proliferation via 
FOS-mediated signalling (Chambard et al., 2007). The ERK/FOS pathways have 
been shown to be involved in regulating IGF-I/IGF-IR-mediated vascular smooth 
muscle cell (VSMC) growth and proliferation (Li et al., 2008). Recent studies within 
our laboratory have demonstrated that the IGF-I:IGFBP:VN complex prolongs cell 
survival through activation of the MAPK/ERK pathway (Kashyap et al., 2011). Thus, 
it is possible that activation of the MAPK/ERK pathway by IGF-I:IGFBP-5:VN 
complex may also influence the activation of the FOS pathway, in turn promoting 
cell survival.  
 Chapter 3: Identifying changes in gene expression profile associated with VN- and IGF:VN complex-stimulated 
breast cancer cell survival 113 
In addition to network analysis, canonical pathway analysis was performed to 
relate the differentially expressed genes to well documented biological pathways. 
Amongst the signalling pathways identified, the AHR signalling pathway was the 
most significant pathway associated with differentially expressed genes at 48 hours 
(Table 3.3). This pathway was also one of the highest ranking pathways associated 
with genes differentially expressed at 12 hours. The proposed underlying 
mechanisms of AHR signalling in promoting cancer cell survival are multifaceted. 
AHR signalling has been reported to inhibit the expression of key tumour suppressor 
genes as well as altering proliferation and differentiation by influencing the 
physiologic processes of cell-cycle, apoptosis and cell–matrix interactions (reviewed 
in Feng et al., 2013). Importantly, the implication of AHR in cell plasticity and 
motitility is also supported in studies using xenibiotic ligands such as TCDD 
(2,3,7,8-tetrachlorodibenzo-[p]-dioxin) for this receptor where treatment of MCF-7 
breast cancer cells with TCDD increrased cell surface, appearance of lamellipodia-
like morphology and subsequent higher cell adherence and motility (Diry et al., 
2006). This sugessts the possibility that VN may also stimulates cell attachemnt and 
subesequently migration and poliferation through activation of AHR and its 
downstream signalling. Furthermore, TGFβ signalling, one of the most important 
pathways in cancer progression was also identified to be highly associated with 
genes differentially expressed in response to VN and the IGF:VN complexes. 
Differentially expressed genes namely, c-FOS, c-JUN, RRAS, Smad6, TGIF1, 
TGFβ2 and TGFβ2 receptor were found to be involved in this pathway. The TGFβ 
receptor along with its transcriptional mediators, the Smad proteins are known to 
enhance bone metastasis of breast cancer through regulation of genes such as CTGF 
(Kang et al., 2003). These data suggest the possibility that the components of AHR 
signalling and TGFβ canonical pathways and/or their downstream target genes 
whose deregulation was observed in our data, may be important in VN- and IGF:VN-
mediated actions.  
Amongst the differentially expressed genes associated with pathways identified 
in network and canonical pathway analyses, we observed genes with previously 
reported roles in cancer cell survival such as TGFβ2, Cyr61, CTGF, RASGRP1, c-
FOS, c-JUN, CAV1, and LAMB1. The presence of these proteins in the top 
functional networks and signalling pathways highlights the potential role of these 
genes in VN- and IGF:VN complex-stimulated survival. These genes and several 
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others either commonly or uniquely regulated in response to the treatments were 
assessed using qRT-PCR to aid the validation of our microarray data. Overall, there 
was a high concordance between the qRT-PCR results and the differential expression 
determined via microarray analysis, whereby a strong correlation between the two 
was identified (Figures 3.12 and 3.13). This gives us confidence in our microarray 
data and the sets of genes identified to be differentially regulated by cells in response 
to VN alone, the IGF-II:VN and IGF-I:IGFBP-5:VN complexes. 
The most important finding of microarray studies was the identification of a 
number of genes differentially expressed in cells survived in response to VN and the 
IGF:VN complexes that are associated with biological processes highly relevant to 
cell survival. It was also shown that VN and the IGF:VN complexes also regulate 
differential expression of genes with roles in critical cellular functions including, cell 
growth, proliferation and migration (Figure 3.7 and 3.8). The studies reported in this 
chapter have added valuable knowledge to our understanding of the mechanisms 
responsible for VN- and IGF:VN complex-stimulated cancer cell survival. This 
might provide insights into the early molecular events promoting breast cell 
metastasis, whereby tumour cells proliferating within the primary tumour site, gain 
the ability to migrate and invade away from their original tissue of origin and acquire 
the ability to survive within their new tissue microenvironment. 
3.5 CONCLUSION 
In summary, data acquired within this chapter has identified for the first time 
unique gene expression patterns underlying VN- and IGF:VN complex-stimulated 
breast cancer cell survival. Moreover, functional analysis found a number of these 
genes to be highly relevant to biological processes involved in cell growth, migration 
and survival. Herein, it is also reported that the FAK-Src complex, PI3-K/AKT 
MAPK/ERK, and NF-κB intracellular signalling pathways as well as AHR and 
TGFβ canonical pathways may play central roles in VN- and IGF:VN complex-
mediated actions. The following chapter (Chapter 4) uses this dataset to identify 
candidate genes involved in mediating the cell survival observed in response to VN 
and the IGF:VN complexes as well as the biochemical mechanisms underlying their 
regulation. Findings within this chapter suggest that VN is likely the key component 
driving the differential gene expression profile, with the IGF family members 
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stimulating additional subsets of transcriptional programs possibly contributing to the 
increased cell survival observed above that of VN alone. Therefore, we decided to 
further investigate genes commonly regulated by VN and the IGF:VN complexes. 
This strategy aimed at selecting candidate genes to target not only VN- but 
potentially IGF:VN complex-mediated actions. Since the IGF-I containing 
complexes are thought to play more significant roles not only in mediating cell 
survival responses but also in other processes involved in breast cancer metastasis, 
further studies focused only on trimeric IGF-I:IGFBP-5:VN complexes. However, 
given the role of IGF-II:VN complex on cell proliferation and migration, it would 
indeed be worthwhile in the future to investigate the functional role of genes 
differentially expressed by the dimeric IGF-II:VN complexes and will add valuable 
knowledge to the molecular mechanisms underlying these responses. 
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4.1 INTRODUCTION 
It is widely accepted that cellular behaviour and functions in vivo is largely 
influenced by its interactions with the ECM components, neighbouring cells, and 
soluble local and systemic cues presented within the cellular microenvironment, 
namely hormones, cytokines, and growth factors (Nelson & Bissell, 2006; Rondeau 
et al., 2014). However, the components of the ECM are known to be active 
contributors to cellular behaviour and biological responses through mediating 
changes in downstream gene expression programs in normal and malignant cells 
(Roskelley et al., 1995; Spencer et al., 2007; Birnie et al., 2008). As outlined in the 
previous chapter, we have used microarray analysis to identify for the first time the 
transcriptional responses of MCF-7 breast cancer cells to VN and the trimeric IGF-
I:IGFBP:VN complex at the early (12 hour) and the late (48 hour) time points 
(reported in Chapter 3). This revealed a number of genes were identified to be 
differentially expressed by at least ±1.5-fold in response to VN and the trimeric 
complex compared to the control treatment (SFM) at these time points (Chapter 3, 
Figure 3.6). The majority of these genes were observed to be commonly regulated by 
both VN and the trimeric complex, suggesting that VN is the key component 
responsible for inducing the majority of differential gene expression stimulated by 
the trimeric complex. Hence, the studies reported in this chapter aim to identify 
candidate genes to target for inhibiting not only VN-, but potentially also trimeric 
complex-mediated downstream functional responses.  
Our previous gene ontology and functional pathway enrichment analyses of 
differentially expressed genes in common by VN and the IGF-I:IGFBP:VN complex 
identified a number of genes that are highly associated with biological functions 
relevant to cell survival and proliferation. Among these highly up-regulated genes 
were members of the ECM-associated CCN matricellular family, namely 
Cyr61/CCN1 and CTGF/CCN2. Based on previously published literature of their 
role in breast cancer progression and metastasis (Tsai et al., 2000; Xie, Nakachi, et 
al., 2001; Kang et al., 2003), Cyr61 and CTGF were selected as our lead candidates 
for further functional validation. To understand the mechanisms underlying the VN- 
and IGF-I:IGFBP:VN-stimulated expression of Cyr61 and CTGF, the studies 
reported in this chapter also investigate the involvement of key cell surface receptors, 
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namely the IGF-IR and VN-binding αv-integrins, and the contribution of downstream 
signalling intermediates (Src/PI3-K/ERK) to this regulation.   
 
4.2 EXPERIMENTAL METHODS 
The following is a brief summary of the materials and procedures used to 
generate the data presented in this chapter. Full details of materials and methods used 
in experimental procedures are described in Chapter 2. 
4.2.1 Cell lines 
The human breast cancer cell lines used in this chapter were MCF-7, MDA-
MB-231, MDA-MB-468 and T47D cells. Cell lines were maintained following 
procedures described in section 2.3. Since microarray studies reported in Chapter 3 
were performed using MCF-7 cells, this cell line was used for the majority of studies 
implemented in this chapter. Cells from luminal (MCF-7 and T47D), basal (MDA-
MB-468) and claudin-low (MDA-MB-231) cell lines were used to represent major 
breast cancer subtypes were also chosen to screen VN- and the trimeric IGF-
I:IGFBP-5:VN complex-regulated Cyr61 and CTGF expression. The mechanistic 
studies reported in this chapter were performed using MCF-7 (weakly 
metastatic/luminal) and MDA-MB-231 (highly metastatic/basal B/claudin-low) cell 
lines.  
4.2.2 Heatmap analysis and presentation of target genes using the R program 
To get a visual representation of the global changes in the gene expression 
patterns induced by VN and the IGF:VN complexes, the data containing normalised 
gene values were imported into R 3.0.2 language to generate and plot the heatmaps, 
using the “gplots” version 2.12.1 package. The expression of each individual gene 
presented in the heatmap was compared across all the conditions and indicated using 
different colour keys. The genes and treatments were clustered using hierarchical 
cluster analysis based on ‘similarity in expression’ using algorithms based on Ward's 
minimum variance method within the R package “gplots” and results were added to 
the heatmap as dendrograms (hierarchical tree). 
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4.2.3 Gene-function interaction network presentation using Cytoscape 2.8.1 
Cytoscape is an open source software platform for visualising molecular 
interaction networks and integrating these networks with gene expression profiles 
(Cline et al., 2007). Data from the IPA containing the top five biological functions 
significantly (p<0.05) associated with genes differentially expressed in common by 
VN and IGF-I:IGFBP:VN treatments were imported into the open source software 
platform for molecular network interaction visualisation. Gene-network interactions 
were represented as node and edges where the nodes were the biological function and 
the associated genes being the edges.  
4.2.4 Pre-binding of proteins 
The approach used to pre-bind proteins to 6-well plates for use in viability 
assays was according to protocols in section 2.4. Nunclon™ surface 6-well plates 
were prepared by pre-binding with proteins as described in section 2.4.1 For all 2D 
functional assays described throughout this chapter, including receptor and signalling 
studies, treatment combinations for the pre-binding steps were VN alone and the 
trimeric IGF-I:IGFBP-5:VN complex with concentrations of proteins added into the 
culture wells being as follows: VN, 1 μg/mL; IGF-I, 30 ng/mL; and IGFBP-5, 90 
ng/mL. For attachment study, in addition to VN, cell culture plates were coated with 
Poly-l-Lysine, 5 μg/mL; FN, 1 μg/mL; and type I collagen, 1 μg/mL. These 
concentrations were chosen to coat polystyrene culture plates since visual inspection 
of cells 1 hour post seeding demonstrated relatively similar levels of overall cell 
attachment when compared to wells treated with VN.  
4.2.5 RNA and protein isolation to assess receptor involvement and signal 
transduction  
Sub-confluent cells were serum-starved for 4 hours, detached using a cell 
dissociation buffer (TrypLE™) and resuspended in DMEM/F12-SFM + 0.05% BSA. 
To assess the signal transduction pathways involved in VN- and IGF-I:IGFBP:VN-
mediated regulation of CTGF and Cyr61, MCF-7 cells were pre-treated with 
pharmacological inhibitors LY294002 (10 µM), U0126 (10 µM) or PP2 (20 µM) for 
60 minutes at 37°C, 5% CO2 prior to seeding. The LY294002 and PP2 inhibitors 
were used to specifically block PI3-K and Src-family kinases pathways. The MEK 
inhibitor U0126 was also used to inhibit activation of MAPK (ERK 1/2) by 
inhibiting the kinase activity of MAP Kinase (Davies et al., 2000). To investigate the 
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involvement of possible integrin receptors in CTGF and Cyr61 regulation, MCF-7 
and MDA-MB-231 cells were also pre-incubated for 30 minutes at room temperature 
with monoclonal antibodies against αv-integrin subunit (1:10), αvβ3 (10 μg/mL), αvβ5 
(10 μg/mL), β1-subunit (10 μg/mL) receptors and IGF-IR (10 μg/mL). Cells were 
then seeded onto 6-well plates pre-coated with either VN alone or the IGF-I:IGFBP-
5:VN complex and incubated for a total of 48 hours at 37 °C, 5% CO2 (refer to 
section 4.2.6 for proteins pre-bound and concentrations used). During this incubation 
spent medium was replaced after 24 hours with fresh medium containing the 
respective pharmacological inhibitors and receptor-blocking antibodies. Following 
the complete 48 hour incubation both floating and attached cells were lysed for RNA 
and protein solation using TRIzol
®
 reagent and completed protein lysis buffer, 
respectively according to the protocols outlined in section 2.8.2 and 2.12.1.  
4.2.6 qRT-PCR analysis of target genes 
RNA was extracted from cell lysates using the Direct-zol™ MiniPrep Kit 
(Zymo Research) following the manufacture’s protocol and stored at -80 °C until 
further use (for full details on this method please refer to section 2.8.2.). RNA 
concentration was measured using the Nanodrop
®
 ND-1000 Spectrophotometer. 
Only RNA samples with A260/A280 and A230/A260 ratios of 2.00-2.15 were considered 
as having valid purity (ideal A260/A280 and A230/A260 ratio for RNA is ~2). RNA 
samples which passed the purity check were then reverse transcribed into cDNA 
using the SuperScript
®
 III First-Strand Synthesis SuperMix kit (Life Technologies) 
following the manufacture’s protocol as briefly outlined in section 2.11.2. The 
relative fold expression levels of target genes were then measured using qRT-PCR 
analysis as outlined in section 2.11.3. The cycle threshold (Ct) value of the gene of 
interest for each reaction was obtained and directly normalised to the housekeeping 
gene and then compared, using the ΔΔCt method of qPCR data analyses. The relative 
fold-change in the expression of the gene of interest compared to the control sample 
(SFM) was then calculated using the 2^(-ΔΔCt) method. 
4.2.7 Immunoblotting 
The protein concentration was determined using the colorimetric Coomassie 
Plus
®
 kit (Thermo Fisher Scientific), with BSA used as standards. Proteins (20-60 μg 
per sample) were resolved on pre-made NuPAGE
®
 gradient SDS-PAGE gels (4%-
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12%) and transferred onto nitrocellulose membranes. Western immunoblotting was 
performed following procedures outlined in section 2.13. The primary antibodies 
used in this chapter were anti-Cyr61 (1:1000) and anti-CTGF (1:1000) (R&D 
system). To detect the total levels of these proteins, the same membranes were 
stripped using Restore
®
 Western blot stripping buffer and probed with anti-GAPDH 
to validate equal loading of proteins onto the gel. 
4.2.8 Immunofluorescence staining of cells in 2D culture 
For full details on this method please refer to section 2.14. The 2D cell cultures were 
stained using fluorescently labelled dyes and antibodies. All incubations were 
performed at room temperature. MCF-7 cells growing in 96-well optical-bottom 
plates pre-coated with VN, IGF:IGFBP-5:VN and poly-l-lysine (control), were fixed 
after 48 hours with 4% paraformaldehyde, washed twice with PBS:Glycine and then 
permeabilised with 0.4% Triton-X. Cells were then blocked with 5% BSA, washed 
with 0.1% PBS-Tween-20 (PBS-T) and incubated for 1 hour either with primary 
mouse anti-Cyr61 or anti-CTGF antibody (Santa Cruz Biotechnology) diluted 1:100 
in 5% BSA + PBS-T. Subsequently, cells were washed twice with PBS-T and 
incubated with fluorophore conjugated secondary AlexaFluor
®
 594 (red) or 488 
(green) goat anti-mouse IgG antibodies (1:250). Cells were also stained for actin 
cytoskeleton and nucleus using fluorescently conjugated AlexaFluor
®
 633 (red) or 
488 (green) phalloidin (1:40, in PBS) and DAPI (1:10,000 in PBS), respectively. The 
plates were stored at 4 °C in the dark until imaging with the DeltaVision microscope 
(Applied Precision - GE Healthcare).  
4.3 RESULTS 
4.3.1 VN-induced genes are highly associated with biological processes 
relevant to cell survival  
Using the Illumina
® 
HumanHT-12 v4.0 BeadChip
®
 array technology a number 
of genes were identified to be differentially expressed by at least ±1.5-fold in 
response to VN and the trimeric IGF-I:IGFBP:VN complex compared to the control 
treatment (SFM) at 48 hour (Chapter 3, Figure 3.6). Cells treated with VN and the 
trimeric complex over 48 hours were seen to uniquely express 121 out of 568 and 
147 out of 594 differentially genes, respectively (Figure 4.1 A). Moreover, as 
previously observed (Chapter 3, Figure 3.6) there was a considerable overlap of 
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differentially regulated genes amongst both the treatments. Specifically, 447 genes 
were regulated in common by VN and the trimeric complex (Figure 4.1 A). 
Differentially expressed genes from this list of 447 were used to select for candidates 
to potentially target not only VN-mediated but also the trimeric complex-mediated 
actions. For ease of reference we will refer to these 447 genes as the VN-induced 
Gene Expression Signature (or VNGES). 
To place the VNGES in a biological context, the IPA knowledge base was 
utilised. The biological functions assigned to the VNGES were ranked according to 
the significance of that biological function to the data set. The top five biological 
functions (in order of significance) associated with these commonly regulated genes 
that were identified by IPA are represented in Figure 4.1 B. Of particular relevance 
to this study, “cell growth and proliferation” was identified as the most significant 
functional category, containing 125 genes (p = 2.22 x 10
-8
 to 8.81 x 10
-2
). In addition, 
the “cell death and survival” function was amongst the highest-ranking functional 
categories (p = 1.31 10
-8
 to 8.52 x 10
-2
) with 106 genes present in our VNGES 
(Figure 4.1 B). These data suggest that the VNGES is highly enriched in genes with 
previously reported roles in cell growth and survival providing a suit of genes to 
target for inhibition of VN- and trimeric IGF-I:IGFBPVN complex-induced cell 
survival effects.   
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Figure 4.1: Top five biological functions associated with the VNGES.  
Microarray analyses identified a number of differentially expressed genes in MCF-7 cells in response 
to VN alone and the IGF-I:IGFBP-5:VN complex (TRI) compared to the control (SFM) treatment. (A) 
Statistically significant (p<0.05) differentially expressed genes with a ±1.5-fold change threshold were 
identified using one-way ANOVA with BHFDR. The Venn diagram demonstrates the number of 
genes in common or uniquely expressed by VN or the TRI complex when compared to the expression 
in cells treated with SFM. (B) IPA was utilised to investigate genes commonly regulated by VN and 
the TRI complex (VNGES) with more specific functions within the broader cell survival category. 
Top five significant biological functions (p<0.05) associated with VNGES were identified and 
mapped (using Cytoscape) to corresponding gene objects (Red: Up-regulated/Green: Down-
regulated). Size of the function represents number of involved genes and increasing darkness of colour 
represents increasing significance (p values) of the function. VNGES = VN-induced Gene Expression 
Signature,  SFM = Serum Free Media and TRI = trimeric IGF-I:IGFBP:VN complex.  
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4.3.2 Matricellular CCN family proteins Cyr61/CCN1 and CTGF/CCN2 
associate with breast cancer cell survival   
To identify gene clusters that may be involved in cancer cell survival, those 
associated with both the “cellular growth and proliferation” and the “cell death and 
survival” biological functions (80 genes) were further sub-categorised. The 
association of these genes with biological processes relevant to cell growth, survival, 
proliferation and cell death in a variety of tumour cell types, including breast cancer 
was identified (As presented in a gene:function interaction network map using the 
Cytoscape software platform; Figure 4.2). Relative expression levels and the 
relationship between these genes was then analysed using hierarchical clustering (As 
represented in the heatmap and associated dendrogram; across VN, the trimeric 
IGF:IGFBP:VN complex and SFM treatments over 12 and 48 hour time points; 
Figure 4.2). Several genes were identified with multiple roles in cell proliferation, 
growth, apoptosis and survival in a range of tumour cells. prominent among these 
genes were, TGFβ1/2, S100A4, CCN1/Cyr61, CCN2/CTGF, c-JUN, c-FOS, 
ANXA2, SMAD6, CAV1 and mir21, whose deregulation have been reported to 
correlate with breast cancer progression and shown to play critical roles in breast 
cancer cell survival (Figure 4.2; heatmap).  
The further analysis of this gene subset revealed the ECM-associated 
matricellular CCN family members, Cyr61/CCN1 and CTGF/CCN2, to be 
dramatically up-regulated by VN and the trimeric IGF-I:IGFBP:VN complex 
(identified by microarray analysis; Table 3.4). Cyr61 and CTGF were also found to 
be involved in the most significant networks associated with differentially expressed 
genes (identified by IPA) in response to VN and the IGF-I:IGFBP:VN complex 
(Chapter 3; Figures 3.9 & 3.10). Previous published literatures indicated the 
important role of Cyr61 and CTGF overexpression in breast tumorigenesis and 
metastasis (Tsai et al., 2000; Xie, Nakachi, et al., 2001; Kang et al., 2003). 
Considering their roles in cell survival and breast cancer progression and their 
association with key survival pathways commonly implicated in VN- and IGF-
I:IGFBP:VN-mediated functions (identified by IPA), Cyr61 and CTGF were selected 
as our top lead candidates for further functional validation. 
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Figure 4.2: VNGES association with biological functions relevant to cell survival.  
The cluster heat map was generated for 80 genes identified to be associated with the “cell growth and proliferation” and the “cell death and survival” biological functions 
using R program the “gplots” package. This heatmap represents the changes in gene expression between treatments (SFM, VN and TRI) and time points (12 and 48 hours) 
(Red: Up-regulated/Green: Down-regulated). The clusters (hierarchical tree) were generated using hierarchical cluster analysis algorithms (Ward's minimum variance method) 
within the R package “gplots”. The right and top dendrogram are clustering of genes and treatments, respectively based on similarity in expression levels. The IPA tool was 
used to determine the association these genes to the sub-functions (circles coloured blue). The Cytoscape software was then used to map these associations (grey lines 
between gene name and sub-function). VNGES = VN-induced Gene Expression Sinature; SFM = Serum Free Media and TRI = trimeric IGF-I:IGFBP-5:VN complex. 
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4.3.3 VN- and IGF-I:IGFBP:VN complex-induce Cyr61 and CTGF expression 
The differential regulation of Cyr61 and CTGF that was identified by 
microarray analysis was validated using SYBR-green based qRT-PCR. qRT-PCR 
analysis confirmed that Cyr61 and CTGF expression in MCF-7 cells was 
significantly increased (p<0.01) in response to VN at 12 and 48 hour time points 
compared to the SFM only (control), respectively (Figure 4.3 A). Similarly, trimeric 
IGF-I:IGFBP-5:VN complex increased the expression of Cyr61 and CTGF at both 
time points, whereby both genes were elevated at 48 hours as compared to the 12 
hour time point (Figure 4.3 A). The increase in Cyr61 and CTGF gene expression 
was also confirmed at the protein level wherein western blot analysis demonstrated a 
substantial increase in Cyr61 and CTGF protein expression in response to VN and 
the trimeric complex over 12 and 48 hours compared to SFM controls (Figure 4.3 B). 
As reflected in the microarray data, no significant differences in the degree of 
increased expression of either target genes were observed between VN alone and the 
trimeric complex trreaments. 
To examine whether VN was the major component of the trimeric complex 
mediating increased expression of Cyr61 and CTGF, we substituted native IGF-I 
with the [L24][A31]-IGF-I analogue to form the trimeric complex. This analogue 
retains its affinity for IGFBPs, thus forms heterotrimeric complexes (Kricker et al., 
2003), but has a very low affinity for the IGF-IR (Milner et al., 1995; Forbes et al., 
2002). No appreciable differences in Cyr61 and CTGF protein expression were 
evident in cells treated with VN alone or trimeric complex containing either native 
IGF-I or the [L24][A31]-IGF-I analogue (Figure 4.3 C). This suggests that VN 
mediates the increased expression of Cyr61 and CTGF induced by the trimeric IGF- 
complex. Taken together these results clearly show that VN and the trimeric IGF-
I:IGFBP-5:VN complex can strongly induce Cyr61 and CTGF expression, whereby 
VN is the major driver of this increased expression. 
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Figure 4.3: VN- and the IGF-I:IGFBP:VN complex-induce expression of Cyr61 and CTGF in human 
breast cancer cells.  
Serum starved MCF-7 cells were seeded onto 6-well plates coated with VN (1 μg/mL) either alone 
(VN) or with IGF-I (30 ng/mL) and IGFBP-5 (90 ng/mL) combination (TRI). (A) RNA was harvested 
at 12 and 48 hours and expression levels of Cyr61 and CTGF were measured by qRT-PCR analysis. 
mRNA expression of each target gene was normalised to GAPDH and data from each treatment were 
expressed as the fold change to control treatment (SFM).The data are pooled from three experiments 
with treatments tested in at least three wells in each replicate experiment. The asterisks indicate 
treatments with significant differences compared to their respective control treatment (*p<0.05, 
**p<0.01, two-tailed student’s t-test). Error bars indicate SEM. (B) Western blotting was used to 
determine the protein expression levels of Cyr61 and CTGF. The membranes were stripped and re-
probed to determine GAPDH levels to confirm equal loading. (C) Cyr61 and CTGF protein 
expression was also determined in response to TRI complex containing the [L24][A31]-IGF-I 
analogue and compared against TRI complex containing native IGF-I. SFM = Serum Free Media, TRI 
= trimeric IGF-I:IGFBP:VN complex and Analog = [L24][A31]-IGF-I.  
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4.3.4 Stimulated expression of Cyr61 and CTGF is specific to integrin ligation 
by ECM proteins 
Cyr61 and CTGF expression were both up-regulated in MCF-7 cells cultured 
in VN-coated plates compared to those cultured on non-coated plates. To confirm 
that the up-regulation of Cyr61 and CTGF expression is mediated through a VN-cell 
interaction and not via a non-specific cell adhesion effect (as MCF-7 cells adhere 
poorly to non-coated vessels in SFM), MCF-7 cells were seeded onto plates coated 
with poly-l-lysine (Figure 4.4 A). In addition, to investigate if this was a VN-specific 
effect or wether additional ECM proteins could also increase Cyr61 and CTGF 
expression, cells were also seeded in wells coated with Fibronectin (FN) and 
Collagen type-I (Figures 4.4 B & C). Cells treated with only SFM and 10% FBS 
were used as controls.  
Immunofluorescent staining of cells with anti-human Cyr61 and CTGF 
antibodies following a 48 hour treatment with VN and the trimeric complex resulted 
in substantial immunoreactivity compared to cells treated with poly-l-lysine (Figure 
4.4 A). This was also confirmed using qRT-PCR and western blotting (Figure 4.4 B 
and C). Importantly, no differences were observed in Cyr61 and CTGF expression in 
cells grown in wells pre-bound with poly-l-Lysine compared to cells in SFM control 
treatment wells. This suggests that the increased expression of Cyr61 and CTGF is 
mediated by VN-engagement of cells via integrin receptors, and is not due to non-
specific cell adhesion and spreading.  
Analysis of cells treated with FN and collagen type-I also showed significant 
increases (p<0.01) in Cyr61 and CTGF mRNA expression compared to cells treated 
with SFM only (Figure 4.4 B). This was also confirmed at the protein level wherein 
cells treated with FN and collagen type-I substantially increased Cyr61 and CTGF 
protein levels compared to SFM-treated cells (Figure 4.4 C). Moreover, mRNA 
expression of Cyr61 in cells treated with VN was greater compared to cells treated 
with FN and collagen type-I (Figure 4.4 B). However, at the protein level no 
considerable differences were observed in Cyr61 expression in cells treated with VN, 
FN and collagen type-I (Figure 4.4 C). Moreover, VN and FN similarly induced the 
highest expression of CTGF among all treatments, followed by collagen type-I, 
suggesting the important role of ECM proteins in CTGF regulation.  
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Taken together, these results demonstrate that non-specific attachment of cells 
to tissue culture surface is not sufficient to induce Cyr61 and CTGF expression. 
These results also suggest that while VN is a potent stimulator of Cyr61and CTGF 
expression in MCF-7 cells is not a specific effect and they can also be regulated via 
additional ECM proteins via an integrin-mediated mechanisms.  
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Figure 4.4: ECM protein-induced expression of Cyr61 and CTGF. 
(A) Serum starved MCF-7 cells were seeded onto 96-well optical-bottom plates pre-bound with poly-
l-lysine, VN and the IGFI:IGFBP-5:VN complex andwere fixed with 4% paraformaldehyde at 48 
hours, stained with phalloidin for actin (green for Cyr61 and red for CTGF), DAPI for nucleus (blue) 
and antibodies against Cyr61 (red) and CTGF (green). Cells were imaged using DeltaVision 
microscopy. Scale bars indicate 10 μm. To examine the effect of other integrin-responsive ECM 
proteins, serum starved MCF-7 cells were seeded onto 6-well plates coated with either VN (1 μg/mL), 
FN (1 μg/mL) and collagen type I (1 μg/mL). Cells treated with SFM and 10% FBS were used as 
negative and positive controls, respectively. To investigate the effect of cell attachment of Cyr61 and 
CTGF expression, plates were also coated with poly-l-lysine (5 μg/mL) to provide attachment of cell 
in the absence of any ECM proteins. (B) RNA was harvested at 48 hours and mRNA expression of 
Cyr61 and CTGF was measured using qRT-PCR. Data were expressed as fold change of gene 
expression in control SFM. The asterisks indicate treatments with significant increases compared to 
the SFM control (**p<0.01). Error bars indicate SEM. (C) The protein expression of Cyr61 and 
CTGF was also determined using immunoblot analysis. The membranes were stripped and re-probed 
to determine the GAPDH protein levels to confirm equal loading in all wells. SFM = Serum Free 
Media and TRI = trimeric IGF-I:IGFBP:VN complex. 
  
B 
 
C 
A 
 Chapter 4: Investigation of the mechanisms underlying the regulation of Cyr61 and CTGF expression induced by 
VN and the IGF:IGFBP:VN complex. 131 
4.3.5 VN and the IGF-I:IGFBP:VN complex regulate expression of Cyr61 and 
CTGF via αv-subunit of containing integrin receptors 
Since VN is known to mediate the majority of its biological effects through the 
ligation of cell surface integrin receptors (Felding-Habermann & Cheresh, 1993), the 
involvement of specific integrin subunits in VN- and trimeric IGF-I:IGFBP:VN 
complex-mediated expression of Cyr61 and CTGF was investigated. Meyer and co-
workers (1998) have shown that MCF-7 cells express the αv and β1 subunits (forming 
αvβ1 integrin heterodimer) and the αvβ5 integrin (Meyer et al., 1998). Therefore, the 
contribution of these integrins, as well as the IGF-IR, in VN- and trimeric-induced 
expression of Cyr61 and CTGF was determined by pre-incubating MCF-7 cells with 
function blocking monoclonal antibodies specific for these integrins as well as the 
IGF-IR.  
Treatment of cells with the antibody against the αv-integrin subunit 
significantly down-regulated the mRNA expression of Cyr61and CTGF in response 
to both VN and the trimeric complex when compared to the cells treated with the IgG 
isotype control antibody (Figure 4.5 A). Similarly, a dramatic reduction in the protein 
expression of Cyr61 and CTGF was observed in cells pre-incubated with the αv-
integrin blocking antibody (Figure 4.5 B). Although, no appreciable changes were 
observed in Cyr61 expression at mRNA levels, immunoblot analyses demonstrated a 
slight reduction in VN- and trimeric complex-induced Cyr61 expression in cells pre-
incubated with blocking antibodies against the αvβ5 heterodimer and the β1-integrin 
subunit, which effectively blocks the αvβ1 integrin heterodimer. This suggests the 
possibility that αvβ5 and the αvβ1 integrin expressed on the surface of MCF-7 cells 
may have redundant roles in mediating the expression of Cyr61 and CTGF in MCF-7 
cells as the general αv-integrin blocking antibody (inhibiting both αvβ5 and αvβ1 
integrins and possibly other αv-containing integrins) leads to a significant reduction 
in Cyr61 and CTGF expression (Figures 4.5 A & B). As expected from the previous 
study using the [L24][A31]-IGF-I analogue (Figure 4.3 D), no appreciable changes 
were observed in Cyr61 and CTGF expression at both the mRNA and protein levels 
in cells treated with the IGF-IR blocking antibody (Figures 4.5 A & B). From these 
data it is clear that the αv–integrin subunit is critical for VN- and IGF-I:IGFBP:VN 
complex-mediated regulation of Cyr61 and CTGF.   
 Chapter 4: Investigation of the mechanisms underlying the regulation of Cyr61 and CTGF expression induced by 
VN and the IGF:IGFBP:VN complex. 132 
 
Figure 4.5: Involvement of VN-binding integrins and the IGF-IR in VN and IGF-I:IGFBP:VN-
induced expression of Cyr61 and CTGF in MCF-7 cells. 
VN- and TRI-mediated expression of Cyr61 and CTGF in MCF-7 cells was determined in the 
presence of monoclonal function-blocking antibodies against αv (1:10), αvβ5 (10 µg/mL) and β1 (10 
µg/mL) integrins, IGF-IR (10 µg/mL) or control mouse isotype matched IgG antibody (10 µg/mL). 
Serum-starved MCF-7 cells were treated with blocking antibodies for 30 minutes at room temperature 
prior to seeding onto 6-well plates coated with VN or the IGF-I:IGFBP-5:VN complex. RNA and 
protein were harvested at 48 hours and the expression levels of Cyr61 and CTGF were measured using 
qRT-PCR (A) and immunoblot (B) analyses. The data are expressed as the fold change of gene 
expression in control wells containing mouse isotype matched IgG antibody. The asterisks indicate 
treatments with significant differences compared to the control IgG treatment (**p<0.01). Error bars 
indicate SEM. TRI = trimeric IGF-I:IGFBP:VN complex. 
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4.3.6 VN and the IGF-I:IGFBP:VN complex regulate Cyr61 and CTGF 
expression via Src/PI3-K/AKT and Src/MAPK/ERK signalling pathways, 
respectively 
To identify the downstream signalling pathways involved in the integrin-
mediated regulation of Cyr61 and CTGF, pharmacological inhibitors of the FAK/Src 
kinase, PI3-K/AKT and MAPK/ERK signal transduction pathways were utilised. 
These pathways are commonly activated following integrin ligation and have 
reported roles in mediating the downstream biological effects of ECM proteins, 
including VN (Giancotti & Ruoslahti, 1999; Hapke et al., 2003; Playford & Schaller, 
2004; Hurt et al., 2010). We have previously reported PI3-K/AKT and ERK/MAPK 
to be activated by VN and the trimeric IGF-I:IGFBP:VN complex (Hollier et al., 
2008; Kashyap et al., 2011). Moreover, all three signal transduction pathways were 
identified to have central roles in gene networks associated with differential gene 
expression induced by VN and the trimeric complex (Chapter 3, Figures 3.9, 3.10 & 
3.11). The relative contributions of these signalling pathways to the increased 
expression of Cyr61 and CTGF was determined using pharmacological inhibitors 
(LY294002, U0126 and PP2 directed against PI3-K, MEK/ERK and Src-family 
kinases, respectively).  
Inhibition of the Src-family kinases via the PP2 inhibitor significantly down-
regulated VN-induced and trimeric IGF-I:IGFBP:VN complex-induced expression of 
Cyr61 and CTGF mRNA levels as compared to DMSO vehicle control treated cells 
(Figure 4.6 A). Similar results were also observed at the protein level where western 
blot analysis of cells treated with PP2 demonstrated substantial reductions in Cyr61 
and CTGF expression in response to VN and the trimeric complex (Figure 4.6 B). 
Treatment of cells with LY294002 directed against the PI3-K/AKT pathway led to 
decreased VN- and trimeric complex-stimulated Cyr61 expression at both the mRNA 
and protein level. Interestingly, CTGF mRNA and protein expression was not altered 
by inhibition of the PI3-K/AKT pathway (Figures 4.6 A & B). Conversely, inhibition 
of the ERK/MAPK pathway using the U0126 inhibitor resulted in reduced mRNA 
and protein levels of CTGF, but not Cyr61 as compared to DMSO vehicle control 
treated cells. This effect was common to both VN and the trimeric complex (Figures 
4.6 A & B). Altogether, these results have revealed a novel bifurcation of signalling 
downstream of FAK/Src activation to mediate Cyr61 and CTGF expression via PI3-
K/AKT and ERK/MAPK pathways, respectively.   
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Figure 4.6: Involvement of PI3-K, ERK and Src cell signalling mediators in VN- and IGF-
I:IGFBP:VN-induced expression of Cyr61 and CTGF in MCF-7 cells. 
VN and TRI regulation of Cyr61 and CTGF in MCF-7 cells was determined in the presence of 
pharmacological inhibitors LY294002 (10 µM), U0126 (10 µM) and PP2 (20 µM) against PI3-
K/AKT, ERK/MAPK and Src intracellular signalling pathways, respectively. Cells treated with 
DMSO (20 µM) were used as the control. Serum-starved MCF-7 cells were treated with 
pharmacological inhibitors for 1 hour prior to seeding onto 6-well plates coated with VN or the IGF-
I:IGFBP-5:VN complex. RNA and protein were harvested at 48 hours and the expression levels of 
Cyr61 and CTGF were measured using qRT-PCR (A) and immunoblot (B) analyses. The data are 
expressed as the fold-change of gene expression in control wells containing DMSO. The asterisks 
indicate treatments with significant differences compared to the DMSO control treatment (*p<0.05, 
**p<0.01). Error bars indicate SEM. TRI = trimeric IGF-I:IGFBP:VN complex.  
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4.3.7 Basal-like breast cancer cells have increased levels of Cyr61 and CTGF  
Breast cancer cell lines can be classified into luminal, basal A, basal B and 
claudin-low molecular subtypes. (Neve et al., 2006; Prat et al., 2010). The basal-like 
breast cancer subtype is associated with poor clinical outcomes, development of 
distant metastasis and a relatively higher rate of mortality (Banerjee et al., 2006; 
Fulford et al., 2007). In contrast, the luminal-like subtype is correlated with lower 
tumour grades, longer survival and a better prognosis (Sotiriou et al., 2003). The 
recently identified claudin-low subtype is known to be enriched in markers of EMT 
and cancer stem cell-like features (Prat et al., 2010). In addition to these 
characteristics, claudin-low tumours/cells are also triple negative (PR
-
, ER
-
 & Her2
-
), 
making them highly associated with therapeutic resistance and poor survival 
outcomes (X. Li et al., 2008; Creighton et al., 2009; Gupta et al., 2009). 
To investigate the broader relevance of VN-induced Gene Expression 
Signature VNGES across breast cancer subtypes, hierarchical clustering analysis was 
performed using the VNGES across 51 cell lines representing the major breast cancer 
subtypes using gene expression data published by Neve et al. (2006) (Figure 4.7). 
The results revealed the VNGES to be highly associated with Basal B cell lines, 
whereby the VNGES could cluster together the majority of the basal B cell lines 
apart from the luminal and basal A cell models. Further examination of these cell 
lines revealed them to be predominantly claudin-low cell lines, as recently classified 
by Prat and colleagues, 2010 (Figure 4.7). Interestingly, based on the VNGES 
expression, all 9 known claudin-low cell lines, as the originally published claudin-
low predictor signature (Prat et al., 2010) were clustered together in their own 
distinct group. The results suggest that expression patterns observed in the VNGES 
are highly associated with expression patterns of these genes in claudin-low breast 
cancer subtypes.  
In addition, using the Neve et al., (2006) data sets it was identified that Cyr61 
and CTGF are up-regulated in basal-like (A and B) and claudin-low breast cancer 
cell sub-types (Figure 4.8). Interestingly, 6 out of 9 claudin-low cell lines were found 
to have high expression of Cyr61 and CTGF. Among these, MDA-MB-231, HS578T 
and SUM1315 cell lines were found to have the highest expression of Cyr61 and 
CTGF (Figure 4.8). These data suggest that Cyr61 and CTGF may play roles in 
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maintaining or stimulating the aggressive phenotype of basal-like breast cancers, in 
particular claudin-low subtypes. 
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Figure 4.7: Association of the VNGES across breast cancer molecular subtypes. 
Gene expression data from the profiling of 51 breast cancer cell lines representing the major intrinsic 
subtypes reported by Neve et al. 2006 was used to investigate the expression of the VNGES across 
multiple representative cell models. The VNGES was observed to be associated with the Basal B and 
Claudin-low cell lines. The colour bars indicate the subtype classification for individual cell lines 
according to Neve et al. 2006 (bottom) and Prat et al. 2010 (top) (blue: luminal; red: basal A; orange: 
basal B and yellow: claudin-low). The heatmap was generated using the heatmap function in the 
“gplots” package of R program. The left and top dendrograms (hierarchical tree) are clustering of 
genes presented in VNGES and the similar genes in breast cancer cell lines, respectively based on 
similarity in expression levels. The clusters were generated using hierarchical cluster algorithms based 
on Ward's minimum variance method within the R package “gplots”. The expression of the gene is 
compared across all treatments, where low expression is indicated by green, while high expression is 
indicated in red. VNGES = VN-induced Gene Expression Signature. 
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Figure 4.8: Differential expression of Cyr61 and CTGF across luminal, basal A, basal B and claudin-low breast cancer cell lines. 
Gene expression data across 51 cell lines representing the major breast cancer subtypes used in studies performed by Neve et al. 2006 was used to investigate Cyr61 and 
CTGF gene expression pattern among luminal, basal A, basal B and cludin-low breast cancer cell types. Data are presented in a form of heat map using the heatmap function 
in the “gplots” package of R program. Target genes and cell lines were clustered (top dendrogram) based on similarity in expression using hierarchical cluster algorithms 
based on Ward's minimum variance method within the R package “gplots” Low expression is indicated by green, while high expression is indicated in red. Colour keys 
indicate the subtype classification of each cell line (blue: luminal; red: basal A; orange: basal B and yellow: claudin-low) as reported by Prat et al. 2010.  
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4.3.8 Screening of breast cancer cell lines for expression of Cyr61 and CTGF in 
response to VN and the IGF-I:IGFBP:VN complex  
In order to validate the data outlined above and to also confirm the increased 
expression of Cyr61 and CTGF by VN and the IGF-I:IGFBP:VN trimeric complex in 
a broader range of breast cancer cell types, additional cell lines representing the 
luminal (T47D), basal-like (MDA-MB-468) and claudin-low (MDA-MB-231) 
subtypes were used. Figure 4.9 A, represents a heatmap view of the cycle threshold 
(Ct) gene expression values of target genes measured by qRT-PCR analysis in cell 
lines treated with VN, the trimeric complex and SFM alone (control). We observed 
VN and the trimeric complex to stimulate expression of both Cyr61 and CTGF in all 
cell lines tested compared to their respective SFM control treatments, with exception 
to CTGF expression in MDA-MB-231 cells where no significant increase was 
observed in response to VN and the trimeric complex. This is most likely due to very 
high endogenous levels of CTGF in MDA-MB-231 cells. For quantitative 
comparisons, relative fold-changes in expression of Cyr61 and CTGF in response to 
VN and the trimeric complex were also normalised to their respective SFM treatment 
using the 2^(-ΔΔCt) method (Figure 4.9 B). Cyr61 and CTGF were found to be up-
regulated in all cell lines (except CTGF expression in MDA-MB-231 cell line) 
treated with VN and the trimeric complex compared with cells treated with SFM 
only. Furthermore, the endogenous expression of Cyr61 and CTGF is generally 
higher in basal-like (MDA-MB-468) and claudin-low (MDA-MB-231) cell lines 
compared to luminal cells (MCF-7 and T47D). Since MDA-MB-231 cells are highly 
aggressive and metastatic cells with a claudin-low phenotype enriched in our 
VNGES with high levels of endogenous Cyr61 and CTGF, as compared to MCF-7 
cells (Figure 4.9 C), they were selected for further studies as an additional cell model 
to investigate the role of these two proteins. 
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Figure 4.9: Cyr61 and CTGF regulation by VN and the IGF-I:IGFBP:VN complex in human breast 
cancer cell lines.  
Serum-starved MCF-7, T47D, MDA-MB-231 and MDA-MB-468 cell lines were seeded onto 6-well 
plates coated with VN and the IGF-I:IGFBP-5:VN complex. (A) RNA was harvested at 48 hours and 
the cycle threshold (Ct) values of target genes were measured using qRT-PCR analysis. Ct values 
were then visualised in a form of heatmap using the “gplots” package of R program. (B) The fold-
change in expression of Cyr61 and CTGF in response to VN and the TRI complex were calculated 
using the formula 2^(-ΔΔCt) method. The data are expressed as the relative fold change in gene 
expression compared to the control (cells in SFM). (C) Regulation of Cyr61 and CTGF by VN and the 
TRI complex in MDA-MB-231 cells. The data are expressed as the relative fold change in gene 
expression compared to the control (MCF-7 cells in SFM). The data are pooled from three 
experiments with treatments tested in at least three wells in each replicate experiment. The asterisks 
indicate treatments with significant differences compared to the SFM control treatment 
(**p<0.01).The data are pooled from three experiments with treatments tested in triplicate wells in 
each replicate experiment. Error bars indicate SD. SFM = Serum Free Media, TRI = trimeric IGF-
I:IGFBP:VN complex.  
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4.3.9 VN and the IGF-I:IGFBP:VN complex regulate expression of Cyr61 and 
CTGF via αv-integrin subunit receptor in MDA-MB-231 cells 
To confirm the key involvement of the αv-integrin in VN- and trimeric IGF-
I:IGFBP:VN complex-mediated regulation of Cyr61 and CTGF observed in the 
MCF-7 cell line, we performed similar studies (as presented in section 4.3.5) using 
the MDA-MB-231 cell line. MDA-MB-231 are reported to express high levels of the 
αv-integrin subunit (Meyer et al., 1998) and are well known for their increased 
expression of the “classical” VN-receptor, the αvβ3 integrin heterodimer (Menendez 
et al., 2005). Both αv and αvβ3 are reported to have functional roles in the aggressive 
behaviour of MDA-MB-231 cell model (Chen et al., 2001; Zhao et al., 2014). Hence 
the relative contribution of the αv-subunit and αvβ3 integrin, as well as the IGF-IR, 
for VN- and trimeric complex-induced expression of Cyr61 and CTGF were 
determined (as outlined in section 4.3.5).  
As shown in Figure 4.10 A, inhibition of the αv-integrin subunit in MDA-MB-
231 cells with its respective function blocking antibody caused a significant down-
regulation of Cyr61 and CTGF mRNA expression (p<0.01) in response to VN and 
the trimeric complex, as compared to the IgG control. This was also seen in 
immunoblot results where Cyr61 and CTGF protein levels were considerably 
reduced in cells following αv-integrin blockade (Figure 4.10 B). These results are in 
accordance with those we observed for MCF-7 cells (Figure 4.5). An antibody 
specific for inhibition of the αvβ3 integrin led to a significant (p<0.05) reduction in 
Cyr61 mRNA levels, however, no alteration to Cyr61 protein level was observed 
(Figures 4.10 A & B). Moreover, no alteration to CTGF expression in MDA-MB-231 
cells treated with the anti-αvβ3 antibody was observed. Similarly, treatment of cells 
with antibody against IGF-IR did not cause any significant alternation in Cyr61 and 
CTGF expression. (Figure 4.10 A & B).   
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Figure 4.10: Involvement of VN-binding integrins and the IGF-IR in VN- and IGF-I:IGFBP:VN-
induced expression of Cyr61 and CTGF in MDA-MB-231 cells. 
VN- and IGF-I:IGFBP:VN-mediated expression of Cyr61 and CTGF in MDA-MB-231cells were 
determined in the presence of monoclonal blocking antibodies against αv (1:10) and αvβ3 (10 µg/mL) 
integrins, IGF-IR (10 µg/mL) and the αv + IGF-IR combination or control mouse isotype matched 
IgG antibody (10 µg/mL). Serum- starved MDA-MB-231 cells were treated with blocking antibodies 
for 1 hour prior to seeding onto 6-well plates coated with either VN alone or IGF-I+IGFBP-5 
combination (TRI). RNA and protein were harvested at 48 hours and the expression levels of Cyr61 
and CTGF were measured using qRT-PCR (A) and immunoblot (B) analyses. The data for qRT-PCR 
analysis are expressed as the fold change of gene expression in control wells containing mouse isotype 
matched IgG antibody. The asterisks indicate treatments with significant differences compared to the 
control IgG antibody treatment (*p<0.05, **p<0.01). Error bars indicate SEM. TRI = trimeric IGF-
I:IGFBP:VN complex. 
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4.4 DISCUSSION 
ECM-cell interactions recruit pathways that transmit signals to promote cell 
survival which is one of the key processes contributing to cancer development and 
progression (Jacks & Weinberg, 2002; Stupack & Cheresh, 2002). Compelling 
experimental evidences from our laboratory and others demonstrate that the ECM 
glycoprotein VN is able to promote cell survival in a variety of cells including breast 
cancer cells (Uhm et al., 1999; Kashyap et al., 2011; Hazawa et al., 2012). However, 
there exist no studies investigating the changes in gene expression that are associated 
with VN-stimulated breast cancer cell survival. Indeed, the data presented in the 
previous chapter (Chapter 3) identified a number of genes differentially regulated in 
MCF-7 breast cancer cells that have survived in response to VN. The results reported 
in Chapter 3 also indicated a number of genes differentially expressed in MCF-7 
cells in response to the trimeric IGF-I:IGFBP:VN complex. This complex was shown 
to provide greater cell viability responses in breast cancer cells than those obtained 
with VN alone. However, the majority of genes differentially expressed were found 
to be in common between VN and the IGF-I:IGFBP:VN treatments. This suggests 
that VN is the key component responsible for inducing the majority of differential 
gene expression stimulated by the IGF-I:IGFBP:VN complex. Hence, the studies 
reported in this Chapter focussed on assessing the genes commonly regulated by VN 
and the IGF-I:IGFBP:VN complex for further functional studies. This strategy aimed 
at selecting candidate genes to target not only VN but potentially IGF:VN complex-
mediated actions 
Comparison of genes differentially regulated by VN and the IGF-I:IGFBP:VN 
complex indicated a considerable overlap between both treatments. Specifically, 447 
genes were regulated in common by VN and the IGF-I:IGFBP:VN complex as 
opposed to those treated with SFM only (Figure 4.2.1). Importantly, this VN-induced 
gene expression signature (VNGES) was found to be enriched in genes with 
biological roles important in cell survival, including the “cell growth and 
proliferation” and the “cell death and survival”. This suggests that the differential 
expression of genes involved in these cell survival related biological functions may 
be responsible for the observed VN- and IGF-I:IGFBP:VN-induced increases in cell 
survival responses. Interestingly, the gene expression patterns observed in the 
VNGES are highly associated with expression patterns of these genes in basal-like 
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and claudin-low breast cancer subtypes. This suggests that the gene expression 
profile induced by VN may contribute to these phenotypes in certain breast cancer 
subtypes. Furthermore, to identify the genes that may be involved in cancer cell 
survival, genes with reported roles in both “cell growth and proliferation” and the 
“cell death and survival” biological functions (80 genes) were further sub-
categorised (Figure 4.2). A number of candidates within these 80 genes, including 
TGFβ1/2, S100A4, Smad6, S100P, ANXA2, RAPGAP, Cyr61/CCN1, CTGF/CCN2, 
Slug, Caveolin-1, mir-21, c-JUN and c-FOS were deemed to be biologically 
interesting due to their importance in regulating cell survival while their deregulation 
has been reported to correlate with breast cancer progression. Among these genes, 
multifunctional secreted ECM-associated CCN family proteins, Cysteine-rich 61 
(Cyr61/CCN1) and Connective Tissue Growth Factor (CTGF/CCN2) were selected 
as top candidates in this study to investigate the mechanisms underpinning their 
regulation by VN and the IGF:VN complex and further functionally validate their 
role in VN- and IGF:IGFBP:VN-induced breast cancer cell survival. Indeed, qRT-
PCR and western blot analyses confirmed that breast cancer cells treated with VN 
and the IGF-I:IGFBP:VN complex dramatically induced the mRNA and protein 
expression of Cyr61 and CTGF (Figure 4.3).  
The CCN family, in addition to Cyr61/CCN1 and CTGF/CCN2, consists of the 
nephroblastoma overexpressed (NOV/CCN3), Wnt-induced secreted proteins-1 
(WISP-1/CCN4), -2 (WISP-2/CCN5) and -3 (WISP-3/CCN6) proteins. These 
proteins regulate key biological functions, including ECM production (Frazier et al., 
1996; Quan et al., 2006), stimulation of cell adhesion (Babic et al., 1999), survival 
(Menendez et al., 2005; Wang et al., 2009), differentiation (Zuo et al., 2010), 
angiogenesis (Brigstock, 2002), and tumorigenesis (Xie et al., 2004) as well as 
wound healing (Chen et al., 2001) in a variety of cell types. CCN proteins are a 
subset of ECM proteins known as ‘matricellular proteins’ which are dynamically 
expressed and serve as regulatory proteins more so than structural proteins 
(Bornstein & Sage, 2002; Chen & Lau, 2009).  
Once secreted into the extracellular microenvironment, Cyr61 and CTGF 
promote adhesion, predominantly through their interactions with integrins (Leu et al., 
2002; Gao & Brigstock, 2004) and heparan-sulfate containing proteoglycans 
(HSPGs), including syndecan 4 and perlecan (Grzeszkiewicz et al., 2002; Y. Chen et 
 Chapter 4: Investigation of the mechanisms underlying the regulation of Cyr61 and CTGF expression induced by 
VN and the IGF:IGFBP:VN complex. 145 
al., 2004). It is also known that CTGF can bind to growth factor receptors, including 
fibroblast growth factor receptor (FGFR) (Aoyama et al., 2012) and vascular 
endothelial growth factor receptor (VEGFR) (Inoki et al., 2002) to possibly enhance 
its biological activities through the activation of signalling pathways downstream of 
these receptors. For example, CTGF binding to FGFRs is reported to affect the 
phosphorylation of ERK and the differentiation of osteoblastic cells (Aoyama et al., 
2012). Interestingly, growth factors such as TGFβ and VEGF are reported to induce 
expression of both Cyr61 (Parisi et al., 2006; Athanasopoulos et al., 2007) and CTGF 
(Suzuma et al., 2000; Leivonen et al., 2005). In particular, TGFβ-induced expression 
of Cyr61 and CTGF through its transcriptional mediators Smad family proteins 
(mainly Smad 2, 3 and or 4) is known to be a key mechanism underlying the 
initiation of bone metastasis in breast cancer (Kang et al., 2003; Bartholin et al., 
2007). Additionally CTGF directly binds TGFβ to activate its downstream signals by 
enhancement of receptor binding and indirectly potentiating the phosphorylation of 
Smad-responsive promoters induced by TGFβ1 (Abreu et al., 2002). Interestingly, in 
the study reported herein TGFβ2 was significantly up-regulated in excess of 10-fold 
in response to VN and the IGF-I:IGFBP:VN complex (Figure 3.13 A). This suggests 
the possibility that TGFβ may act in a concerted fashion with Cyr61 and CTGF to 
drive biological functions such as cell migration and survival in response to VN and 
the IGF:VN complexes.  
In addition to their ability to bind integrins, HSPGs and growth factor 
receptors, Cyr61 and CTGF can interact with, and bind to VN (Francischetti et al., 
2010) and FN (Hoshijima et al., 2006) with high affinity. Thereby, potentially 
functioning as a local scaffold that coordinates the interaction of ECM proteins with 
the tumour cells (Jun & Lau, 2011). Furthermore, Cyr61 and CTGF expression is 
reported to stimulate the production of ECM proteins such as FN and collagen type-I 
(Frazier et al., 1996; Quan et al., 2006). No studies to date have reported the 
involvement of ECM proteins in the regulation of Cyr61 and CTGF expression.  
Overexpression of Cyr61 and CTGF has been reported to contribute to breast 
cancer progression and metastasis and is often associated with the more advanced 
clinical stage of the disease (Tsai et al., 2000; Xie, Nakachi, et al., 2001; Kang et al., 
2003). Overexpression of Cyr61 in MCF-7 breast cancer cells was found to be 
sufficient to promote growth and colony formation in vitro and to induce 
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tumorigenesis in vivo (Tsai et al., 2002). Induced expression of Cyr61 in MCF-7 
cells was also found to stimulate cell proliferation and cell survival, and significantly 
hinder chemotherapy drug-induced apoptosis, with more than 10-fold resistance to 
Taxol, doxorubicin, paclitaxel and β-Lapachone being observed (Lin et al., 2004; 
Menendez et al., 2005). In addition, blocking the effects of Cyr61 using a function-
blocking monoclonal antibody significantly reduced cell proliferation, migration and 
invasion in vitro in the highly metastatic breast cancer cell line MDA-MB-231, and 
also inhibited tumour growth and node metastasis in vivo (Lin et al., 2012).  
In a similar fashion, up-regulation of CTGF is found to be critically involved in 
bone metastasis in breast cancer (Kang et al., 2003; Shimo et al., 2006). 
Overexpression of CTGF has been shown to enhance the migratory ability of both 
weakly metastatic MCF-7 and highly metastatic MDA-MB-231 breast cancer cell 
lines (Chen et al., 2007). Moreover, CTGF expression enhances MCF-7 and MDA-
MB-231 cell viability and confers resistance to apoptosis on exposure to doxorubicin 
and paclitaxel (Wang et al., 2009). Furthermore, TAZ (transcriptional co-activator 
with PDZ-binding motif), a protein involved in drug resistance, has been shown to 
induce Taxol resistance in breast cancer cells through the activation of Cyr61 and 
CTGF promoters and stimulation of their gene and protein expression (Lai et al., 
2011). Cyr61 and CTGF have also been found to activate critical intracellular 
cascades, specifically the cell survival pathways, including FAK-Src, PI3-K/AKT, 
ERK/MAPK and NF-κB pathways (Chen & Lau, 2009; Lau, 2011). These findings 
suggest the possibility that up-regulation of Cyr61 and CTGF by VN and the IGF-
I:IGFBP:VN complex may play an important role in cell survival, cell migration and 
drug-induced apoptosis in breast cancer cells exposed to VN and the IGF-I:VN 
complex. These phenotypes have been reported previously and are in alignment with 
the previous findings by our group (Hollier et al., 2008; Kashyap et al., 2011).  
Taken together, considering the up-regulation of Cyr61 and CTGF by VN and 
the IGF-I:IGFBP:VN complex and their reported overexpression in mediating breast 
cancer cell survival, drug-induced apoptosis and migration, these genes were selected 
as our top candidates to investigate the mechanisms underlying their expression. 
More importantly, these genes were functionally validated for their roles in VN- and 
IGF-I:IGFBP:VN-induced breast cancer cell survival. Interestingly, Cyr61 and 
CTGF have similar biological activities to VN in many aspects, including interaction 
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with integrin receptors, supporting cell attachment and inducing adhesive signalling 
as well as pro-angiogenic and survival properties (Brigstock, 2002) in addition to 
their interactions with growth factors. 
To investigate the broader relevance of Cyr61 and CTGF across breast cancer 
subtypes, hierarchical clustering was used to analyse the expression of Cyr61 and 
CTGF among 51 cell lines representing the major breast cancer subtypes using gene 
expression data published by Neve et al. (2006) and Part et al. (2010). The results 
revealed that the claudin-low and basal B-like breast cancer cell lines generally have 
higher Cyr61 and CTGF endogenous levels compared to luminal- and basal A-like 
breast cancer cell subtype models (Figure 4.7 B). Since claudin-low and basal B 
breast tumours are metastatic and associated with an aggressive clinical behaviour 
(Banerjee et al., 2006; Fulford et al., 2007; Taube et al., 2010), it is possible that 
Cyr61 and CTGF expression may correlate with increasing aggressiveness of 
metastatic breast cancer cells. Importantly, VN and the IGF-I:IGFBP:VN complex 
were found to increase the expression of Cyr61 and CTGF in all cell lines tested 
ranging from luminal-like MCF-7 and T47D cell lines to basal-like MDA-MB-468 
and claudin-low MDA-MB-231 cell lines (Figure 4.8). This suggests that VN and the 
IGF-I:IGFBP:VN complex are not only capable of stimulating Cyr61 and CTGF 
expression in luminal-like breast cancer cells with low endogenous expression levels, 
but also in cells highly expressing these proteins. Thus, we further extended our 
investigation into the mechanisms underlying VN- and IGF-:IGFBP:VN-induced 
Cyr61 and CTGF expression in the highly aggressive claudin-low MDA-MB-231 
breast cancer cell line, in addition to weakly-metastatic MCF-7 cells. 
The studies reported in this chapter demonstrated that Cyr61 and CTGF 
expression is specific to VN-engagement of cell adhesion and not due to non-specific 
cell attachment and spreading (Figure 4.4) Furthermore, it was also found that in 
addition to VN other integrin-associated ECM constituents such as FN and collagen 
type I are capable of stimulating Cyr61 and CTGF expression in MCF-7 cells (Figure 
4.4). This suggests the possibility that integrin-mediated cell:ECM interactions are a 
key mechanism underlying VN- and IGF-I:IGFBP:VN-induced Cyr61 and CTGF 
expression.  
ECM:cell interactions in breast cancer cells are known to be predominantly 
facilitated via the αv and β1 integrin subunits (Wong et al., 1998; Park et al., 2008) as 
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well as the αvβ3 and αvβ5 heterodimeric integrins (Maeshima et al., 2001; Bartsch et 
al., 2003). MCF-7 cells with high expression of αv, β1 and αvβ5 integrins and MDA-
MB-231 cells with high expression of αvβ3 (Meyer et al., 1998; Bartucci et al., 2001) 
were used to investigate the relative involvement of these receptors in VN- and IGF-
I:IGFBP:VN-induced expression of Cyr61 and CTGF. Incidentally, these cell line 
models also have a high endogenous expression of the IGF-IR making these ideal 
cell models to investigate both integrin- as well as IGF-IR-mediated cell signalling 
events. Blocking the αv-integrin subunit caused substantial reduction in VN- as well 
as IGF-I:IGFBP:VN-induced expression of both Cyr61 and CTGF (Figures 4.5 & 
4.10). This suggests that the VN- and IGF-I:IGFBP:VN-induced expression of Cyr61 
and CTGF is extensively dependent on the αv-integrin subunit. This can also be seen 
in studies demonstrating the blockade of VN ligation to αv integrin reduces VN-
mediated activation of p38 MAPK and uPA in MDA-MB-231 cells (Han et al., 2002) 
which possibly effect the regulation of genes downstream these signals.  
In order to investigate the specific heterodimeric integrin involved, the αvβ5 
heterodimer was inhibited using an anti-αvβ5 antibody. Although, no appreciable 
changes were observed in Cyr61 expression at mRNA levels, only a slight reduction 
was observed in the VN- and IGF-I:IGFBP:VN-induced Cyr61 expression at the 
protein level (Figure 4.5). Similarly, only a slight reduction in Cyr61 protein 
expression was observed in MCF-7 cells treated with the anti-β1 integrin antibody 
which effectively inhibit αvβ1 integrin (Figure 4.5). This suggests a redundancy 
between the αv-containing integrins, whereby blocking specific αv-containing 
integrin heterodimeric integrins gets compensated for the other one. Thus, blocking 
all αv-containing integrins with αv blocking antibody is required for the maximal 
inhibition of VN and the IGF-I:IGFBP:VN-induced expression of Cyr61. Moreover, 
inhibition of the “classical” VN-receptor αvβ3 heterodimer integrins in MDA-MB-
231 cells did not alter Cyr61 and CTGF expression (Figure 4.10). Such additional 
function blocking studies are required to investigate the involvement of other 
heterodimer receptors such as α2β1, α3β1 α5β1 which are also highly expressed in 
MDA-MB-231 cells (Morini et al., 2000). Furthermore, No appreciable changes 
were observed in Cyr61 and CTGF expression in cells treated with antibodies 
directed against IGF-IR compared to cells treated with IgG control (Figure 4.5 & 
4.10 B). 
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Upon ECM ligation to integrins FAK is phosphorylated and binds to the N-
terminus of Src homology 2 (SH2) domain forming the FAK-Src complexes which 
subsequently activate the Src kinase signalling mediator and its downstream 
intermediates such as PI3-K, AKT, ERK and MAPK. (Stupack & Cheresh, 2002; 
Guo & Giancotti, 2004; Mitra & Schlaepfer, 2006). In view of this, phosphorylation 
and recruitment of the FAK-Src signalling downstream of VN/αvβ integrin 
engagement is reported to be critical for differential expression of genes known to 
drive breast and prostate cancer stem cell differentiation such as, K14, K8, Nanog, 
SMO, Oct3/4, BMI and cytokeratins (Hurt et al., 2010). In a similar fashion, VN has 
been shown to induce changes in gene expression promoting cell proliferation and 
migration in ovarian cancer cells in a αvβ3/FAK/Src/MAPK pathway-dependent 
mechanism (Hapke et al., 2003). Considering the important role of FAK-Src 
signalling in regulation of gene expression induced by VN-binding integrins, the 
studies reported herein investigated the involvement of this Src protein in VN- and 
IGF-I:IGFBP:VN-induced expression of Cyr61 and CTGF. However, further studies 
are still required to exclusively investigate the involvement of FAK in this process. 
In addition, PI3-K/AKT and ERK/MAPK, two of the known signalling pathways 
downstream of FAK-Src signal, were also investigated. These pathways are known 
to be critical for a range of cellular functions, in particular cell survival and migration 
(Datta et al., 1997; Bouchard et al., 2007). More importantly, these pathways were 
found to map within the centre of the top-ranking networks identified in this project 
associated with differentially expressed genes in response to VN and the IGF-
I:IGFBP:VN complex (Figures 3.9, 3.10 & 3.11).  
Experiments using pharmacological inhibitors of these pathways in MCF-7 
cells revealed a critical role for the recruitment and activation (via phosphorylation) 
of FAK-Src in stimulating the expression of both Cyr61 and CTGF by VN and the 
IGF-I:IGFBP:VN complex (Figure 4.6). Cells treated with pharmacological inhibitor 
against PI3-K demonstrated a considerable decrease in Cyr61 expression at both the 
mRNA and protein level whereas CTGF expression was substantially reduced in 
cells treated with an ERK inhibitor. Taken together, these results propose a 
mechanism in which VN and the IGF-I:IGFBP:VN complex regulate Cyr61 and 
CTGF expression through interactions with αv-subunit containing integrins and 
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recruitment of FAK-Src signalling, which then bifurcates downstream to regulate 
Cyr61 via PI3-K and CTGF via ERK pathways.  
In summary, the studies reported in this chapter have revealed that VN and the 
IGF-I:IGFBP:VN complex can induce expression of Cyr61 and CTGF in multiple 
breast cancer cell lines ranging from luminal to the basal/claudin-low subtypes. The 
studies reported throughout this Chapter also highlight that the regulation of CCN 
family members is through the engagement of cells with the components of the ECM 
and not due to the non-specific cell attachment and spreading to the culture plastic. 
Furthermore, it was found that VN-induced expression of Cyr61 and CTGF is 
mediated through VN:αv engagement and recruitment of Src/PI3-K and Src/ERK 
pathways, respectively. Indeed, these findings add new valuable knowledge to our 
current understanding of the mechanisms underlying VN and the IGF:VN complex-
mediated gene regulation. However, the functional role of these molecular targets 
still needs to be investigated. Considering the important role of Cyr61 and CTGF in 
mediating various biological functions it is plausible that VN, and potentially other 
ECM elements such as FN and collagen, stimulate the expression as well as the 
secretion of Cyr61 and CTGF to sustain a positive feedback loop in an autocrine 
fashion to regulate biological functions critical to cancer metastasis. 
4.5 CONCLUSION 
The studies reported in this chapter identified a number of genes differentially 
regulated in common by VN and the IGF-I:IGFBP:VN complex which were 
significantly associated with biological processes related to cell survival. Among 
these genes, the ECM-associated Cyr61 and CTGF proteins (found to be up-
regulated), with previously reported roles in breast cancer cell survival, cell invasion, 
and drug-induced apoptosis, were selected as the top candidates to investigate their 
functional roles in VN- and IGF-I:IGFBP:VN-stimulated breast cancer cell survival. 
The studies reported throughout this chapter for the first time support a new 
mechanism, in which VN and the IGF-I:IGFBP:VN complex stimulate Cyr61 and 
CTGF expression through αv-integrin receptors and the recruitment of the Src 
signalling mediator after which the signal bifurcates to uniquely regulate Cyr61 
through PI3-K and CTGF through ERK. The involvement of Cyr61 and CTGF in 
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mediating VN- and IGF-I:IGFBP:VN-stimulated breast cancer cell survival is 
unknown and is the objective of the following chapter (Chapter 5).  
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5.1 INTRODUCTION 
Using microarray analysis, we have identified for the first time a VN-induced 
gene expression signature (VNGES) in breast cancer cells that have survived in 
response to VN. More importantly, gene ontology analysis has elucidated a number 
of genes within the VNGES with important roles in cell survival. Furthermore, the 
studies performed within the previous chapter (Chapter 4) demonstrated that the 
ECM-associated matricellular proteins Cyr61 and CTGF with previously reported 
roles in breast cancer progression are highly up-regulated at both mRNA and protein 
levels in cells treated with both VN and the IGF-I:IGFBP:VN complex. In addition, 
cell signalling studies demonstrated that VN and the IGF-I:IGFBP:VN complex 
induced the expression of Cyr61 and CTGF through the recruitment of αv-integrin 
and the activation of the Src signalling axis and recruitment of its bifurcated 
downstream pathways of PI3-K/AKT and ERK/MAPK, respectively. Cyr61 and 
CTGF both have documented roles contributing to the enhancement of a number of 
key biological functions, including growth, survival, migration invasion and 
angiogenesis (reviewd in Brigstock, 2002, 2003; Perbal & Takigawa, 2005; Leask & 
Abraham, 2006), to contribute to breast cancer progression and have been associated 
ate be often associated with more advanced stages of disease (Xie, Nakachi, et al., 
2001; Tsai et al., 2002; Kang et al., 2003). However, the functional role and the 
extent of involvement of these genes in mediating VN- and IGF-I:IGFBP:VN 
complex-induced effects, namely cell survival and cell migration  remain to be 
validated. In view of this, the studies reported in this chapter are directed at 
addressing this knowledge gap.  
Briefly, the gene knockdown studies performed within this chapter provide the 
first evidence highlighting the importance of CTGF in VN- and IGF-I:IGFBP:VN-
induced cell survival of the poorly metastatic MCF-7 cell lines in both 2D and 3D 
culture models. In contrast, the highly invasive and metastatic MDA-MB-231 cells 
genetically engineered to have reduced expression of CTGF did not change their cell 
viability in 3D cultures. However, these cells were observed to be less-invasive in 3D 
Matrigel™ cultures and adopt a more rounded morphology, reminiscent of MCF-7 
cell colonies. Cyr61 was also demonstrated to be important for VN- and IGF-
I:IGFBP:VN -stimulated cell survival of MCF-7 and MDA-MB-231 cells. Taken 
together, results from this chapter provide the first functional evidence for the role of 
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Cyr61 and CTGF in VN- and IGF-I:IGFBP:VN complex-mediated biological effects, 
including the growth, survival and invasion of breast cancer cells.  
 
5.2 EXPERIMENTAL METHODS 
The following is a brief summary of the materials and procedures used to 
generate the data presented in this chapter. Full details of materials and methods used 
herein are described in Chapter 2. 
5.2.1 Cell lines 
MCF-7 and MDA-MB-231 cells were utilised throughout this chapter. Cell 
lines were maintained following procedures described in section 2.3. The highly 
metastatic MDA-MB-231  breast cancer cell line was chosen to screen and select the 
best shRNA owing to the high expression of the target genes detected within these 
cells. The functional studies reported in this chapter were performed using both 
MCF-7 and MDA-MB-231 cells. Validation experiments assessing the effect of 
shRNA knockdown on cell survival and migration, were cross-validated with the 
parental (MOCK, non-transfected) as well as the non-targeting shFF3-containing 
control cells (shCntrl). 
5.2.2 Lentiviral shRNA mediated knockdown of target genes 
To assess the putative functional role of candidate genes; namely Cyr61 and 
CTGF, lentiviral-mediated transduction of gene specific shRNA sequences was 
performed to stably suppress target gene expression (knockdown). For details on the 
lentiviral vector system used refer to section 2.15.1. For all the cloning protocols 
applied to produce these vectors refer to section 2.14.  
Virus production in HEK293T packaging cells 
The pLKO.1 vector containing the target shRNA of interest and the viral 
packaging plasmids, pCMV-VSV-G and pCMV delta R8.2, were transiently 
transfected into HEK293T cells to produce lentiviral particles as per the procedures 
described in section 2.15.2. Virus-rich supernatants were harvested at 48 and 72 
hours post-transfection. The viral supernatant was clarified by centrifugation at 1000 
rpm for 5 minutes, filtered through a 0.45 μm cut-off filter, pooled together and 
stored at -80 °C until use. Prior to harvesting viral supernatants, HEK293T cells 
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transfected with the GFP-containing control vector pLKO.3G were visually 
inspected for green fluorescence under a fluorescence microscope to confirm 
HEK293T transfection efficiency.  
Transduction of target cell lines 
For full details on the transduction protocols refer to section 2.15.3. Target 
cells at 30-40% confluency were transduced with 2 mL of the lentivirus-containing 
supernatant medium obtained above. Protamine sulphate (6 μg/mL) was added to 
facilitate virus uptake. Following overnight incubation, the viral supernatant was 
removed and cells were allowed to recover for 24 hours in regular growth medium. 
The following day, transduced cells were subjected to selection with 2 μg/mL 
puromycin. This high concentration of puromycin was maintained until all the 
untransfected negative control cells died, after which the transduced cells were 
maintained in 1 μg/mL puromycin-containing growth medium. Cells transduced with 
the pLKO.3G-lentiviral particles were visually inspected for green fluorescence to 
confirm and judge the transduction efficiency of target cells. Positively selected 
target cells were observed for any changes in morphology compared to the shFF3-
containing control cells (shCntrl). RNA and proteins were isolated to analyse 
shRNA-mediated knockdown of the gene of interest through qRT-PCR and 
immunoblotting, respectively. 
5.2.3 qRT-PCR to assess target gene expression 
RNA was extracted from cell lysates using the Direct-zol™ MiniPrep Kit 
(Zymo Research) following the manufacture’s protocol (for full details on this 
method please refer to section 2.8.2.). RNA samples were then reverse transcribed 
into cDNA using the SuperScript
®
 III First-Strand Synthesis SuperMix kit (Life 
Technologies) following the manufacture’s protocol as briefly outlined in section 
2.11.2.  
5.2.4 Immunoblotting to assess protein expression  
To assess down-regulation of protein expression MCF-7 and MDA-MB-231 
cells containing either the control or target gene shRNA were seeded in 10 cm 
culture dishes, washed with PBS, and lysed directly by adding 600 μL of Radio 
Immuno-Precipitation Assay (RIPA) buffer containing  (Sigma-Aldrich) phosphatase 
(Thermo Fisher Scientific) (1:10) and protease (Roche Diagnostics) (1:10) inhibitors 
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to each dish. The plates were then incubated on ice for 5 minutes and the cells were 
dislodged into suspension using a rubber policeman. For full details on this method 
refer to section 2.12.1. 
The protein concentrations were determined using Coomassie Plus
®
 Protein 
Quantitation kit. Proteins (20-60 μg per sample) were then resolved on pre-made 
NuPAGE
®
 gradient SDS-PAGE gels (4%-12%) and transferred onto nitrocellulose 
membranes. Western immunoblotting was performed following procedures outlined 
in section 2.12.2. The primary antibodies used in this chapter were anti-Cyr61 
(1:1000) and anti-CTGF (1:1000) (R&D system). To detect the total levels of these 
proteins, the same membranes were stripped using Restore
®
 Western blot stripping 
buffer and probed with anti-GAPDH to validate equal loading of proteins onto the 
gel.  
5.2.5 MTS assay for cell viability measurements 
For full details on this method refer to section 2.5. Briefly, MCF-7 and MDA-
MB-231 cells containing either non-targeting control shRNA or shRNA specific for 
the target gene were serum-starved for 4 hours before seeding 5 x 10
3
 cells 
suspended in 100 μL serum-free DMEM/F12 medium (SFM) + 0.05% BSA into 96-
well plates pre-coated with VN and IGF-I:IGFBP-5:VN combinations (refer to 
section 2.4.1 for proteins pre-bound and concentrations used). Treatments with 
medium containing 10% FBS and only SFM served as positive and negative controls, 
respectively. After 72 hours, 20 µL MTS reagent was added into each well and the 
absorbance was recorded after 2 hours and 30 minutes at 490 nm using a 96-well 
plate reader (Benchmark Plus, Bio-Rad). 
5.2.6  CyQUANT for cell proliferation assay 
Similar to MTS assay, for CyQUANT assay, serum-starved MCF-7 cells 
seeded onto 96-well plates per-coated with VN either alone or in combination with 
IGF-I+IGFBP-5 and allowed to grow for 72 hours at 37 °C, 5% CO2. After 
incubation duration, media was aspirated from wells and plated were wrapped in 
parafilm and stored at -80 °C overnight. The following day plates were thawed at 
room temperature and 100 µL of lysis buffer and CyQuant GR fluorescent dye 
mixture [provided by the CyQUANT cell proliferation assay kit (Life Technologies)] 
was added to each well and mix thoroughly. Plates were incubated at room 
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temperature in the dark for 5 minutes and the absorbance was recorded after 5 
minutes with excitation at 485 nm and emission detection at 530 nm at using a 96-
well plate reader (Benchmark Plus, Bio-Rad). To convert sample fluorescence values 
into cell numbers, 1 x 10
6
 MCF-7 cells were collected as a cell pellet, supernatant 
removed and the pellet stored at -80 °C overnight. The following day, cell pellet was 
lysed by adding 1 mL of the CyQUANT GR dye/cell-lysis buffer and serial dilution 
generated corresponding to cell numbers ranging from 50 to 50,000 cells per 100 µL 
adding to each well. Wells with no cells containing 100 µL of the CyQUANT GR 
dye/cell-lysis buffer, also used as a control. Fluorescent intensity was measured and 
standard curve was obtained using linear regression analysis. 
5.2.7 Transwell® migration assays 
For full details on this method refer to section 2.6.  
5.2.8 3D Matrigel™ assay 
For full details on this method refer to section 2.7. Briefly, assays were 
performed in 96-well plates. MCF-7 and MDA-MB-231 cells containing either non-
targeting control shRNA or shRNA specific for the target gene were suspended in 3D 
growth medium (DMEM/F12 for MCF-7 cells and RPMI 1640 for MDA-MB-231 
cells; 2.5% Matrigel™ + 1% FBS) and were seeded onto a 100% Matrigel™ layer. 
Cells were incubated for three days without medium change. On Day 3 the spent 
medium from the treatment-wells was removed and replaced with solutions of 3D 
growth medium containing VN (1 μg/mL) alone or complexed with IGFBP-5 (300 
ng/mL), and IGF-I (100 ng/mL). To facilitate protein complexes being formed, these 
protein + 3D growth medium solutions were incubated for 2 hours at 37 °C, 5% CO2 
prior to adding them into the respective wells. Solutions containing 3D growth 
medium with 1% serum served as the negative control. Cells were incubated for 
further 6 days (for MDA-MB-231 cells) or 9 days (for MCF-7 cells), with spent 
medium being replaced every three days with fresh 3D growth medium containing 
the respective protein solutions. 
Analysis of 3D cell survival using AlamarBlue assay 
For full details on this method refer to section 2.7.1. 
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ImageJ analysis for spheroid size calculations 
For full details on this method refer to section 2.7.3. The 3D cultures were 
fluorescently stained, images recorded and subjected to analysis via ImageJ. The 
threshold value above/below which the spheroids were considered viable was set to 
include small colonies but to omit debris accumulated within the 3D culture (these 
appear as small dots within the image). For MCF-7 which form round colonies the 
size (area of pixels occupied in μm2) of the spheroids detected within the image was 
calculated and results were exported to Microsoft Excel for data analysis. Treatments 
were tested in duplicate in each experiment. When cultured as 3D, the MCF-7 cells 
grow as a mass resembling an irregular “spheroid” (Kenny et al., 2007), closely 
representing an in vivo primary tumour (Chishima et al., 1997; Ravizzini et al., 
2009). As opposed to the spheroid-like colonies of MCF-7 cells, the highly 
metastatic cells have a spindle-like morphology and invade the 3D culture in 
different directions resembling invasive tumours in vivo (Benton et al., 2014). Thus, 
the studies reported herein used ImageJ to measure the size of spheroids in MCF-7 
cells to relatively quantify the colony formation ability in this cell line. ImageJ was 
also used to measure the relative circularity in MDA-MB-231 cells to quantify the 
change in cell appearance in response to various treatments.  
 
5.3 RESULTS 
5.3.1 Plasmid/viral delivery to packaging HEK 293T and target MDA-MB-231 
cells 
Lentiviral transduction was the method chosen to deliver shRNA against Cyr61 
and CTGF into the target cells. Lentiviruses were produced within HEK293T 
packaging cells (refer to section 2.4.2) which had the pLKO vector containing either 
shCyr61 or shCTGF. For use as controls, lentiviruses were also produced to contain 
an shRNA sequence targeting firefly luciferase (pLKO.shFF3). To enable coincident 
assessment of transfection efficiency, cells were transfected in parallel with GFP-
containing vector, pLKO.3G. Using the pLKO.3G-transfected HEK293T cells, visual 
inspection via fluorescence microscopy revealed that the majority of cells to be 
positive for GFP. (Figure 5.1).  
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Once it was confirmed that the pLKO vectors were transfected efficiently into 
HEK293T cells, the transduction efficiency of the viral particles was confirmed 
using the target MDA-MB231 cell line. Similarly, it was observed that the majority 
of MDA-MB-231 cells were effectively transduced with pLKO.3G lentiviral 
particles as observed by GFP fluorescence (Figure 5.1). This confirmed that our 
pLKO lentiviral system for the delivery of shRNA into human cells was working 
effectively. In addition, the majority of the pLKO.1 infected target cells remained 
viable upon selection with the antibiotic puromycin (2 μg/mL), indicating the 
successful stable incorporation and expression of the pLKO-shRNA sequences in 
target cells.  
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Figure 5.1: Visualisation of transfection and transduction efficiency 
A schematic flow-chart is depicted of the steps involved in the production of lentiviral particles using 
HEK293T packaging cells and its subsequent infection into the target cells (here MDA-MB-231). 
Fluorescence microscopy images of HEK293T and MDA-MB-231 cells emitting GFP fluorescence 
post transfection and transduction, respectively, are also depicted. Scale bars indicate 100 μm. 
  
GFP positive Packaging cells 
(HEK 293T) 
shRNA 
vector 
Delta 
R8.2 
VSV-G 
Packaging vectors 
+ FuGENE 6 
transfection 
 Overnight 
infection 
Virus produced 
 by 293T cells 
GFP positive Target cells 
(MDA-MB-231) 
 Chapter 5: Functional validation of Cyr61 and CTGF in VN- and IGF-I:IGFBP:VN-stimulated breast cancer cell 
survival 162 
5.3.2 Screening and selection of shRNA sequences resulting in optimal 
suppression of Cyr61 and CTGF in MDA-MB-231 cells 
The MDA-MB-231 cell line with high endogenous Cyr61 and CTGF 
expression (Chapter 4; Figure 3.9) was used to screen five individual shRNA 
sequences cloned into the pLKO.1 vector for the optimal suppression of endogenous 
Cyr61 and CTGF expression. MDA-MB-231 cells were transduced with pLKO.1 
containing viral particles containing individual shRNA sequences and RNA collected 
following puromycin selection. qRT-PCR was performed to assess the expression 
level of Cyr61 and CTGF transduced with specific shRNA sequences. MDA-MB-
231 parental (MOCK) and MDA-MB-231 cells containing non-targeting control 
shFF3 shRNA (shCntrl) were used as controls. Gene expression in MDA-MB-231 
clones containing gene-specific shRNAs was compared to shCntrl cells and the 
relative levels of gene expression were assessed (Figures 5.2 A & B). Expression of 
the target genes was also confirmed at the protein level using immublotting (Figure 
5.2 C).  
The mRNA expression of Cyr61 was found to be significantly down-regulated 
(p<0.01) by three of the five candidate shRNAs, including shCyr61-1, -2 and -4 
compared to the shCntrl cells (Figure 5.2 A). Maximal reduction in the expression of 
Cyr61 was observed in shCyr61-4 cells, with 75 ± 9% down-regulation observed 
compared to the shCntrl cells. Similarly, immunoblot analysis demonstrated a 
substantial down-regulation of Cyr61 at the protein level in cells transfected with 
Cyr61-4 sequence (Figure 5.2 C). Thus, the shCyr61-4 clone was used to down-
regulate Cyr61 in MCF-7 cell line in the subsequent experiments. Furthermore, out 
of five different shRNAs tested for CTGF, four shRNAs resulted in a significant 
down-regulation of mRNA CTGF expression in MDA-MB-231 cells (Figure 5.2 B). 
However, the shCTGF-3 clone was chosen for subsequent experiments since it 
resulted in the maximal down-regulation of CTGF, with 84 ± 7% down-regulation 
observed compared to the shCntrl cells. This was also confirmed by western blot 
analysis wherein cells transfected with the shCTGF-3 sequence demonstrated a 
substantial reduction in the CTGF protein expression level (Figure 5.2 C). 
Importantly, no significant differences were observed in the expression of either 
Cyr61 or CTGF between the MDA-MB-231 parental (MOCK) and the shCntrl cells 
(Figures 5.2 A, B & C). This suggests that the pLKO vector backbone as such had no 
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effects on the gene expression and that shCntrl was suitable to be used as a negative 
control as it did not induce any off-target effects. Moreover, the morphology of 
shCyr61 and shCTGF cells remained unchanged and resembled control shCntrl cells 
(Figure 5.2. D). 
In summary, among the various shRNA sequences for Cyr61 and CTGF the 
shCyr61-4 and shCTGF-3 were selected as the best shRNA sequences for the 
maximal suppression of Cyr61 and CTGF, respectively. These shRNAs were then 
tested in MCF-7 cells for which the results are reported in the following section.  
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Figure 5.2: Screening of gene-specific shCyr61 and shCTGF sequences in MDA-MB-231 cells using 
qRT-PCR and immunoblotting. 
 
(A & B) Five shRNA sequences were designed each against Cyr61 (A) and CTGF (B) and were 
transduced into MDA-MB-231 cells generating 5 clones per target gene. Expression of the target 
genes was assessed through qRT-PCR and data analysed was performed using the ΔΔCt approach. 
Data are expressed in log scale as relative fold expression of the target genes in each shRNA-
containing cell line compared to that of the control non-targeting shRNA cell line (shCntrl). Target 
gene expression of un-transduced parental MDA-MB-231 cells (MOCK) is also included for control 
purposes. The asterisks indicate shRNAs-containing cells with significant down-regulation (*p<0.05, 
**p<0.01, two-tailed student’s t-test) in target gene expression compared to the shCntrl cells. Error 
bars indicate SEM. (C) Down-regulation of Cyr61 and CTGF was confirmed using immunoblott 
analysis in cells containing the best-targeting shCyr61-4 and shCTGF-3 shRNAs, respectively. (D) 
Phase contrast images of monolayer cultures of MDA-MB 231 cells were used to compare the 
morphology of the control cells (shCntrl) versus the knockdown cells (shCyr61-3 and shCTGF-4). 
Scale bar indicates 100 μm. MOCK = parental MDA-MB-231 cells; shCntrl = MDA-MB-231 cells 
containing the non-targeting shRNA. 
A B 
C 
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5.3.3 Generation of constitutive MCF-7 shRNA knockdown models 
MCF-7 cells with reduced expression of Cyr61 and CTGF were generated 
using shCyr61-4 and shCTGF-3 as outlined above for the MDA-MB-231 cell line (as 
observed in Figure 5.2). The shCyr61-4 and shCTGF-3 sequence constructs will be 
henceforth simply called shCyr61 and shCTGF. Monolayer cultures of MCF-7-
shCyr61 and MCF-7-shCTGFcells were lysed and RNA and protein was extracted. 
qRT-PCR analysis confirmed a significant reduction (p<0.01) of Cyr61 gene 
expression in MCF-7-shCyr61 cells, with 68 ± 5% down-regulation observed 
compared to shCntrl cells (Figure 5.3 A). Likewise, expression of CTGF at mRNA 
levels was found to be significantly (p<0.01) decreased in MCF-7-shCTGFcells, with 
83 ± 1% down-regulation in gene expression observed compared to shCntrl cells 
(Figure 5.3 A). Similar results were observed at protein levels wherein immunoblot 
analysis detected a considerable reduction in Cyr61 and CTGF protein expression 
(Figure 5.3 B). Down-regulation of Cyr61 did not have cross-targeting effect in 
regulation of CTGF. Likewise, no change in Cyr61 expression was observed in cells 
containing shCTGF. In addition, no differences in the mRNA and protein expression 
of target genes were observed in either MCF-7-shCntrl control or MOCK parental 
MCF-7 cells. Furthermore, the morphology of shCyr61 and shCTGF cells remained 
unchanged and resembled shCntrl (Figure 5.3 C) and parental (MOCK) cells (data 
not shown).  
Taken together, these data demonstrate the successful generation of MCF-7 
breast cancer cell models with knockdown of endogenous Cyr61 and CTGF 
expression. 
  
 Chapter 5: Functional validation of Cyr61 and CTGF in VN- and IGF-I:IGFBP:VN-stimulated breast cancer cell 
survival 166 
 
 
Figure 5.3: Validation of Cyr61 and CTGF in MCF-7 breast cancer cells. 
(A & B) The best shRNA sequences with maximal knockdown for Cyr61 and CTGF genes, shCyr61-
4 and shCTGF-3, were used to produce MCF-7 cells with reduced Cyr61 and CTGF expression. 
Down-regulation of Cyr61 and CTGF was confirmed in MCF-7-shCyr61and MCF-7-shCTGF cells 
using qRT-PCR analysis (A) and western immunoblotting (B). The asterisks indicate shRNAs-
containing cells with significant down-regulation (**p<0.01, two-tailed student’s t-test) in target gene 
expression compared to the shCntrl control MCF-7 cells. Error bars indicate SEM. (C) Phase contrast 
images of monolayer cultures of MCF-7 cells were used to compare the morphology of the control 
cells (shCntrl) versus the knockdown cells (shCyr61-3 and shCTGF-4). Scale bar indicates 100 μm. 
MOCK = parental MDA-MB-231 cells; shCntrl = MCF-7 cells containing the non-targeting shRNA.  
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5.3.4 Suppression of Cyr61 and CTGF expression in MCF-7 cells reduces VN- 
and IGF-I:IGFBP-5:VN-stimulated cell viability and proliferation in 2D 
monolayer cultures 
The main purpose of performing the gene knockdown studies was to 
investigate the potential involvement of Cyr61 and CTGF in VN- and trimeric IGF-
I:IGFBP:VN complex-stimulated breast cancer cell survival. In view of this, MCF-7 
cells either with reduced Cyr61 (MCF-7-shCyr61) or CTGF (MCF-7-shCTGF) were 
seeded along with non-transfected parental (MOCK) and the control non-targeting 
shRNA-containing (MCF-7-shCntrl) cells into 96-well plates pre-coated with either 
VN alone or the trimeric complex. Cell viability and cell proliferation were then 
assessed after 72 hours using MTS and CyQUANT reagents, respectively. Cells 
suspended in SFM only and medium containing 10% FBS were used as the negative 
and positive controls, respectively.  
 MCF-7-ShCyr61cells showed significant decreases (p<0.01) in VN- and 
trimeric complex-induced viability compared to that observed for parental MCF-7 
cells (Figure 5.4 A). Likewise, MCF-7-shCTGF cells were observed to have a 
significant reduction (p<0.05) in cell viability in response to VN and the trimeric 
complex compared to the parental cells. The cell viability of shCyr61 cells was also 
seen to be significantly reduced in response to the SFM control treatment. Similar 
results were observed for the proliferation assay wherein cell numbers calculated 
over 72 hours in response to VN and the trimeric complex were significantly lower 
in MCF-7-shCyr61 and -shCTGF cells compared to the parental controls (Figure 5.4 
B). Additionally, shCyr61 and shCTGF containing cells significantly decreased 
(p<0.05) proliferation in response to the 10% serum treatment. This suggests the 
possibility that other growth-promoting components present in the serum might also 
induce MCF-7 cell proliferation through induction and regulation of Cyr61 and 
CTGF expression. Importantly, no changes were observed in viability and 
proliferation of shCntrl cells compared to the parental cells, suggesting that shCntrl 
did not induce any additional effects on cell function. 
Taken together, these data suggest that Cyr61 and CTGF play roles in VN and 
the trimeric IGF-I:IGFBP:VN complex-induced MCF-7 cell survival. 
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Figure 5.4: Effects of Cyr61 and CTGF knockdown on VN- and IGF-I:IGFBP-5:VN-stimulated MCF-
7 cell viability and proliferation. 
Viability (A) and proliferation (B) of MCF-7 parental (MOCK), shCntrl, shCyr61 and shCTGF cells 
seeded for 72 hours into 96-well plates pre-coated with VN alone or the trimeric IGF-I:IGFBP-5:VN 
complex (TRI) were assessed using the MTS and CyQUANT assays, respectively. Cells suspended in 
SFM or SFM supplemented with 10% FBS were used as the negative and positive controls, 
respectively. For the viability assay the data are expressed as average percent stimulation of the 
MOCK cells treated with SFM, whereas for the proliferation assay fluorescent intensity was measured 
after 72 hours and the relative cell number was obtained and depicted using standard serial dilution 
and linear regression analysis. The data were pooled either from three experiments (for viability) or 
two experiments (for proliferation), with treatments tested in at least six wells in each replicate 
experiment. The asterisks indicate treatments with significant differences compared to their respective 
MOCK (parental) controls (*p<0.05, **p<0.01, two-tailed student’s t-test). Error bars indicate SEM. 
SFM = Serum Free Media; TRI = trimeric IGF-I:IGFBP-5:VN complex; 10% FBS = growth medium 
containing 10% FBS. Fluorescent intensity was measured and standard curve was obtained using 
linear regression analysis.   
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5.3.5 Suppression of Cyr61 and CTGF decreases VN- and IGF-I-IGFBP-5:VN-
stimulated MCF-7 spheroid formation and long-term cell viability in 3D 
cultures 
As outlined in Chapter 1, cells behave differentially when grown in 3D 
matrices as opposed to those grown in 2D monolayer cultures on plastic. Studies 
performed in our laboratory (unpublished data) and by others (Weigelt & Bissell, 
2008) have demonstrated that the weakly metastatic and poorly-invasive MCF-7 
breast cancer cells grown in a 3D matrix such as Matrigel™ form round spheroids 
resembling in vivo primary breast tumours. To investigate the effects of Cyr61 and 
CTGF down-regulation on MCF-7 spheroid formation and growth in a 3D setting 
and to also explore effects on VN- and IGF-I:IGFBP:VN-stimulated spheroid 
growth, MCF-7 cells containing either shCyr61 or shCTGF (along with the shCntrl 
cells) were grown in 3D Matrigel™ cultures as per the protocols described in section 
2.7. Cells were exposed to either VN alone or the trimeric complex. Cells suspended 
in the base 3D growth medium (3D-GM; comprising DMEM/F12 + 1% FBS + 2.5 % 
Matrigel™) served as the negative control. On day 12, the cultures were stained for 
viable cells using fluorescein diacetate (FDA) and either visually assessed via 
fluorescent microscopy (Figure 5.5 A) or the size of spheroids was quantified using 
ImageJ software (Figure 5.5 B). The whole-culture cell viability was measured using 
the AlamarBlue assay (Figure 5.5 C).  
Fluorescence microscopy images clearly demonstrated that in the VN and 3D-
GM treatment the size of spheroids formed by shCyr61 and shCTGF cells remained 
relatively small compared to the control shCntrl cells (Figure 5.5 A). The trimeric 
complex treatment caused a substantial increase in the size of the spheroids in the 
shCntrl cells compared to cells treated with VN or 3D-GM alone. These observations 
are in accordance with previous findings from our laboratory demonstrated by Dr 
Abhishek Kashyap during his PhD (unpublished data). Interestingly, no such 
increase in spheroid size was observed in shCyr61and shCTGF cells treated with the 
trimeric complex (Figure 5.5 A). Based on the visual inspection of the spheroid 
colonies these results suggest that Cyr61 and CTGF may play a role in VN- and 
trimeric complex-induced spheroid formation and growth ability of MCF-7 cells in a 
3D culture model. To quantify the changes in spheroid size, ImageJ software was 
used to calculate the amount of pixels occupied by each spheroid to eventually obtain 
the surface area of each spheroid (in µm
2
). The box-and-whisker plot of these data 
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(Figure 5.5 B) clearly demonstrate a dramatic downward shift in the size of VN- and 
trimeric complex-treated spheroids both the shCyr61 and shCTGF cells compared to 
shCntrl control cells. A similar result was also observed in cells treated with 3D-GM 
only.  
AlamarBlue assay was performed in order to quantify the viability of the cells 
cultured in 3D Matrigel™. In addition to the reduced sizes of the spheroids, the 
overall cell viability in shCyr61 cell cultures was significantly reduced (p<0.01) in 
response to VN and the trimeric complex compared to cultures containing shCntrl 
cells (Figure 5.5 C). In a similar fashion, the suppression of CTGF led to 
significantly reduced viability in response to VN (p<0.05) and the trimeric complex 
(p<0.01). This effect was also observed for shCyr61 and shCTGF cells treated with 
3D-GM only.  
Altogether the evidence obtained from the visual inspection of cultures 
combined with their quantitative assessment (Figure 5.5) suggest that Cyr61 and 
CTGF are essential for the VN and trimeric IGF-I:IGFBP:VN complex-stimulated 
MCF-7 breast cancer cell growth, long-term survival and colony formation in a 3D 
environment.  
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Figure 5.5: Effects of Cyr61 and CTGF suppression on MCF-7 cell growth in 3D in response to VN 
and the IGF-I:IGFBP:VN complex.  
One thousand MCF-7 shCntrl, shCyr61 and shCTGF cells suspended in 3D growth medium with 1% 
serum were seeded onto 100% Matrigel™ and allowed to grow for 3 days and form spheroids. Spent 
medium was replaced with 3D growth medium containing 1 μg/mL of VN either alone (VN) or pre-
complexed with IGF-I (100 ng/mL) and IGFBP-5 (300 ng/mL) (TRI). (A) Cells were fluorescently 
stained using FDA and images were recorded on Day 12. Box-and-whisker plot (B) depicts mean 
spheroid size (μm2) at Day 12 for each treatment, calculated using ImageJ software. Data in the graph 
are the average size of all spheroids present in a single field of view at 40x magnification from eight 
fields of view (boxes), where the lower bars and the upper bars (whiskers) indicate the smallest and 
the largest size of spheroids presented in all images, respectively. (C) AlamarBlue assay was 
performed on day 12 of the 3D culture, with data expressed as average percent cell viability compared 
to the VN treatment of shCntrl cells. Data are pooled from three replicate experiments with treatments 
tested in duplicate wells in each replicate experiment. The asterisks indicate significant differences in 
cell viability compared to their respective shCntrl cells (*p<0.05, **p<0.01). Scale bars indicate 100 
μm. Error bars indicate SEM. 3D-GM = 3D growth medium containing 1% FBS; TRI = trimeric IGF-
I:IGFBP-5:VN complex; shCntrl = non-targeting control shRNA-containing cells.  
A 
B C 3D viability 
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5.3.6 Cyr61 knockdown reduces VN- and IGF-I:IGFBP-5:VN-stimulated MDA-
MB-231 cell viability in 2D cultures 
Having shown the involvement of Cyr61 and CTGF in the weakly metastatic 
MCF-7 cell line, the involvement of these genes in the highly aggressive MDA-MB-
231 cells was further investigated. More specifically, to determine whether Cyr61 
and CTGF are crucial determinants in MDA-MB-231 cell viability in response to VN 
and the trimeric IGF-I:IGFBP:VN complex, non-transfected MDA-MB-231 parental 
(MOCK) and the shCntrl cells were seeded along with cells with reduced expression 
of Cyr61 and CTGF onto 96-well plates pre-coated with either VN and the trimeric 
IGF-I:IGFBP-5:VN complex. Cell viability was then assessed after 72 hours using 
MTS reagent. Cells suspended in SFM only and medium containing 5% FBS were 
used as the negative and positive controls, respectively. 
Treatment of MDA-MB-231 cells with VN and trimeric complex caused 
significant increases (p<0.01) in cell viability in MDA-MB-231-parental and MDA-
MB-231-shCnrtl cells compared to that observed in cells treated with SFM only 
(Figure 5.6). Interestingly, the parental MDA-MB-231 and MDA-MB-231-shCntrl 
cells treated with the trimeric complex significantly increased (p<0.05) viability 
compared to cells treated with VN alone. This suggests that VN and trimeric 
complex can promote cell survival in the highly aggressive MDA-MB-231 cell 
models. Importantly, the MDA-MB-231-shCyr61 cells had significantly reduced cell 
viability (p<0.05) in response to VN and the trimeric complex compared to the 
parental and shCntrl cells (Figure 5.6). No appreciable alternation in cell viability 
was observed in shCTGF cells in response to VN and the trimeric complex.  
In summary, this data demonstrate for the first time that VN and the trimeric 
IGF-I:IGFBP:VN complex are capable of stimulating  increased MDA-MB-231 cell 
viability. The data also suggest that Cyr61 plays and important role in VN- and the 
trimeric IGF-I:IGFBP:VN-induced viability in the metastatic MDA-MB-231 cell 
line.   
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Figure 5.6: Effects of Cyr61 and CTGF knockdown on VN- and IGF-I:IGFBP-5:VN-stimulated 
MDA-MB-231cell viability. 
Viability of MDA-MB-231 parental (MOCK), shCntrl, shCyr61 and shCTGF cells seeded for 72 
hours into 96-well plates pre-coated with VN alone or the trimeric IGF-I:IGFBP-5:VN complex (TRI) 
was assessed using the MTS assay. The data are expressed as average percent stimulation of the 
respective MOCK cells in the SFM negative control. The data are pooled from two experiments with 
treatments tested in at least six wells in each replicate experiment. The asterisks indicate significant 
differences between treatments (* p<0.05). Error bars indicate SEM. SFM = Serum Free Media; TRI 
= trimeric IGF-I:IGFBP-5:VN complex; 5% FBS = growth medium containing 5% FBS. 
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5.3.7 Involvement of Cyr61 in regulating cell survival and CTGF in mediating 
spreding of MDA-MB-231 cells in response to VN and the IGF-
I:IGFBP:VN complex in 3D cultures  
To examine the role of Cyr61 and CTGF in cell growth, survival and invasive 
properties of MDA-MB-231 cells in a 3D setting in response to VN and the IGF-
I:IGFBP:VN complex, MDA-MB-231 cells with reduced expression of either Cyr61 
or CTGF were grown along with shCntrl cells in 3D Matrigel™ cultures and treated 
with either VN alone or the IGF-I:IGFBP:VN complex. Cells suspended in the base 
3D-GM again served as negative controls. On day 9, viable cells were fluorescently 
stained using FDA and the morphology was assessed visually via fluorescence 
microscopy (Figure 5.7 A). Since MDA-MB-231 cells are highly invasive in this 
culture system (reflecting their in vivo metastatic ability) and do not form defined 
colonies, ImageJ was used to assess the effect of candidate gene suppression on cell 
invasiveness and morphology, rather than colony size as for MCF-7 cultures. Thus, 
the morphological changes in MDA-MB-231 3D cultures were analysed by 
measuring cell circularity and the relative frequency distribution using ImageJ 
(Figure 5.7 B). As previously, the whole-culture cell viability was also measured 
using the AlamarBlue assay (Figure 5.7 C).  
As expected, MDA-MD-231 cells formed meshworks of spindle-like 
mesenchymal colonies where cells were seen to invade in different directions within 
the Matrigel™ matrix (Figure 5.7A). Visual inspection of cultures indicated no 
apparent differences in growth and morphology were observed in MDA-MD-231-
shCntrl cells cultured with VN, trimeric complex or the 3D-GM control treatments 
(Figure 5.7 A). Interestingly, however MDA-MB 231-shCTGF cells were observed 
to have lost their spindle-like morphology (Figure 5.7 A), and instead formed more 
rounded epithelial-like spheroids resembling the MCF-7 3D culture spheroids 
(Figure 5.5 A). These results were also reflected in the ImageJ analyses of the 
circularity of the cell colonies wherein round colonies were over represented in the 
shCTGF cultures as compared to the shCntrl cultures (Figure 5.7 B).  
Upon assessing the viability of 3D cultures using AlamarBlue it was observed 
that unlike the responses observed for MCF-7 cultures, there was a non-significant 
increase in shCntrl cell viability observed in cultures treated with the trimeric 
complex compared to the cells treated with VN or 3D-GM alone. Importantly, the 
MDA-MB-231-shCyr61 cells had a significantly reduced (p<0.05) viability in 
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response to VN and the trimeric complex compared to shCntrl cells (Figure 5.7). In 
contrast to the 2D viability results, no appreciable changes in cell viability were 
observed in cultures containing MDA-MB-231-shCTGF cells as compared to MDA-
MB-231-shCntrl cultures.  
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Figure 5.7: Effects of Cyr61 and CTGF suppression on growth and morphological appearance of 
MDA-MB-231 cells cultured in 3D Matrigel™ in response to VN and the IGF-I:IGFBP:VN complex 
Eight hundred MDA-MB-231-shCntrl, -shCyr61 and -shCTGF cells suspended in 3D growth medium 
with 1% serum were seeded onto 100% Matrigel™ and allowed to grow for 3 days and form 
spheroids. Spent medium was replaced with 3D growth medium containing 1 μg/mL of VN either 
alone (VN) or pre-complexed with IGF-I (100 ng/mL) and IGFBP-5 (300 ng/mL) (TRI). (A) Cells 
were fluorescently stained using FDA and images were recorded on day 9 using Nikon Eclipse TS100 
microscope. (B) ImageJ was then used to measure the circularity of the cell colonies (ranging from 0 
to 1) cultured in Matrigel™ and the results were plotted as a frequency distribution graph. 0 = not 
circular/more invasive to 1 = circular/less invasive. (C) AlamarBlue assay was performed on Day 9 on 
these cell cultures and the data were expressed as average percent cell viability compared to the 
shCntrl cells of the VN treatment. Data are pooled from two replicate experiments with treatments 
tested in duplicate wells in each replicate experiment. The asterisks indicate significant differences 
compared to the MDA-MB-231-shCntrl cells within the respective treatment group (*p<0.05, two-
tailed student’s t-test). Scale bars indicate 100 μm. Error bars indicate SEM. 3D-GM = 3D growth 
medium containing 1% FBS; TRI = trimeric IGF-I:IGFBP-5:VN complex.  
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5.3.8 CTGF suppression decreases breast cancer cell migration in response to 
VN and the IGF-I:IGFBP:VN complex.  
It is well documented that VN promotes migration in a variety of epithelial cell 
types, including breast cancer cells (Carriero et al., 1999; Madsen et al., 2007; Pola et 
al., 2013). Additionally, studies within our laboratory have demonstrated that the 
trimeric IGF-I:IGFBP:VN complex can mediate breast cancer cell migration above 
the response observed with VN alone (Hollier et al., 2008; Kashyap et al., 2011). 
Importantly, the studies reported herein demonstrated that suppression of 
endogenous CTGF expression can alter the morphological appearance of MDA-MB-
231 cells in 3D cultures (Figure 5.7 A). Thus, the effect of CTGF down-regulation in 
addition to Cyr61 was further investigated in VN and IGF-I:IGFBP:VN-stimulated 
migration of MCF-7 and MDA-MB-231 cells. Transwell
®
 migration plates were 
coated on the under-surface with VN or the IGF-I:IGFBP-5:VN complex. MCF-7 
and MDA-MB-231 cells containing shRNA against either Cyr61 or CTGF or the 
non-targeting control shRNA (shCntrl) were seeded onto the upper-surface of the 
inserts. Cells suspended in SFM only and medium containing 10% FBS (for MCF-7 
cells) or 5% FBS (for MDA-MB-231 cells) were used as the negative and positive 
controls, respectively. 
Treatment of the MCF-7-shCntrl cells with VN and the trimeric complex 
stimulated a significant increase (p<0.01) in cell migration compared to the SFM 
control treatment cells (Figure 5.8 A). As previously reported by our laboratory 
(Hollier et al., 2008), the trimeric complex significantly enhanced (p<0.01) the 
migration of MCF-7 cells compared to the VN treatment. MCF-7 cell migration was 
seen to be significantly reduced in the shCTGF cells in response to both VN (p<0.05) 
and the trimeric complex (p<0.01) compared to shCntrl cells (Figure 5.8 A). This 
suggests a role for CTGF in VN as well as trimeric complex-induced MCF-7 cell 
migration. No significant differences were observed in migration of cells with 
reduced Cyr61.  
In a similar fashion to MCF-7-shCntrl cells, treatment of the control MDA-
MB-231 cells (MDA-MB-231-shCntrl) with VN and the trimeric complex 
significantly increased (p<0.01) cell migration compared to cells treated with SFM 
only (Figure 5.8 B). Again, the migration of MDA-MB-231-shCntrl cells treated 
with the trimeric complex was significantly higher (p<0.01) than cells treated with 
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VN alone. Importantly, VN- and trimeric complex-induced migration in MDA-MB-
231 cells containing shCTGF (MDA-MB-231-sh-CTGF) was observed to be 
significantly reduced (p<0.01) compared to that observed in MDA-MB-231-shCntrl 
cells (Figure 5.8 B).This suggests that suppression of CTGF not only reduces the 
migratory responses induced by VN, but also can influence IGF-I-stimulated 
migration in breast cancer cells. MDA-MB-231-shCyr61cells did not alter migration 
in response to either VN or the trimeric complex.   
Taken together, these results indicate a potential role for CTGF but not Cyr61 
in the migratory abilities of both MCF-7 (weakly metastatic) and MDA-MB-231 
(highly metastatic) breast cancer cell lines in response to VN- and the trimeric IGF-
I:IGFBP:VN complex. 
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Figure 5.8: The effects of Cyr61 and CTGF down-regulation on MCF-7 and MDA-MB-231 cell 
migration in response to VN and the IGF-I:IGFBP:VN complex. 
shCyr61 and shCTGF containing MCF-7 (A) and MDA-MB-231 (B) cells along with shCntrl were 
seeded into Transwells® pre-coated with VN alone or the trimeric IGF-I:IGFBP-5:VN complex (TRI) 
were allowed to migrate for 14 hours and the levels of migration were assessed using crystal violet 
staining. The data are pooled from two independent experiments with treatments tested in duplicate 
wells in each replicate experiment. All treatments significantly increased (p<0.01) migration 
compared to the control SFM treatment. The asterisks indicate the shCntrl cell treated with the IGF-
I:IGFBP:VN complex which significantly increased (p<0.01) migration compared to cells treated with 
VN alone. The asterisks also indicate shCTGF cells which significantly decreased migration 
compared to shCntrl cells (*p<0.05; **p<0.01). Error bars indicate SEM. SFM = Serum Free Media; 
TRI = trimeric IGF-I:IGFBP-5:VN complex. 
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5.4 DISCUSSION 
Microarray analysis of the MCF-7 breast cancer cells that remained viable in 
response to VN and the IGF-I:IGFBP:VN complex revealed a number of 
differentially expressed genes with key roles in breast cancer cell survival. Among 
these genes, Cyr61 and CTGF genes were selected as top candidates to functionally 
validate their roles in VN- and trimeric IGF-I:IGFBP:VN complex-induced cell 
survival. Indeed, the results presented in Chapter 4 confirmed that VN and the IGF-
I:IGFBP:VN complex dramatically up-regulated the expression of Cyr61 and CTGF 
at both mRNA and protein levels in MCF-7 breast cancer cells. It was also shown 
that VN and the IGF-I:IGFBP:VN complex are capable of stimulating Cyr61 and 
CTGF expression in a range of breast cancer cells from weakly metastatic luminal-
like to the highly metastatic basal-like and claudin-low breast cancer cell types. 
However, the extent of the involvement of these two genes in regulating the 
functions of VN and the trimeric complex remain to be validated. In view of this, 
studies performed in this chapter comprise the first investigations into the 
involvement of Cyr61 and CTGF in VN- and IGF-I:IGFBP:VN-induced cell 
functions, namely cell survival and cell migration, using in vitro 2D and 3D culture 
assays.  
A loss-of-function approach was employed to functionally validate the 
involvement of Cyr61 and CTGF in VN- and IGF-I:IGFBP:VN-stimulated cell 
responses. Lentiviral gene delivery was used to deliver gene specific shRNA to target 
Cyr61 and CTGF. The target cells chosen were the weakly metastatic MCF-7 and the 
highly metastatic MDA-MB-231 breast cancer cells. The MCF-7 cell line was the 
obvious choice given that these genes were previously reported (Chapter 4) to be 
dramatically up-regulated in MCF-7 cells in response to VN and the IGF-
I:IGFBP:VN complex. Nevertheless, the basal expression levels of Cyr61 and CTGF 
in MCF-7 cells are quite low making them sub-optimal for testing shRNA sequences 
for maximal gene suppression. This was apparent from studies presented in Chapter 
4 wherein basal expression of Cyr61 and CTGF protein is barely detectable in MCF-
7 cells cultured under short-term serum depleted conditions. This is consistent with 
findings from others, namely Menendez et al. (2005), Chen et al. (2007) and Lin et al 
(2012) who reported a low expression of Cyr61 and CTGF at both mRNA and 
protein levels in MCF-7 cells grown under serum-free conditions. Hence, given their 
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high endogenous levels of both Cyr61 and CTGF (Xie, Miller, et al., 2001; Chen et 
al., 2007), MDA-MB-231 cells were used to screen multiple shRNA sequences for 
each target gene. This would also serve the dual purpose of functional validation in 
an additional breast cancer cell line with metastatic properties. The shRNA construct 
with maximal down-regulation of Cyr61 and CTGF in MDA-MB-231 cells identified 
at both mRNA and protein levels was selected (Figure 5.2 A & B) and consequently 
were used to further supress these candidates in MCF-7 cells (Figure 5.3 A & B). 
The overexpression of Cyr61 has been reported to enhance cell survival and 
proliferation in response to serum (Sampath et al., 2001; Tsai et al., 2002; Lin et al., 
2004; Menendez et al., 2005), and conversely its inhibition has been shown to 
attenuate the viability of MCF-7 cells in 2D monolayer cultures (Espinoza et al., 
2011). In view of this, experiments were performed to assess the impact of Cyr61 
down-regulation on VN- and IGF-I:IGFBP:VN complex-induced MCF-7 cell 
viability as well as proliferation using conventional 2D monolayer assays. Cells with 
down-regulated Cyr61 demonstrated significant decreases in VN-mediated cell 
viability and proliferation (Figure 5.4). Interestingly, these cells were also found to 
significantly reduce viability and proliferation induced by the IGF-I:IGFBP:VN 
complex. This suggests that targeting the key downstream mediators of VN, which is 
the major component of the IGF-I:IGFBP:VN complex, can also influence IGF-I-
mediated biological functions. In addition to its effects on VN- and IGF-
I:IGFBP:VN-induced cell survival, Cyr61 suppression also resulted in a significant 
decrease in serum-stimulated cell viability and proliferation. As reported previously 
(Sampath et al., 2001; Tsai et al., 2002; Lin et al., 2004; Menendez et al., 2005). 
Serum is a complex mixture of growth factors, hormones, proteins, lipids and 
minerals that are required for successful in vitro cell culture. Therefore, it is possible 
that growth-promoting and ECM elements present within the serum may support cell 
viability and proliferation through the induction and regulation of Cyr61. 
Importantly, serum contains high levels of VN, which in turn may be the component 
responsible for serum-induced Cyr61 effects.  
In addition to MCF-7 cells, the studies performed in this chapter also 
functionally validated the effect of Cyr61 and CTGF down-regulation in VN- and the 
IGF-I:IGFBP:VN complex-induced viability of  MDA-MB-231 cells. Similar to 
those responses observed for MCF-7 cells, VN and the IGF-I:IGFBP:VN complex 
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substantially increased viability of MDA-MB-231 cells compared to those cells in 
serum-free medium devoid of any added protein treatments (Figure 5.6). Importantly, 
MDA-MB-231 cells with down-regulation of Cyr61 had reduced VN- and IGF-
I:IGFBP:VN-induced viability (Figure 5.6). This is in accordance with studies 
performed by others demonstrating that blocking Cyr61 expression using Zoledronic 
acid, a bisphosphonate with anti-cancer properties, considerably reduced MDA-MB-
231 cell viability in 2D cultures by inhibiting cell growth and inducing apoptosis 
(Espinoza et al., 2011). Likewise, treatment of MDA-MB-231 cells with humanised 
anti-Cyr61 monoclonal antibody (093G9) inhibited cell proliferation in vitro and in 
vivo (Lin et al., 2012). Considering the dramatic up-regulation of Cyr61 by VN and 
the IGF-I:IGFBP:VN complex in MCF-7 and MDA-MB-231 cells (Figure 4.8) and 
the effect of its down-regulation in inhibition of survival induced by VN and the 
IGF-I:IGFBP:VN complex (Figures 5.4 & 5.6), it is clear that Cyr61 is critically 
involved in VN- and IGF-I:IGFBP:VN complex-induced cell survival effects.  
A growing body of evidence suggests that the use of in vitro 3D cell culture 
models, in contrast to 2D monolayer cultures on plastic, replicate more accurately the 
actual microenvironment where cells reside in tissue. Therefore, the behaviour of 
cells cultured in 3D is likely to reflect more closely in vivo responses (Debnath & 
Brugge, 2005; Weigelt & Bissell, 2008; Muthuswamy, 2011; Weigelt et al., 2014). In 
view of this, in addition to the 2D studies reported herein, the impact of Cyr61 and 
CTGF suppression on VN- and IGF-I:IGFBP:VN-induced cell growth/survival of 
breast cancer cells in 3D Matrigel™ cultures was assessed. The “3D on-top” 
approach was employed to culture cells on a 3D matrix where cells suspended in 
Growth Factor Reduced (GFR)-Matrigel™ (2.5%) + 1% FBS were layered on top of 
a 100% GFR-Matrigel™ layer. This approach was deemed more amenable to our 
experimental systems than the “3D embedded” approach where the cells are grown 
within the 100% Matrigel™ matrix making it difficult to study the cell-protein 
interactions in such a dense matrix. 
On visual assessment it was observed that the size of spheroids formed by 
MCF-7 cells with reduced Cyr61 expression in response to both VN as well as the 
IGF-I:IGBFP:VN complex was substantially smaller compared to spheroids formed 
by shCntrl control cells (Figure 5.5 A). The ImageJ calculations for spheroid size and 
the AlamarBlue results also correlated well with fluorescent microscopy images of 
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MCF-7 cell spheroids (Figure 5.5 B & C). The results indicated that cells with 
suppression of Cyr61 had significantly decreased long-term viability/proliferation in 
response to VN and the IGF-I:IGFBP:VN complex compared to the control cells. 
Hence, reducing viability/proliferation of cells within the spheroids leading to 
formation of smaller sized spheroids. Interestingly, the long-term viability and the 
size of spheroids in response to the IGF-I:IGFBP:VN complex was reduced to the 
levels as observed for the VN alone treatment with suppression of Cyr61. This 
suggests that targeting Cyr61 not only influences the VN- but also the IGF-I-induced 
long-term viability and spheroid formation of MCF-7 cells in a 3D environment. 
These results are in concordance with previous studies showing the expression of 
Cyr61 to influence the MCF-7 outgrowth and long-term viability in 3D cultures, 
including Matrigel™ (Tsai et al., 2002) and soft agar cultures (Lin et al., 2004; 
Menendez et al., 2005). This is likely due to the stimulatory effect of Cyr61 
expression on cell proliferation in the MCF-7 cell line (Sampath et al., 2001; O'Kelly 
et al., 2008). Similar effects have also been reported in epidemiological studies 
where a high level of Cyr61 expression was found to positively correlate with tumour 
size in breast cancer patients (O'Kelly et al., 2008). These findings suggest the 
possibility that Cyr61 may be a promising therapeutic target for the inhibition of 
tumour growth and progression in breast cancer patients where VN and IGF-I are 
implicated. 
In contrast to MCF-7 cells, analysis of fluorescence images demonstrated no 
apparent changes in overall spheroid size or invasive morphology of MDA-MB-231 
cells with reduced Cyr61 levels grown in 3D Matrigel™ cultures (Figure 5.7 A). 
However, AlamarBlue analysis showed a significant reduction in long-term 
viability/proliferation of MDA-MB-231-shCyr61 cells compared to the control 
MDA-MB-231-shCntrl cells (Figure 5.7 C). Similar results were reported by 
Espinoza et al. (2011), whereby zoledronic acid-mediated down-regulation of Cyr61 
reduced outgrowth and cell viability of MDA-MB-231 cells grown in 3D Matrigel™ 
cultures. Moreover, treatment of nude mice bearing MDA-MB-231 cells with anti-
Cyr61 monoclonal antibody 093G9 significantly reduced the tumour growth (Lin et 
al., 2012). This suggests that targeting Cyr61 may not only hold promise for 
inhibition of the growth properties of luminal-like breast cancer subtypes (such as 
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MCF-7 cells), but also for treatment of aggressive tumours with a basal-like/claudin-
low phenotype. 
In a similar fashion, the suppression of CTGF significantly reduced VN- and 
IGF-I:IGFBP:VN-induced MCF-7 cell viability and proliferation in 2D cultures 
(Figure 5.4). These results were also observed in 3D cultures wherein MCF-7 cells 
with reduced CTGF appreciably decreased VN- and the IGF-I:IGFBP:VN complex-
stimulated spheroid  formation and long term viability of MCF-7 cells in 3D 
Matrigel™ cultures (Figure 5.5). It has been reported that CTGF can promote cell 
survival through stimulation of cell cycle (Kothapalli et al., 1998), cell proliferation 
and protection of cells from apoptosis (Babic et al., 1999). Indeed, it has been shown 
that overexpression of CTGF in MCF-7 cells increased their colony formation ability 
and viability in response to chemotrophic agents (Wang et al., 2009). Consequently, 
it is possible that CTGF down-regulation reduces cell survival in MCF-7 cells in 
response to VN and the trimeric complex via cell cycle arrest and/or less protection 
of cells from apoptosis. However, further biological assays specifically assessing cell 
cycle using flow cytometry and apoptosis will be necessary to confirm these 
mechanisms in our model. In contrast, the suppression of CTGF levels showed no 
appreciable inhibition of MDA-MB-231 cell viability in 2D monolayer cultures 
(Figure 5.6). This result was also reported in findings by others wherein down-
regulation of CTGF in MDA-MB-231 cells did not alter growth, proliferation or 
viability in this cell line (Chen et al., 2007; Wang et al., 2009). 
Visual assessment of 3D cultures also revealed the suppression of CTGF to 
reduce the invasive morphology of MDA-MB-231 cells. Reduced CTGF levels were 
observed to revert MDA-MB-231 cells and changed their morphology from their 
characteristic spindle-like invasive phenotype to more rounded non-invasive 
spheroid morphology (Figure 5.7 A), resembling MCF-7 cell spheroids (Figure 5.5 
A). We attempted to quantify this switch in morphology using ImageJ analysis, 
whereby MDA-MB-231-shCTGF cell cultures contained more “circular” spheroid-
like colonies compared to MDA-MB-231-shCntrl cells that contained predominantly 
“non-circular” invasive colonies (Figure 5.7 B). This finding is consistent with other 
observations where suppression of CTGF in MDA-MB-231 cells led to 
morphological alterations from fibroblast-like to epithelial-like morphology in 2D 
cultures (Chen et al., 2007). However, our study has demonstrated this phenotypic 
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reversion for the first time in a more complex 3D culture which more accurately 
mimics the in vivo cellular environment. These results suggest CTGF may have a 
role in maintaining the invasive and migratory phenotype of breast cancer cells, 
particularly in tumours where components of the VN and/or IGF axis are 
dysregulated. 
To more directly assess if CTGF has a role in the migratory phenotype of 
breast cancer cells in response to VN and the IGF-I:IGFBP:VN complex, Transwell
®
 
migration assays were performed on MCF-7-shCTGF and MDA-MB-231-CTGF 
cells. Cells with reduced Cyr61 were also used in these assays to investigate the 
effect of Cyr61 down-regulation in VN- and IGF-I:IGFBP:VN-induced migration of 
target cell lines. Pre-binding Transwells
®
 with VN was sufficient to significantly 
increase migration of the control MCF-7-shCntrl cells compare to control SFM 
treatment (Figure 5.8 A). In addition, migration of shCntrl cells in response to the 
IGF-I:IGFBP:VN complex was significantly higher than those observed in response 
to VN. This corroborates the data observed in studies previously performed within 
our laboratory showing that the IGF-I:IGFBP:VN complex can induce migration to 
significantly higher levels than those observed for cells treated with VN alone 
(Hollier et al., 2008; Kashyap et al., 2011). Importantly, down-regulation of CTGF 
attenuated both VN- and IGF-I:IGFBP:VN complex-induced MCF-7 cell migration 
(Figure 5.8 A). This fits well with studies showing that MCF-7 cells stably 
transfected with full-length CTGF increased migration in both FN- and VN-coated 
Boyden chambers, with more significant increase on VN-coated chambers (Chien et 
al., 2011). This result again highlights the fact that targeting VN-induced CTGF 
expression can also influence IGF-I:IGBFP:VN complex-mediated effects.  
Similar results were also observed for MDA-MB-231 cells, wherein, down-
regulation of CTGF significantly reduced both VN- and IGF-I:IGBFP:VN complex-
stimulated migration (Figure 5.8 B). This can also been seen in the studies performed 
by Chen et al. (2007) showing the reduction of CTGF expression in MDA-MB-231 
by antisense CTGF cDNA impaired cellular migration in a wound scratch assay. 
Recently, overexpression of bone morphogenic protein 9 (BMP-9) in MDA-MB-231 
cells was shown to inhibit breast cancer bone metastasis through down-regulation of 
CTGF (Ren et al., 2014). In addition, enhanced expression of CTGF through 
activation of ERK1/2 signalling by parathyroid hormone-related peptide (PTHrP) 
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was also found to be one of the key mechanisms involved in osteolytic metastasis of 
breast cancer (Shimo et al., 2006). This correlates well with findings reported in 
Chapter 4 showing that VN and the IGF-I:IGFBP:VN complex induce expression of 
CTGF through the Src/ERK signalling axis (Figure 4.6). Taken together, these 
findings suggest that increased expression of CTGF by VN and the IGF-I:IGFBP:VN 
complex plays an important role in their stimulatory effects on breast cancer cell 
migration which may possibly be regulated through activation and recruitment of the 
ERK signalling pathway. Moreover, no correlation was found between Cyr61 
regulation and the migratory responses induced by VN and the IGF-I:IGFBP:VN 
complex in MCF-7 and MDA-MB-231 cells, suggesting that Cyr61 is more 
predominantly involved in cell survival whereas CTGF is more involved in cell 
migration.  
In summary, the studies reported in this chapter demonstrate for the first time 
the critical roles of Cyr61 and CTGF in VN- and the IGF-I:IGFBP:VN complex-
induced breast cell viability and proliferation in 2D cultures. These results were also 
confirmed in 3D Matrigel™ cultures where down-regulation of Cyr61 and CTGF 
reduced long-term cell viability and colony formating ability of MCF-7 cells induced 
by VN and the IGF-I:IGFBP:VN complex. Cyr61 was also found to be important for 
VN- and IGF-I:IGFBP:VN -stimulated MDA-MB-231 cell viability in 2D and 3D 
cultures. The most exciting part of the studies presented in this chapter was the data 
demonstrating the effect of CTGF suppression on transforming the invasive spindle-
like morphological appearance of the highly metastatic MDA-MB-231 cells to more 
round epithelial-like colonies. The data presented herein also provide the first 
evidence for the key functional role of CTGF in VN- and IGF-I:IGFBP:VN-
enhanced MCF-7 and MDA-MB-231 cell migration.  
5.5 CONCLUSION 
The data acquired in this chapter for the first time reveals the functional roles 
of Cyr61 and CTGF in VN- and the trimeric IGF-I:IGBFP:VN complex-stimulated 
breast cancer cell survival and migration. These results suggest that Cyr61 plays a 
more predominant role in cell survival, whereas CTGF is more involved in cell 
migration responses induced by VN and the IGF-I:IGFBP:VN complex. 
Additionally, the studies reported in the previous chapter (Chapter 4) demonstrated 
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that VN and the IGF-I:IGBFP:VN complex dramatically induced Cyr61 and CTGF 
expression through interaction with αv-integrins and activation of the Src/PI3-K/AKT 
and Src/ERK/MAPK pathways, respectively. Since AKT signalling is known to play 
a crucial role in cell survival (Datta et al., 1997) and MAPK in cell migration (Huang 
et al., 2004), we propose that VN and the IGF-I:IGFBP:VN complex induce 
expression of Cyr61 through PI3-K/AKT to mediate cell survival and CTGF though 
ERK/MAPK pathway to enhance cell migration. 
The functional studies reported throughout this chapter provides the rationale 
for the use of Cyr61 and CTGF as diagnostic and prognostic biomarkers predicting 
the severity of breast cancer, in particular in patients with overexpression or 
increased deposition of VN and/or IGF system components specifically within the 
tumour microenvironment. Targeting Cyr61 and CTGF proteins or associated 
signalling pathways also holds promise in the development of specific therapeutic 
targets for inhibiting the biological functions of VN and possibly other integrin-
mediated ECM components relevant to breast cancer progression.  
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It is well established that alteration in the dynamics of ECM components 
within the mammary gland is among the most important factors contributing to 
breast cancer progression, from pre-malignancy to the proliferation, invasion, and 
survival of the malignant tumour and its subsequent metastasis (Lochter & Bissell, 
1995; Hansen & Bissell, 2000; Weigelt & Bissell, 2008; Place et al., 2011). However 
the daunting task is to determine which of these ECM factors actually confers 
causative effects and/or promotes cancer, and to identify the downstream mediators 
of such biological functions. In this regard, a growing body of evidence indicates that 
the ECM glycoprotein VN with its multifunctional roles can modulate breast cancer 
progression and metastasis by promoting cell differentiation, adhesion, and migration 
while also providing tumour cells with survival advantages (Carriero et al., 1999; 
Aaboe et al., 2003; Hurt et al., 2010; Leavesley et al., 2013). Given the correlation 
between VN and the progression/metastasis potential of breast cancer and the 
localisation of VN and VN-binding integrins at the leading edges of invasive 
tumours (Carriero et al., 1997; Aaboe et al., 2003; Kadowaki et al., 2011), the 
underlying aim of this PhD project was to identify for the first time the molecular 
mediators responsible for VN-stimulated cellular functions relevant to breast cancer 
progression, in particular cellular survival.  
Previous work within our laboratory has also demonstrated that IGF ligands 
can associate with VN forming multiprotein complexes of IGF-I:IGFBP:VN and 
IGF-II:VN (Upton et al., 1999; Kricker et al., 2003) that are capable of stimulating 
breast cancer cell migration, survival and inhibiting drug-induced apoptosis (Hollier 
et al., 2008; Kashyap et al., 2011). As such, the studies reported herein also aimed at 
identifying the molecular mediators underpinning IGF:VN complex-mediated breast 
cancer cell survival. Identification of molecular mediators underlying VN and the 
IGF:VN complexes may help to identify the molecular targets to inhibit the effects of 
VN- as well as the IGF:VN complex-induced responses, including promoting cancer 
cell survival.  
In order to identify the candidate molecular mediators, DNA microarrays 
were performed on RNA samples isolated from cells which had survived in response 
to VN with or without growth factors pre-bound to polystyrene cell culture plates. 
This “pre-bound” approach was implemented to more accurately mimic the in vivo 
microenvironment which these breast cancer cells normally encounter where cells 
 Chapter 6: General Discussion 190 
are more likely to be exposed to growth factors that are present in association with 
ECM proteins (Hynes, 2009). Moreover, in vivo the binding of growth factors to 
ECM proteins can result in the maintenance of a uniform growth factor 
concentration, alter diffusion rates through the matrix regulating its local 
concentration, and also modulate growth factor receptor interactions (Taipale & 
Keski-Oja, 1997). Hence, this approach was adopted in an attempt to more accurately 
depict the situation cells encounter in vivo and identify genes that represent the actual 
cellular and molecular processes involved in cell survival induced by these proteins 
and growth factors.  
DNA microarray analysis studies reported in Chapter 3 identified a number of 
genes to be differentially expressed by at least ± 1.5-fold in MCF-7 breast cancer 
cells that survived in response to substrate-bound VN and the IGF:VN complexes. 
Furthermore, these genes were found to be significantly associated with a range of 
biological functions such as “cellular growth and proliferation”, “cellular 
movement”, “cellular development”, “cell cycle”, “cellular assembly and 
organisation”, “cell death and survival”, “cell morphology”, “cell-cell signalling and 
interactions” and “molecular transport”. The results from these studies have provided 
valuable new knowledge regarding the gene expression profile underlying the 
functional impact of VN and the IGF:VN complexes, which can also be used by 
others with interest in any of these areas. Furthermore, the analysis outlined in 
Chapter 3 revealed that the vast majority of the differential gene expression induced 
by the IGF:VN complexes highly overlapped with those regulated by VN alone. This 
suggests that in terms of breast cancer cell survival VN is the key component driving 
differential gene expression observed in response to the IGF:VN complexes.  
The behaviour of a cell in vivo is largely determined by its interactions with 
the ECM, neighbouring cells, and soluble local and systemic cues presented within 
the cellular microenvironment, namely hormones, cytokines, and growth factors 
(Nelson & Bissell, 2006; Rondeau et al., 2014). However, the components of the 
ECM are known to be active participants in these biological responses that can 
induce or supress gene expression in normal and malignant cells (Roskelley et al., 
1995; Spencer et al., 2007; Birnie et al., 2008). Thus, are not simply just passive 
bystanders that maintain tissue structure and integrity. Hence, we hypothesised that 
the identification and subsequent targeting of candidate genes differentially 
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expressed in common by VN and the IGF:VN complex (simply called the VN-
induced gene expression signature or VNGES) will inhibit not only VN, but 
potentially also IGF:VN complex-mediated survival. This was supported via gene 
ontology analysis revealing VNGES to be enriched by genes with previously 
reported roles in cell growth and survival. Thus, VNGES likely contains drivers of 
VN- and trimeric IGF-I:IGFBP:VN complex-mediated cell survival effects.  
The ability of cancer cells to survive during invasion and migration through 
the blood and lymphatic vessels and subsequently within distant inhospitable tissue 
microenvironments is a key factor in cancer progression and metastasis in vivo 
(Scheel & Weinberg, 2012). The interactions between malignant epithelial cells and 
the surrounding ECM involves the transmission of anti-apoptotic as well as 
proliferative signals critical for survival and proliferation of cancer cells during 
tumour development, metastasis and resistance against chemotherapeutic agents 
(Jacks & Weinberg, 2002). Earlier experimental evidence has established that 
disruption of interactions between epithelial cells and the ECM can induce apoptosis 
(Frisch & Francis, 1994). Likewise, the blockade of ECM-binding cell surface 
receptors such as integrins is well known to inhibit cell growth and induce apoptosis 
in a number of tumours, including the tumours of the lung (Sethi et al., 1999), breast 
(Weaver et al., 2002; Park et al., 2006) and prostate (Bisanz et al., 2005). As 
previously discussed, components of the ECM can control cell behaviour and 
function by regulating the changes in gene expression patterns. To date, a number of 
genes have been found to be regulated by specific components of the ECM to 
promote cancer progression and metastasis. However, there is still a lack of studies 
investigating the direct effect of specific ECM proteins on the global transcriptional 
responses in cancer cells and whether these transcriptional alterations are critical for 
biological phenotypes relevant to metastasis.  
For instance, regulation of cellular proto-oncogene c-JUN and mir-21 by 
components of the ECM such as collagen type I and hyaluronan has been reported to 
inhibit apoptosis and promote the survival of breast cancer cells (Li et al., 2011; 
Chen & Bourguignon, 2014). Moreover, coordination of MMP-9 and CD44 
expression (receptor for hyaluronan) can activate latent TGFβ promoting tumour cell 
growth and invasion (Yu & Stamenkovic, 2000). Furthermore, an increased autocrine 
TGFβ loop can protect breast cancer cells from apoptosis and enhance their 
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proliferation (Hoshino et al., 2011), while also providing resistance to paclitaxel in 
triple negative breast cancers (Bhola et al., 2013). Interestingly, Smad proteins, the 
downstream transcriptional mediators of TGFβ are also found to be up-regulated by 
ECM components such as type I collagen and are involved in mediating the growth 
of pancreatic cancer cells (Imamichi et al., 2007).  
In a similar fashion, studies reported in this PhD thesis have added significant 
new information to our understanding of how the ECM can instruct the 
transcriptional and biological responses of tumour cells. Based on previous 
experimental evidences we have identified that the VNGES contains numerous genes 
relevant to survival, including TGFβ1/2, Smad6, S100A4, S100P, ANXA2, 
RAPGAP, Cyr61/CCN1, CTGF/CCN2, Snail 2 (Slug), Caveolin-1, mir-21, c-JUN 
and c-FOS. Deregulation of these genes is reported to correlate with breast cancer 
progression and metastasis, and their expression is also found to be directly or 
indirectly associated with other ECM components. Since these genes were found to 
be differentially expressed by VN and their regulation is shown to correlate with 
breast cancer progression and metastasis, we propose these genes could form a 
prognostic and/or predictive biomarker signature for breast cancer progression in 
patients with increased intra-tumoral deposition of VN. This will need to be 
confirmed in human breast cancer patient cohorts using either IHC staining of these 
target genes in Tissue Microarrays (TMA) or meta-analysis of publicly available 
gene expression data available via data repositories such as the Gene Expression 
Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/) and Oncomine (www.oncomine.org). 
Correlation analysis can also be performed to determine the correlation of VN 
expression with VNGES target genes within these cohorts and their relationship to 
clinicopathological parameters, such as tumour recurrence, time to distant metastasis 
and overall or disease specific survival outcomes.  
Although the genes outlined above are found to be critically involved in 
breast cancer progression, the extent of their contribution in mediating VN- and the 
IGF:VN complex-induced biological effects was unknown. Hence, a loss-of-function 
approach was utilised to identify their role in breast cancer progression. Select target 
genes were suppressed using shRNA and their effect on VN- and IGF:VN complex-
induced cell survival and migration were analysed. To this end, secreted ECM-
associated matricellular CCN family proteins, Cyr61/CCN1 and CTGF/CCN2, were 
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selected as our lead candidates to investigate their functional role in VN- and IGF-
I:IGFBP:VN complex-induced breast cancer cell survival. Cyr61 and CTGF both 
have roles documented in the enhancement of breast cancer cell growth and survival 
as well as migration (Menendez et al., 2005; Chen et al., 2007; Pandey et al., 2009; 
Wang et al., 2009). In addition, the overexpression of Cyr61 and CTGF is found to 
strongly correlate with breast cancer progression and tumorigenesis, and is often 
associated with advanced clinical stage of the disease (Xie, Nakachi, et al., 2001; 
Tsai et al., 2002; Kang et al., 2003). Indeed, the inhibition of Cyr61 using a novel 
monoclonal antibody was reported to significantly supress the in vivo tumour size 
and proliferation of the highly metastatic MDA-MB-231 breast xenograft models 
(Lin et al., 2012). Overexpression of the CTGF protein has also been strongly 
associated with resistance against drug-induced apoptosis in both MCF-7 and MDA-
MB-231 breast cancer cells (Wang et al., 2009; Lai et al., 2011). Additionally, 
induced expression of CTGF by hydroxytamoxifen, an ER antagonist, has been 
shown to enhance the proliferation of poorly differentiated SKBr3 breast tumour 
cells (Pandey et al., 2009).  
Once the candidate genes Cyr61 and CTGF were selected, 2D monolayer and 
3D Matrigel
TM
 assays were used to assess the impact of Cyr61 and CTGF down-
regulation on VN- and IGF-I:IGFBP:VN-induced MCF-7 and MDA-MB-231 breast 
cancer cell growth/survival. For Cyr61, our results clearly indicate that it is involved 
in VN- and IGF-I:IGFBP:VN complex-induced MCF-7 and MDA-MB-231 breast 
cell survival in both 2D monolayer and 3D cultures. This was shown by a significant 
reduction in the relative size and growth of the MCF-7 cell spheroids in which levels 
of Cyr61 were attenuated by shRNA. Cyr61 is known to play an important role in 
cell proliferation and inhibition of apoptosis (Gery et al., 2005; Todorovic et al., 
2005), and the expression of Cyr61 in MCF-7 cells is thought to be crucial in 
maintaining cell proliferation (Sampath et al., 2001) and resistance to drug-induced 
apoptosis (Lin et al., 2004). Our results are consistent with these findings, and we 
demonstrate that down-regulation of Cyr61 can effectively reduce VN- and the IGF-
I:IGFBP:VN-stimulated MCF-7 cell proliferation. Altogether, it is possible that 
Cyr61 expression can influence key pathways involved in cell cycle progression and 
anti-apoptosis, thereby stimulating cell proliferation and survival induced by VN and 
the IGF-I:IGFBP:VN complex. To validate this, cell signalling studies investigating 
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the involvement of Cyr61 in the apoptotic pathways and cell cycle pathways such as 
the PI3-K/AKT, MEK/ERK, and small GTPase (Rho and Rac) will be required in the 
future.  
Similar to Cyr61, down-regulation of CTGF also significantly decreased 
MCF-7 cell growth and viability. However, in contrast to MCF-7 cells, growth and 
viability of the MDA-MB-231 cells was relatively unaffected by CTGF down-
regulation. Instead, in MDA-MB-231 cells reduced expression of CTGF reversed 
their invasive phenotype in 3D Matrigel
TM
 cultures. The characteristic MDA-MB-
231 invasive spindle-like morphology was transformed to a less invasive and 
rounded morphology. This finding highlights that CTGF plays a role in the invasive 
morphology of MDA-MB-231 cells, which in turn may be responsible for its 
metastatic ability in vivo. Indeed, CTGF is known to play a critical role in breast 
cancer bone metastasis (Kang et al., 2003; Kang et al., 2005) and its down-regulation 
has been recently reported to inhibit the metastasis of MDA-MB-231 cells to bone in 
mouse xenograft breast tumours (Ren et al., 2014).  
Based on these results demonstrating MDA-MB-231 cells had a less invasive 
and migratory phenotype in 3D cultures upon CTGF suppression, we shifted our 
focus in subsequent studies to identify whether or not the down-regulation of Cyr61 
and CTGF has an effect on VN- and IGF-I:IGFBP:VN-stimulated cell migration. 
Results from the migration assays revealed that CTGF down-regulation significantly 
decreased VN- and IGF-I:IGFBP:VN-induced migration of both the MCF-7 
(relatively low migratory phenotype) and MDA-MB-231 (highly motile phenotype) 
cell lines. In contrast, the migration of these cells with reduced Cyr61 expression 
remained relatively unaffected. These results, in combination with previous findings, 
suggest that Cyr61 may be more predominantly involved in the growth and viability 
of breast cancer cells, whereas CTGF is more involved in the invasive/migratory 
behaviour of breast cancer cells in response to VN and the IGF-I:IGFBP:VN 
complex.  
 The role of CTGF in mediating the invasive morphology and conferring 
migratory abilities may be related to its reported role in epithelial-to-mesenchymal 
transition (EMT), a process associated with the increase in the ability of epithelial 
cells to become more migratory and invasive. CTGF is known to reduce cytokeratin 
expression and trigger the expression of mesenchymal markers Vimentin and FN 
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(Burns et al., 2006; Liu et al., 2006), characteristic markers of EMT-induction. While 
beyond the time and scope of the current project, future studies are planned to 
investigate classical markers of EMT, including E-cadherin, Epcam, Vimentin and 
FN in RNA and protein samples we have already collected following suppression of 
CTGF in the mesenchymal MDA-MB-231 cell line. In support for this our 
microarray study revealed Slug, a well-known EMT-inducing transcription factor 
(Bolos et al., 2003) to be up-regulated in our microarray analysis by 12.3- and 14.8-
fold at the 48 hour time point by VN and the IGF-I:IGFBP:VN complex, respectively 
(Figure 4.2). Hence, future research will be directed towards delineating the role of 
Slug in the VN/IGF/CTGF axis.  
In addition to CTGF, VN and the IGF-I:IGFBP:VN complex increased the 
gene expression of TGFβ2 (~10 fold, identified by qRT-PCR) and Smad proteins 
(Smad 4 and 6). TGFβ is known to be one of the key regulatory elements that induce 
the expression of CTGF through Smad and Ras/MEK/ERK signalling axis in a 
number of cell types (Chen et al., 2002; Leivonen et al., 2005; Secker et al., 2008), 
including breast cancer (Giampieri et al., 2009). Interestingly, studies performed by 
Kang et al. (2003 and 2005) revealed that the transcriptional activation of CTGF and 
its elevated expression by TGFβ/Smad-dependent pathways can contribute to the 
bone metastasis of breast cancer in vivo. Based on this result, it may be postulated 
that VN- and the IGF-I:IGBFP:VN complex-induced expression of CTGF and 
resultant migratory responses may also be a consequence of the up-regulation of 
TGFβ and Smad genes that were observed in our study. To explore this, further 
studies involving function blocking antibodies and small molecule inhibitors 
targeting the TGFβ/Smad pathway will be necessary to elucidate its role in the 
expression of CTGF and breast cancer cell migration. 
In the broader context of cancer progression, Cyr61 and CTGF also have well 
established roles in regulating angiogenesis and endothelial cell function (reviewed 
in Brigstock, 2002). This is observed in breast cancer wherein Cyr61 and CTGF 
expression was associated with increased angiogenesis (Tsai et al., 2002; Chien et 
al., 2011), through the stimulation of VEGF expression and secretion in breast cancer 
cells (Espinoza et al., 2014). Recent studies indicate that VN also promotes 
angiogenesis through the regulation of VEGF (Li et al., 2014), suggesting the 
possibility that Cyr61 and CTGF up-regulation by VN may also play an important 
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role in stimulating angiogenesis, and thereby increasing the survival of breast tumour 
cells. As there is a concomitant increase in expression of VN in the sub-endothelial 
area of blood vessel walls surrounding malignant breast tumours (Abbott, 2003; 
Kadowaki et al., 2011), it is plausible that VN-induced regulation of Cyr61 and 
CTGF may have roles in tumour angiogenesis to facilitate tumour growth and 
progression. In future studies, these questions may be better answered through 
angiogenesis assays such as in vitro tube formation assays using endothelial cells 
cultured in Matrigel™ or in vivo chick chorioallantoic membrane assays where the 
chorioallantoic membranes are treated with conditioned media from normal breast 
cancer cells and those that overexpress Cyr61 and CTGF in response to VN and the 
IGF-I:IGFBP:VN complex.  
In addition to unravelling the functional importance of Cyr61 and CTGF in 
mediating biological processes induced by VN and the IGF-I:VN complex, studies 
presented in this thesis have revealed novel mechanisms underpinning their 
regulation in breast cancer cells. Cell signalling studies presented in Chapter 4 
demonstrate that VN and the IGF-I:IGFBP:VN complex stimulate the expression of 
Cyr61 and CTGF via ligation of αv-subunit containing-integrins and subsequent 
recruitment and activation of the Src/FAK signalling axis. Furthermore, the 
regulation of Cyr61 and CTGF was observed to bifurcate at PI3K/AKT and 
ERK/MAPK signalling pathways, respectively, downstream of Src. Previous reports 
have demonstrated that Cyr61 and CTGF can mediate their downstream effects 
through interaction with cell surface integrins and heparan sulfate proteoglycans 
(HSPG) (Syndecan 4, perlecan receptors) as well as growth factor receptors (Leask 
& Abraham, 2006; Holbourn et al., 2008; Jun & Lau, 2011). These interactions can 
lead to activation and recruitment of downstream signalling cascades, including the 
FAK/Src complex, Rac/JNK, PI3-K/AKT, MEK/ERK/MAPK, and NF-κB signalling 
pathways (Secker et al., 2008; Wang et al., 2009; Goodwin et al., 2010; Chuang et 
al., 2012).  
Taking the evidence gathered together, it is proposed that the mechanism by 
which VN and the IGF-I:IGFBP:VN complex enhance expression and secretion of 
Cyr61 and CTGF is through the αv/Src/PI3-K/ERK signalling pathways, with ERK 
predominantly mediating the expression of CTGF and PI3-K mediating Cyr61 
expression. Furthermore, we postulate that upon stimulation of Cyr61 and CTGF, 
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they are secreted and can act in a positive feedback loop in an autocrine fashion 
through their interactions with integrins, HSPG and growth factor receptors to 
modulate cellular functions (Figure 6.1).  
 
 
Figure 6.1:VN and the IGF-I:IGFBP:VN complex-induced Cyr61 and CTGF signalling (identified by 
studies reported herein) in addition to signalling by secreted Cyr61 and CTGF (identified by others).  
VN and the IGF:IGFBP:VN complex mediate expression of Cyr61 and CTGF through interactions 
with αv-integrin and activation and recruitment of Src signalling axis. Their regulation is then 
bifurcated downstream of Src where PI3K/AKT stimulates the expression of Cyr61 and ERK/MAPK 
regulates the expression of CTGF. Studies by others (Chuang et al., 2012; Goodwin et al., 2010; 
Secker et al., 2008; Wang et al., 2009) demonstrated that the secreted Cyr61 and CTGF proteins bind 
cell surface integrins, the heparan sulfate proteoglycan (HSPG) and growth factor receptors (Holbourn 
et al., 2008; Jun & Lau, 2011; Leask & Abraham, 2006). This would then activates and recruits 
downstream signalling mediators, including FAK/Src complex, Rac/JNK, PI3-K/AKT, 
MEK/ERK/MAPK, and NF-κB to mediate the biological effects such as cell proliferation, survival, 
migration and angiogenesis.   
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In addition to elucidating the mechanisms of CTGF and Cyr61 expression 
and function, network analyses performed in Chapter 3 identified a number of 
additional genes and pathways that may also contribute to VN- and the IGF:VN-
mediated functions. For instance, the NF-κB pathway was identified to be one of the 
top functional networks associated with our VNGES (established from VN and 
IGF:VN regulated genes at the 48 hour time point). This is in accordance with 
published reports, which indicate that adhesion and migration of pancreatic 
carcinoma cells on VN is due to the latent activation (24 hours) of signals leading to 
the induction of NF-κB-mediated gene transcription (Yebra et al., 1995). This 
suggests the possibility that in addition to Src/AKT/ERK pathways identified in this 
study, NF-κB may also be involved in regulation of Cyr61 and CTGF expression. As 
such, JNK is known to be activated downstream of the integrin/FAK/NF-κB 
pathway. Indeed, in our dataset, the JNK pathway overlapped with networks 
containing the FAK pathway. Moreover, c-JUN, the transcription factor downstream 
of the JNK pathway, was also identified to be significantly up-regulated by VN and 
the IGF:VN complexes, providing evidence for the potential involvement of the NF-
κB/JNK pathway. Nonetheless, future studies involving specific inhibition of these 
pathways will be critical to determine their contribution to VN- and IGF-
I:IGFBP:VN-induced expression of Cyr61 and CTGF and resultant biological 
effects.  
Drug resistance remains one of the major challenges in designing effective 
cancer therapeutics. In addition to the effect of the ECM in promoting cancer cell 
survival, studies suggest that integrin-mediated attachment of malignant cells to 
ECM components can strongly enhance their resistance to chemotherapeutic agents 
(reviewed in Elliott & Sethi, 2002; Correia & Bissell, 2012). It has been reported that 
expression of Cyr61 and CTGF enhances the resistance of breast cancer cells to 
various chemotherapeutic drugs, in particular Taxols (Lin et al., 2004; Menendez et 
al., 2005; Wang et al., 2009). TAZ (transcriptional co-activator with PDZ-binding 
motif), a novel gene implicated in breast cancer drug resistance, was found to induce 
Taxol resistance through activation of Cyr61 and CTGF gene promoters (Lai et al., 
2011). Conversely, Cyr61 and CTGF suppression completely reversed TAZ-induced 
Taxol resistance in breast cancer cells. Studies reported herein demonstrate that 
integrin-binding ECM components such as VN, FN and type I collagen can further 
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stimulate the expression of Cyr61 and CTGF in breast cancer cells. Collectively, it is 
possible that ECM components such as VN can induce the expression and secretion 
of Cyr61 and CTGF through interactions with integrins, and further contribute to 
drug resistance. Importantly, cell studies performed herein reveal that blockade of αv-
integrin inhibits the VN-stimulated expression of Cyr61 and CTGF. Therefore, using 
an αv-integrin inhibitor alone or in combination with Taxol may provide better 
treatment outcomes for breast cancer patients with high expression of Cyr61 and 
CTGF. Future studies directed at testing the effectiveness of αv-integrin blockade 
alone or in combination with Taxol in Cyr61/CTGF over-expressing breast cancer 
xenografts will be important. Outcomes from such a study may reveal new 
therapeutic combinations, either in the adjuvant setting or to prevent relapse post 
primary therapy in patients with increased levels of VN, Cyr61and CTGF.  
Over the past decade, gene expression profiling has become increasingly 
utilised to predict and characterise breast cancer molecular subtypes and their clinical 
outcome (Perou et al., 2000; van 't Veer et al., 2002; Sorlie et al., 2003; Neve et al., 
2006; Prat et al., 2010). To investigate the broader relevance of the VNGES across 
relevant breast cancer subtypes, hierarchical clustering was employed to analyse the 
expression of the VNGES across 51 cell lines representing the major breast cancer 
subtypes using gene expression data published by Neve et al, 2006. This revealed the 
VNGES to be highly associated with basal B (Mesenchymal) cell lines, whereby the 
VNGES could cluster together the majority of the highly metastatic basal B cell lines 
apart from the less-metastatic luminal and basal A cell models. Further examination 
of these cell lines revealed them to be predominantly claudin-low cell lines (as 
described by Prat et al., 2010). The claudin-low subtype is reported to be enriched in 
markers of EMT and cancer stem cell-like features (Prat et al., 2010). Given these 
characteristics, combined with claudin-low tumours/cell lines being triple negative 
(PR
-
, ER
-
 & Her2
-
), they are associated with therapeutic resistance and poor survival 
outcomes (X. Li et al., 2008; Creighton et al., 2009; Gupta et al., 2009). Based on the 
VNGES expression, all 9 known claudin-low cell lines clustered together in their 
own distinct group. Interestingly, VNGES was just as efficient in clustering together 
the claudin-low cell lines as the originally published claudin-low predictor signature 
generated by comparing the intrinsic molecular differences between the claudin-low 
subtype with the basal-like and luminal sub-types (Prat et al., 2010). 
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A number of VNGES genes, including Cyr61, CTGF, MBNL2, LAMB3, 
ACTG2, MAOA, slug and IGFBP6 are also featured within the 9-cell line claudin-
low predictor signature that was developed by Prat and colleagues to characterise and 
predict the claudin-low phenotype in human breast cancer samples (Part et al., 2010). 
Moreover, using the Prat et al. 2010 data sets, Cyr61 and CTGF were identified to be 
frequently up-regulated in claudin-low breast cancer sub-types. The association of 
the VNGES with the claudin-low subtype is a novel and significant finding, given 
that it was developed using genes commonly regulated by VN in the luminal MCF-7 
cell model. To our knowledge this is the first time a component of the ECM has been 
reported to induce luminal breast cancer cells to transition to a claudin-low-like 
phenotype. While an array of studies will be required to confirm this result, targeting 
the VN/CTGF/Cyr61 axis may provide a targeted treatment option for claudin-low 
tumours. Currently patients diagnosed with claudin-low tumours have no such 
targeted therapies available. Supporting this rationale are the findings in the MDA-
MB-231 cell line following suppression of Cyr61 and CTGF reported above. MDA-
MB-231 is a prototypical claudin-low cell model and supports the potential 
therapeutic targeting of the VN/CTGF/Cyr61 axis in this breast cancer subtype.  
In summary, this PhD project has identified a molecular signature involved in 
VN- and the IGF-I:IGFBP:VN complex-mediated functions critical to breast cancer 
progression and metastasis. In particular, the findings from this project have 
identified Cyr61 and CTGF as key mediators involved in VN- and IGF-I:IGFBP:VN-
induced breast cancer cell survival and migration. By identifying the molecular 
mediators responsible for the functional effects of VN and the IGF:VN complex, we 
have revealed potential targets for inhibiting the biological functions of VN and the 
IGF-I:VN complex. Further refinement of the panel of biomarkers (VNGES) 
identified in this process may help provide prognostic and predictive indicators to 
assist the clinical management of breast cancer, which may be particularly relevant to 
the claudin-low subtype of human breast cancers. In addition, the inhibition of key 
molecular targets identified, namely Cyr61 and CTGF, that are important in VN- and 
IGF-I:VN complex-induced biological effects, may have significant implications in 
designing future therapeutic targets for patient with tumours overexpressing VN 
and/or the components of the IGF:VN axis. 
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Appendices 
Appendix 1: Integrity and quality check of RNA samples prior to array analysis on the Agilent 
Bioanalyser 2100 using the NanoChip protocol. 
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Appendix 2: Details of primers designed using NCBI Primer-BLAST. 
 
Gene 
Symbol 
 
RefSeq ID 
(NCBI) 
Primes 
Sequence (5’3’) Length Start Stop Tm GC% Self 5’ 
complementary 
Self 3’ 
complementary 
Product 
size 
JUN NM_002228.3 F: TTGCCAGAGCCCTGTTGCGG 20 967 986 59.90 65.00 6.00 2.00 125 
R: TCGGACGGGAGGAACGAGGC 20 1108 1089 60.87 70.00 7.00 2.00 
  
        
 
FOS  NM_005252.3 F: CCTGTCAACGCGCAGGACTTCT 22 332 353 59.42 59.09 4.00 3.00 174 
R: GGCGGGGACTCCGAAAGGGT 20 505 486 60.53 70.00 5.00 0.00 
  
        
 
TGFβ2 NM_003238.3 F: ACAGCACCAGGGACTTGCTCCA 22 1583 1604 60.05 59.09 4.00 1.00 147 
R: TGGGCGGGATGGCATTTTCGG 21 1729 1709 60.50 61.90 5.00 1.00 
  
        
 
VAV2 NM_003371.3 F: CCGGTCCCCAGTGTTCACGC 20 2353 2372 59.97 70.00 4.00 2.00 167 
R: TCCGTCCGTTGGTCTCGCCC 21 2519 2500 60.87 70.00 2.00 2.00 
  
        
 
CTGF NM_005080.3 F: CCTGGTCCAGACCACAGAGT 20 345 364 59.77 70.00 5.00 3.00 168 
R: TGGAGATTTTGGGAGTACGG 20 512 492 59.37 61.90 4.00 2.00 
  
        
 
HSBP8 NM_014365.2 F: GCTGGGAGCCTGTCAGTTTATGA 24 1730 1753 58.77 54.17 5.00 2.00 179 
R: ACACACGTCCCGCCCATATACA 22 1908 1887 57.80 54.55 4.00 2.00 
  
        
 
ANXA2 NM_001002857 F: CCCGGAGAGTTTCCCGCTTGG 21 82 102 59.45 66.67 5.00 0.00 179 
R: TGTTCAAAGCATCCCGCTCAGCA 23 260 238 59.38 52.17 5.00 3.00 
  
        
 
XBP1 NM_005080.3 F: GACAGCGCTTGGGGATGGATGC 22 449 470 60.43 63.64 6.00 2.00 125 
R: CTGCTGCAGAGGTGCACGTAGT 22 573 552 59.17 59.09 7.00 2.00 
  
        
 
CD24A  NM_013230.2 F: GCACTGCTCCTACCCACGCA 20 159 178 59.07 65.00 5.00 0.00 146 
R: CCCAGGTACCAGGACTGGCTGG 21 304 284 59.51 61.90 6.00 2.00 
  
        
 
NFIB NM_005596.3 F: CCTCCACCTTCACCGTTGCCA 21 1616 1636 58.97 61.90 4.00 3.00 179 
R: CCCAGGTACCAGGACTGGCTGG 22 1794 1773 60.24 68.18 8.00 3.00 
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Gene 
Symbol 
 
RefSeq ID 
(NCBI) 
Primes 
Sequence (5’3’) Length Start Stop Tm GC% Self 5’ 
complementary 
Self 3’ 
complementary 
Product 
size 
H19 NR_002196.1 F: AAGACGCCAGGTCCGGTGGA 20 1365 1384 59.83 65.00 4.00 3.00 160 
R: TGTGCCGACTCCGTGGAGGA 20 1543 1522 59.55 65.00 6.00 2.00 
  
        
 
SPDEF  NM_012391.1 F: TCTGACCCCAGCATTTCCAGAGCA 24 1692 1715 59.87 54.17 4.00 0.00 185 
R: ATTATCCATTCCCGGGGGCACT 22 1876 1855 57.46 54.55 6.00 2.00 
  
        
 
GABRP NM_014211.1 F: GAACCTATGTTCAGGTTGCGGGT 23 2720 2742 57.04 52.17 8.00 0.00 128 
R: AACTGGAAGCCTTTACCCTGGCA 23 2847 2825 58.16 52.17 5.00 3.00 
  
        
 
RASGRP1 NM_005739.2 F: ACAGTCCAGCAAGGGCCAAAGA 22 4554 4575 58.35 54.55 4.00 0.00 129 
R: ACTAGGCTTGATAAGCCAAAGCC 25 4683 4659 57.33 48.00 8.00 3.00 
  
        
 
Cyr61 NM_001554.3 F: ATGCTACCTGGGTTTCCAGGGCA 24 1354 1377 60.11 54.17 6.00 2.00 190 
R: TTAGTGTCCATCCGCACCAGCA 24 1543 1522 58.25 54.55 3.00 0.00 
  
        
 
NBPF20 NM_0010376 F: AGGCTCAACGGCGTGCTGAT 20 2661 2680 59.07 60.00 5.00 2.00 164 
R: AGGGCGAAGCTGATGTGCTGT 21 2824 2804 58.77 57.14 4.00 2.00 
  
        
 
PAK4 NM_005884.3 F: AACCTGCACAAGGTGTCGCCAT 22 1844 1856 59.28 54.55 4.00 3.00 113 
R: TTGGCCAGGAATGGGTGCTTCA 22 1956 1935 58.67 54.55 6.00 1.00 
  
        
 
LAMB1 NM_002291.1 F: AGCAAGCAAAAGTGCAACAGATG 25 5073 5097 57.04 44.00 4.00 3.00 200 
R: TGGGACGCGTTGAACAAGGTTT 22 5272 5252 57.57 50.00 6.00 2.00 
  
        
 
MTSS1 NM_014751.4 F: GGGCACATTTCTGACCGAACCCT 24 4203 4226 60.11 54.17 5.00 1.00 200 
R: CCTTGAGCAATCGCAGCAGTGT 22 4402 4381 58.10 54.55 4.00 1.00 
  
        
 
FZD8 NM_031866.1 F: AGTGCTTGCTAAGGACGCATGG 22 2870 2891 57.58 54.55 7.00 2.00 177 
R: ACCGTCTTTGGGGAAGGTGCAAA 23 3046 3024 58.93 52.17 4.00 0.00 
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Appendix 3: The correct size of the primers was confirmed by running 5 µl of PCR products on a 2% 
agarose gel at 110V for 30 minutes and visualizing with SYBR safe fluorescence staining under UV 
illumination. For each product two wells were used to confirm the correct size of the product. DNA 
molecular marker XIV (Roche) was also run in parallel. 
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Appendix 4: Vector map for the lentiviral packaging plasmid pCMV-delta R8.2. Obtained from 
addgene.org. 
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Appendix 5: Vector map for the lentiviral packaging plasmid pCMV-VSV-G. Obtained from 
addgene.org. 
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Appendix 6: Molecular and cellular functions associated with differentially expressed genes in response to VN at 12 and 48 hour time points. 
 
VN vs SFM (12 hours) 
VN vs SFM (48 hours) 
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Appendix 7: Molecular and cellular functions associated with differentially expressed genes in response to IGF-II:VN at 12 and 48 hour time points. 
 
 
IGF-II:VN vs SFM (12 hours) 
IGF-II:VN vs SFM (48 hours) 
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Appendix 8: Molecular and cellular functions associated with differentially expressed genes in response to IGF-I:IGFBP-5:VN at 12 and 48 hour time points. 
  
IGF-I:IGFBP-5:VN vs SFM (12 hours) 
IGF-I:IGFBP-5:VN vs SFM (48 hours) 
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Appendix 9: Top five functional networks associated with differentially expressed genes in response to VN at 12 hours. 
Genes are colour coded according to their gene expression determined by the microarray analysis (red, up-regulated; green, down-regulated). Genes in black colour were 
either not on the expression array or not significantly regulated. 
ID Molecules in Network Score 
Focus 
Molecules 
Top Diseases and Functions 
1 
ACHE, Akt, Alp, ANKRD1, CAMK2B, CDH16, COL12A1, collagen, Collagen Alpha1, CTGF, CYR61, 
estrogen receptor, FABP5, GPIIB-IIIA, Growth hormone, GST,GSTA1, GSTM2, JUN/JUNB/JUND, 
KLF10, KRT20, Laminin, mir-21, NT5E, PARM1, PIK3IP1, PLAGL1, PLAUR, PRODH, Rock, Rxr, RXRG, 
Smad, Tgf beta,TGFB2 
36 21 
Connective Tissue Development and 
Function, Embryonic Development, 
Organ Development 
2 
ACTG2, Ap1, ARPC4, BCR (complex), CDKN2B, CEACAM5, Cg, Collagen type I, Collagen type II, 
CXCR4, CYP26B1, ELF5,ERK1/2, FSH,HHAT, KCNN4, Lh, MAP2K1/2, MATK, Notch, PI3K (family) ,Pki 
,PKIA , Rap1, RASGRP1, RUNX2, Sapk, SLC12A4, Smad1/5/8, SNAI2, SOX9, TCF, TIPIN, Wnt, YY2 
29 18 
Developmental Disorder, Hereditary 
Disorder, Skeletal and Muscular 
Disorders 
3 
ALDH3B2, ATRX, COLEC12, Creb, Cyclin A, FOS, Hdac, HIST1H4A (includes others), HIST2H3C 
(includes others), HISTONE, Histone h3, Histone h4, HSPB8, IgG, Igm, IL12 (complex), 
Immunoglobulin, KMT2A, KRT13, LCAT, LDHA, LDL, Mek, MYCT1, NFkB (complex) ,PAK1IP1 
,PSG5,QKI ,Rb ,SH3RF1 ,SLURP1, Sos, TAF1A, TSH, Ubiquitin 
29 18 
DNA Replication, Recombination, 
and Repair, Gene Expression, 
Dermatological Diseases and 
Conditions 
4 
ABHD17B, AGRP, ARID3A, C5orf34, CCP110, CEP290, CETN1, CFL2, CKAP4, CYR61, DICER1, 
ENDOV, FAM216A, FAM81A, KLHL7, MAG, MTFP1, MXRA5, NANOS1, PIWIL1, PRPSAP2, PUM2, 
RBM38, RCCD1, RREB1, SERPINF1, SLC25A30, SLC39A3, SPG20, STAU2, TMEM64, TRIM71, UBC, 
USP49, ZNF493 
25 16 
Cellular Development, Nervous 
System Development and Function, 
Hereditary Disorder 
5 
APP, ASPH, BHMT2, C1QL1, CCDC25, CDK9, CLUAP1, CYP26B1, DMD, DNAJC14, ELAVL1, ERMP1, 
FAM110A, FAM134B, FYN, GNAT2, GPM6B, HSP90AA1, KCNS3, KLHL3, MALL, MATK, NAPG, 
NR2E3, NUAK1, OLFM1, PGM5, PI4K2B, RN7SK, SATB1, TBP, TMTC4, TSPAN12, VKORC1L1, WNK2 
25 16 
Nervous System Development and 
Function, Organ Morphology, Tissue 
Morphology 
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Appendix 10: Top five functional networks associated with differentially expressed genes in response to VN at 48 hours. 
Genes are colour coded according to their gene expression determined by the microarray analysis (red, up-regulated; green, down-regulated). Genes in black colour were 
either not on the expression array or not significantly regulated. 
ID Molecules in Network Score 
Focus 
Molecules 
Top Diseases and Functions 
1 
ACTG2, Akt, ANGPTL4, ANKRD1, ARPC4, ATP2B1, BMF, CADM1, CGA, FAM162A, FSH, GFRA2, GK, HK2, HPGD, 
IGFBP6, ITGB5, KRT20, Lh,LIN7A, MPP6, MTSS1, NUCB2, PARM1, PLAGL1, PRODH, PROK1, PTPase, PTPN21, 
PVRL3, RAP1GAP, ROBO1, SLIT2, STARD13, Vdac 47 27 
Embryonic Development, 
Nervous System 
Development and Function, 
Organ Development 
2 
ABLIM3, AJUBA, AMOT, AMPH, Calcineurin A, CDC14A, CEP70, DHODH, DLEU1, DNAH1, E2f, EPS8L1, F Actin, 
FANCD2, GAD1, Gamma tubulin, GTPase, KIF23, LYNX1, MLKL, MT2A, MYH9, Myosin, NFkB (complex), 
Nicotinic acetylcholine receptor, PDLIM1, PKP1, PRMT2, RACGAP1, RFC3, RGS11, S100A4, S100P, TMOD2, 
TRAIP 
39 27 
Cell Cycle, Cellular 
Movement, Cancer 
3 
ACHE, AChR, ALDOC, ARL4A, ASAP1, CD68, COL11A2, COL18A1, COL4A5, COL5A1, Collagen type II, Collagen 
type IV, Collagen(s), CRAT, CYR61, DCLK1, ERK, GPIIB-IIIA, GPX2, LAMB1, LAMB3 ,Laminin, Laminin1, MATK, 
MT1F, NT5E, PPP1R15A, SERPINA3, SERPINA5, SNAI2, SPDEF, TACC1, TCF, TSKU, UACA 37 25 
Connective Tissue 
Development and Function, 
Embryonic Development, 
Organ Development 
4 
BAG1, C1QL1, CAV1, CAV2, Caveolin, COL12A1, CRABP1, Dynamin, estrogen receptor, FOS, GAL, Growth 
hormone, GST, GSTM3, HBA1/HBA2, Hdac, HHEX, HSPB8, KLF6, KLF10, KRT13, LDL-cholesterol, MALL, MT1A, 
MT1H, PKIB, PREX1, PSG5, QKI, SLURP1, Sos, SPRY2, STAT5a/b, STX11, TGFBI 37 25 
Cellular Assembly and 
Organization, Cellular 
Function and Maintenance, 
Infectious Disease 
5 
ABCC3, ABCC4, Alp, CASC5, COCH, Collagen Alpha1, CPE, Ctbp, CTGF, CYP26B1, DKK1, DLC1, ELF5, FABP5, H19, 
Hedgehog, HOPX, Igfbp, ISG20, KCNN4, LRP, MAOA, MBNL2, NPNT, PI3K (complex), PLAUR, Rb, SALL4, 
SCNN1A, Sox, SOX2, SOX7, SOX9, UVRAG, Wnt 
35 25 
Drug Metabolism, Lipid 
Metabolism, Molecular 
Transport 
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Appendix 11: Top five functional networks associated with differentially expressed genes in response to IGF-II:VN at 12 hours. 
Genes are colour coded according to their gene expression determined by the microarray analysis (red, up-regulated; green, down-regulated). Genes in black colour were 
either not on the expression array or not significantly regulated. 
ID Molecules in Network Score 
Focus 
Molecules 
Top Diseases and Functions 
1 
ACOT11, Alpha catenin, ARPC4,BAG1, CBR3, CDC25C, CDKN2B, Cg, CGA, CXCR4, FABP5, FILIP1L, FSH, 
HDL-cholesterol, IER3,ISG20, KLF10, LDHA, Lh, NFkB (complex), Notch, Nr1h, NR1H3, NR5A2, PAK1IP1, 
PI3K (family), PKP1, PTPN14, Rxr, RXRG, SH3RF1, TDRD5, WDR33, WWOX, YY2 
41 23 
Endocrine System Disorders, 
Organismal Injury and Abnormalities, 
Reproductive System Disease 
2 
ADCY5, Akt, ANKRD1, APC (complex), BCR (complex), CADM1, CD79B, CDC20, Cdk, Cyclin A, Cyclin B, 
Cyclin D, Cyclin E, E2f, ESPL1, HPGD, IGSF1, KCNN4, KNSTRN, KRT13, LETMD1, MPP6, PARM1, PIK3IP1, 
Pki, PKIA, PLAGL1, PRODH, PRR11, PTTG1, PVRL3, RAP1GAP, SLURP1, Sos, Vla-4 
36 20 
Cell Cycle, Cellular Assembly and 
Organization, DNA Replication, 
Recombination, and Repair 
3 
ABCC9, Alp, CDH16, CDK2AP2, CEACAM5, COL11A2, Collagen Alpha1, Collagen type I Collagen type II, 
CTGF, CYR61, ELF5, ERK1/2, FOXP4, GPIIB-IIIA, H19, HBA1/HBA2, HMMR, HSF4, Laminin, Lefty, LYPD3, 
mediator, mir-24, RASGRP1, RUNX2, SLC12A4, Smad, Smad1/5/8, Smad2/3, SNAI2, SOX9, Tgf beta, 
TGFB2,TGFBI 
34 18 
Skeletal and Muscular System 
Development and Function, Tissue 
Development, Connective Tissue 
4 
26s Proteasome, caspase, CD3, CENPA, CENPM, CENPP, CLTCL1, DHRS4,ENSA, GPM6B, GSG2, GTF2A1, 
Hdac, HIRIP3, Histone h3, Histone h4, Hsp90, IgG1, Igm, IL12 (complex), Immunoglobulin, Interferon 
alpha, KLF6, LCAT, LDL-cholesterol, MHC Class II (complex), NUDT1, PER3, PSEN1, PSMD9, RBPJ, 
SLC30A1, SOX7, TOM1L2, Ubiquitin 
29 16 Development and Function 
5 
ABCE1, Actin, ALDH3B2, AMPK, ANG, ASPH, CaMKII, COTL1, CRAT, Ctbp, DNASE1, ERK, F Actin, GPX2, 
HISTONE, IgG, ITPR2, MECOM, Pdgf (complex), PDGF BB, PHF19, PLAUR, Pld, PLD1, PP2A, Rap1, Rock, 
Ryr, SRI, STAT2, TCF, TGIF1, TH, TOB1, TSH 
25 15 Antimicrobial Response, Inflammatory 
Response, Cancer 
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Appendix 12: Top five functional networks associated with differentially expressed genes in response to IGF-II:VN at 48 hours. 
Genes are colour coded according to their gene expression determined by the microarray analysis (red, up-regulated; green, down-regulated). Genes in black colour were 
either not on the expression array or not significantly regulated. 
ID Molecules in Network Score 
Focus 
Molecules 
Top Diseases and Functions 
1 
AMPH, ANXA2, CA12, CDC25C, CDCA2, CDK6, CDKN1A, CDKN2B, CHEK2, Cyclin A, Cyclin D, Cyclin E, DLEU1, 
E2f, ERCC6L , HAUS8, HIST1H4A (includes others), IER3, MBNL2, MELK, NFkB (complex), Notch, OPTN, 
PDLIM1, PKMYT1, PLK1, RAB31, RELB, RNA polymerase II, S1PR3, SLC27A2, SMAD6, SOD2, ST3GAL1 
37 28 
Cell Cycle, Cell Death and 
Survival, Post-Translational 
Modification 
2 
ACTA2, AKR1C1/AKR1C2, B3GNT1, CAV1, CAV2, CITED2, COL4A5, COL5A1, Collagen Alpha1, CTGF, CXCR4, 
DCLK1, DLC1, ELF5, Focal adhesion kinase, FZD8, GPX2, H2AFX, HISTONE, HPGD, IGFBP6, MALL, MAP2K1/2, 
P38 MAPK, PBK,PI3K (family), PPARG, PRODH, RUNX2, SCNN1A, Smad2/3, SNAI2, SPDEF, TAGLN, TP63 
37 26 
Cellular Movement, Cancer, 
Cellular Development 
3 
ACTG2, ADAM15, APOBEC3F, ARPC4, ATP2B1, AUTS2, CD24, CLTCL1, Creb, CTSC, FABP5, FILIP1L, FSH, 
HIST2H3C (includes others), Histone h3, Histone h4, IgG, IL15, IL12 (complex), Interferon alpha, ISG20, 
KIF18A, KIF4A, MT1H, NCAPG2, PDE3B, Pkc(s), PPIF, PTPN21, RND2, RUNX1T1, SMC2, TCR, TFF1, TRAIP 33 26 
Cellular Assembly and 
Organization, Gene Expression, 
DNA Replication, 
Recombination, and Repair 
4 
Ap1, CEACAM5, Cg, Ctbp, CYR61, DAB2, DKK1, ENC1, ERK, ERK1/2, FOS, FZD2, H19, Hdac, ITGB5, JUN, KLF6, 
Mek, mir-24, MT2A, PALLD, PDGF BB, Pka, PKIB, PLAUR, PPP2R2A, PREX1, PSG5, PTGER2, Rac, RASGRP1, 
SFTPD, SOX9, SPRY2, TH 
31 23 
Cancer, Cellular Development, 
Cellular Growth and 
Proliferation 
5 
Akt, ALOXE3, ANG, ANKRD1, ASB9, BAG1, BCR (complex), BMF, CD3, CD68, COL12A1, estrogen receptor, 
GSTA1, Hsp27, Hsp70, Hsp90, IGSF1, Jnk, LDL, Mapk, mir-21, NEDD9, p85 (pik3r), PCDH7, PI3K (complex), 
PIK3IP1, PLIN2, PRKCA, PSRC1, RAP1GAP, Ras, RNF13, S100A4, TGFB2, Vegf 
24 21 
Cell Death and Survival, Organ 
Morphology, Nervous System 
Development and Function 
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Appendix 13: Top five functional networks associated with differentially expressed genes in response to IGF-I:IGFBP-5:VN at 12 hours. 
Genes are colour coded according to their gene expression determined by the microarray analysis (red, up-regulated; green, down-regulated). Genes in black colour were 
either not on the expression array or not significantly regulated. 
ID 
Molecules in Network 
Score 
Focus 
Molecules Top Diseases and Functions 
1 
ACTG2, Actin, Akt, ALDH3B2, ANG, ANKRD1, ARPC4, BCR (complex), CAMK2B, CD79B, CORO1A, 
COTL1, CYP2E1 , EPS8L1, F Actin , FABP5, GST, GSTA1, GSTM2, Ige, IgG, Immunoglobulin, MAP1B, 
Nfat (family), Notch, PARM1, PIK3IP1, Rap1, RASGRP1, RELB, Rock, Rxr, RXRG, SAMD4A, SMOX 
37 22 
Drug Metabolism, Glutathione 
Depletion In Liver, Cell Death and 
Survival 
2 
Alp, ARHGAP4, CDH16, CDKN2B, CEACAM5, COL11A2, collagen, Collagen Alpha1, Collagen type I, 
Collagen type II, CRAT, CTGF, CYR61, DAB2, ELF5,E RK1/2,ETS, HHAT, KLF10,Laminin, mir-24, NT5E, 
PDGF BB, RUNX2, SLC12A4, Smad, Smad1/5/8, SNAI2, SOX9, TCF, Tgf beta, TGFB2, TGIF1, WDR33, 
Wnt 
35 21 
Skeletal and Muscular System 
Development and Function, Tissue 
Development, Connective Tissue 
Development and Function 
3 
ADHFE1, AMT, ANKRD35, BCL2L2, BDKRB1, BDKRB2, C10orf10, C11orf82, C19orf66, CDH10, CLTCL1, 
CTSF, CYR61, ESR1, FAM183A, FZD8, GABRP, GNAQ, GPER1, GUSB, HNF4A, KCNJ13, KCNK4, MMD, 
NFkB (family), RNASE4, RPL14, SEMA7A, SEPP1, SFTPA1, SP2, TEF,T NF, ZFP64, ZNF366 26 17 
Cellular Development, Cellular 
Growth and Proliferation, DNA 
Replication, Recombination, and 
Repair 
4 
ATL1, CENPV, CEP290, CLIP4, CTAGE5, DCAF6, DHODH, ERCC6L, ERP29, FGD3, FZD2, FZD4, FZD6, 
GGT7, GLP1R, GSTM1, HTR2A, KIAA1683, KLHL7, MAP7D1, NAT1, NEK7, NMNAT1, NUCKS1, ODF2L, 
PCNX, PRICKLE1, RAB34, RAMP1, RAMP2, RAMP3, RMI2, SLC31A2, SLC7A5, UBC 
24 17 Cellular Assembly and Organization, 
Cell Signalling, Molecular Transport 
5 
AK4, BDNF, C5orf34, CASC5, CEBPB, ELAVL1, ERMP1, FAM107B, FAM83F, FOXP4, GABRA5, GTF2A1, 
GTF2A2, HEXIM1, HIAT1, HNMT, LYPD1, MBNL2, METTL7A, MKX, NUAK1, NUF2, PI4K2B, RASGEF1C, 
RN7SK, SCAMP4, SLC43A2, SLC7A5, TERF1,TERF2, TMEM50B, TMTC4, UBC, VKORC1L1, ZNF200 
24 17 
Connective Tissue Disorders, 
Developmental Disorder, Cell 
Morphology 
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Appendix 14: Top five functional networks associated with differentially expressed genes in response to IGF-I:IGFBP-5:VN at 48 hours.Genes are colour coded according to 
their gene expression determined by the microarray analysis (red, up-regulated; green, down-regulated). Genes in black colour were either not on the expression array or not 
significantly regulated. 
ID Molecules in Network Score 
Focus 
Molecules 
Top Diseases and Functions 
1 
ABCC9, AKR1C1/AKR1C2, ARL4A, C1QL1, CRABP1, CRAT, CXCR4, DAB2, FAM189A2, FOS, GAD1 
, GOT, GPX2, HBA1/HBA2, hemoglobin, HIPK2, LDHA, MAP1B, MLF1, MT1A, NBPF10 (includes others), 
NQO1, OPTN, PI3K (family), Pias, PKIB, QKI, RPS7, SERPINA5, STAT5a/b, STX11, TCF, TGFBI, Ubiquitin, 
YY2 
41 27 
Neurological Disease, Cancer, 
Cellular Development 
2 
ADAM15, Akt, ANGPTL4, ANKRD1, ARPC4, CADM1, CDK4/6, CGA, CYR61, FAM162A, Fascin, FTO, 
GAL, GFRA2, Growth hormone, HK2, HPGD, IER3, Igfbp, IGFBP6, ITGB5, Lh, MTSS1, NFkB (family), 
NUCB2, PARM1, PRODH, PROK1, PVRL3, RAP1GAP, ROBO1, SLIT2, STARD13,Vdac, Vla-4 
37 26 
Cell-To-Cell Signalling and 
Interaction, Tissue Development, 
Cardiovascular System Development 
and Function 
3 
ACHE ,AChR, ALDOC, Alp, ASAP1, CAV2, Caveolin, COL18A1, COL4A5, Collagen type IV, DCLK1, ERK, GK, 
KLF10, LAMB1, LAMB3, Laminin, Laminin1, MALL, MATK, MGP, MT1F, NFIB, 
NREP, NT5E, Nuclear factor 1, PDGF BB, SERPINA3, SNAI2, SORCS1, SWI-SNF, TACC1, TAGLN, 
TGFB2, UACA 
35 24 
Cell Morphology, Tissue 
Morphology, Tissue Development 
4 
ACTG2, Adaptor protein 2, AJUBA, AKR1C4, Alpha catenin, AMOT, AMPH, ANKRD35, Ap2 alpha, 
ATP2A3, ATP2B1, CD24, Cg, Ck2, Clathrin, CLTCL1, CPLX1, Dynamin, FILIP1L, FSH, GTPase, 
ISG20, JUN, KLF6, MPDZ, MT1X, NR5A2, PTPase, PTPN14, PTPN21,SERCA, SFTPD, SNAP25, 
TDRD5, UNC13D 
33 24 
Cellular Assembly and Organization, 
Cellular Function and Maintenance, 
Infectious Disease 
5 
ALOXE3, BCL3, BCR (complex), C1q, CD79B, CEACAM5, Collagen type II, ENC1, ERK1/2, ETS, FCRLB, 
FUT8, GPIIB-IIIA, Iga, IgG1, Igg3, Igm, IGSF1, KCNN4, KRT13, mir-24, MT1H, NCK, NCKAP5, NEDD9, PIR, 
Rap1, RASGRP1, SEMA3F, SLC12A4, SLURP1, Smad2/3, Sos, SUSD4, VAV2 
27 21 
Cancer, Hematological System 
Development and Function, 
Humoral Immune Response 
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Appendix 15: Images of MCF-7 (A) and MDA-MB-231 (B) cells grown in Matrigel™ cultures. Top 
panel: Images obtained through fluorescence microscopy. Bottom panel: same images being converted 
to monochrome for the analysis of spheroid size (for MCF-7 cells) and circularity (for MDA-MB-231 
cells) via ImageJ. TRI = IGF-I:IGFBP-5:VN. 
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